

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



December 7, 2023

BSE Limited,
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai - 400 001.

Dear Sir / Madam,

Sub: Application under Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023, for the proposed Composite Scheme of Arrangement

With reference to the above application, please find below the additional documents /information as requested by your good office:

Sr. No.	Additional documents/details	Company's remarks
1	As per our records, the listed share capital of Transferee Company is Rs. 2,39,92,76,350/- as against the capital mentioned in clause 5.6 of the draft scheme i.e. Rs. 2,39,93,34,970/. Kindly clarify the difference.	<p>There is difference of 58,620 equity shares which are kept in abeyance. The reasons for difference between the issued capital and listed capital have already been intimated to BSE at time of submission reconciliation of Share Capital Audit Report, on quarterly basis.</p> <p>A copy of Reconciliation of Share Capital Audit Report for the quarter ended September 30, 2023, filed by the Company with BSE on October 10, 2023, is attached herewith at Annexure-1 for your reference.</p>



Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



Sr. No.	Additional documents/details	Company's remarks
2	<p>It is observed that Board of Directors at their meeting held on November 01, 2023, inter alia took on record Draft Certificate of Statutory Auditors confirming compliance of the Accounting Treatment, Draft Certificate of the Statutory Auditors confirming the non-applicability e-voting as per para 10(a) and (b) of Part I of the SEBI Master circular no. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023 and Draft report of the Board of Directors covering the effect of Scheme of Arrangement on shareholders, key managerial personnel, promoter and non-promoter shareholders of the Company respectively. In this regard, kindly clarify as to whether there were any changes in the draft reports taken on record by the Board of directors and final reports issued. Further, kindly also clarify on whether the final reports were taken on record by the Board. If so, kindly submit copy of resolutions passed by Board of the Company inter alia taking the same on record.</p>	<p>We hereby confirm that the draft certificates of Statutory Auditors and report of the Board of Directors on the Scheme were placed before the Board and were approved by the Board with authority to the officers authorised in the Board resolution finalize the same. The report of the Board of Directors was approved and signed at the meeting. There was no change in the draft certificates of the Auditors after approval of the Board of Directors accordingly the signed certificates were not placed before the Board again as Board approval is granted and authorisation is given to the officers of the Company to execute the documents with or without modifications in giving effect to the resolution.</p>
3	<p>Confirmation from the listed entity signed by Company Secretary/ Compliance Officer stating that: a) No material event impacting the valuation has occurred during the intervening period of filing the scheme documents with Stock Exchange and period under consideration for valuation. b) Declaration/ details on any past defaults of listed debt obligations of the entities forming part of the scheme- Not found.</p>	<p>Confirmation letter is attached at Annexure-2</p>



Registered Office: SPARC, Tandajja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



Sr. No.	Additional documents/details	Company's remarks
4	Kindly clarify the non-applicability of Fairness opinion by Independent SEBI Registered Merchant Banker.	Upon the Scheme becoming effective, no shares of the Transferee Company shall be issued and allotted in lieu of shares held by it or its subsidiary companies in the Transferor Companies and the entire paid-up share capital of the Transferor Companies shall be cancelled and extinguished without any further act, deed or instrument as an integral part of this Scheme, there will be no change in the shareholding pattern of the Transferee Company. In view of the same, the Fairness opinion by Independent SEBI Registered Merchant Banker as per Para(A)(2)(d) of Part I of the SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/ 2023/93 dated June 20, 2023 is not applicable to the Scheme referred above.
5	Whether total shareholding of Green Eco Development Centre Ltd is held by Sun Pharma Laboratories Ltd? Please confirm as per the pre-scheme shareholding pattern submitted by Transferor Co 2. (Page 18)	The entire share capital of Green Eco Development Centre Limited, Transferor Company No. 2 is held by Sun Pharmaceutical Industries Limited, Transferee Company and hence the Transferor Company No. 2 is a wholly owned subsidiary of the Transferee Company. There is an inadvertent typo error while mentioning the name of the Company, revised pre and post Shareholding Pattern of Green Eco Development Centre Limited is attached herewith at Annexure-3 .
6	Detailed Compliance Report- Point e of the compliance report should be rectified as not applicable in the current case or "to be complied with".	Revised Compliance Report is attached at Annexure-4
7	An undertaking from the Company clearly stating the reasons for non-applicability of Para 10(a) of SEBI circular dated 20.06.2023 is not certified by the auditor. Further, kindly	Certificate issued by Auditors of the Company clearly stated that both Para (A)(10)(a) and Para (A)(10)(b) of Part I of the SEBI Master Circular are not applicable to the Scheme.

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA

Reaching People. Touching Lives.



Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



Sr. No.	Additional documents/details	Company's remarks
	elaborate the applicability of all 5 exemptions and resubmit the same.	We are working with the Statutory Auditors on possibility of obtaining revised certificate as required by your good office, an update shall be shared subsequently.
8	In Brief details of the transferee/resulting and transferor/demerged companies as per format enclosed at Annexure VIII the pre and post scheme Net worth capital of the Transferee Company is mentioned incorrectly as Rs. 1,93,617.3 Millions instead Rs. 1,93,617.2 Millions and Rs. 1,90,068 Millions instead of Rs. 190,231.9 Millions as per the Net worth certificate.	Revised brief details mentioning the correct net worth is attached at Annexure-5
9	If Net worth of the Transferee Company is getting reduced from Rs. 1,93,617.2 Millions to Rs. 190,231.9 Millions. Please clarify how the scheme is beneficial for the stakeholders of the listed entity?	Even if net worth is reducing marginally, it remains to be strongly positive not having any adverse impact on any of the stakeholders. This together with the benefits enumerated under the rationale above results into scheme is being beneficial to the stakeholders. Detailed note in this regard is attached at Annexure-6
10	Confirmation by the Managing Director/ Company Secretary as per format enclosed as Annexure XI.: a) kindly remove the wordings 'If applicable' from point b) iii) and resubmit. b) kindly submit a snapshot of the scheme related documents submitted on the website of the Company.	Revised confirmation is attached at Annexure-7 Scheme related documents are uploaded in the website of the Company, snapshot is attached herewith at Annexure-8



Registered Office: SPARC, Tandajja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.

Tel. : (91-22) 4324 4324

Fax : (91-22) 4324 4343

Website: www.sunpharma.com

Email: secretarial@sunpharma.com

CIN: L24230GJ1993PLC019050



Sr. No.	Additional documents/details	Company's remarks																								
11	Why GST amount is not paid at 18% for the payment dated 13.02.2023 amounting Rs. 22,500/- and the payment dated 03.11.2023 amounting Rs. 4,05,000/-. Request to process the payment of GST at the earliest.	<p>GST amount of Rs. 4,500/- has been paid on November 03, 2023 vide UTR-IN1ON231103032JH, details are already mentioned in Annexure-18 to the application filed on November 21, 2023.</p> <p>Summary of the processing fee is as follows:</p> <table border="1"><thead><tr><th>Particulars</th><th>Amount (Rs.)</th></tr></thead><tbody><tr><td>Processing fee</td><td>4,00,000</td></tr><tr><td>GST 18%</td><td>72,000</td></tr><tr><td>Total Processing fee →</td><td>4,72,000</td></tr><tr><td>Less: TDS</td><td>40,000</td></tr><tr><td>Net Amount →</td><td>4,32,000</td></tr></tbody></table> <p>Details of the payment made is as follows:</p> <table border="1"><thead><tr><th>Particulars</th><th>Amount (Rs.)</th></tr></thead><tbody><tr><td>Advance processing fee paid on February 13, 2023 vide UTR-IN1ON230213013PG</td><td>22,500</td></tr><tr><td>Remaining fee paid on:</td><td></td></tr><tr><td>• November 03, 2023 vide UTR-IN1ON231103032JD</td><td>4,05,000</td></tr><tr><td>• November 03, 2023 vide UTR- IN1ON231103032JH</td><td>4,500</td></tr><tr><td>Net amount paid</td><td>4,32,000</td></tr></tbody></table>	Particulars	Amount (Rs.)	Processing fee	4,00,000	GST 18%	72,000	Total Processing fee →	4,72,000	Less: TDS	40,000	Net Amount →	4,32,000	Particulars	Amount (Rs.)	Advance processing fee paid on February 13, 2023 vide UTR-IN1ON230213013PG	22,500	Remaining fee paid on:		• November 03, 2023 vide UTR-IN1ON231103032JD	4,05,000	• November 03, 2023 vide UTR- IN1ON231103032JH	4,500	Net amount paid	4,32,000
Particulars	Amount (Rs.)																									
Processing fee	4,00,000																									
GST 18%	72,000																									
Total Processing fee →	4,72,000																									
Less: TDS	40,000																									
Net Amount →	4,32,000																									
Particulars	Amount (Rs.)																									
Advance processing fee paid on February 13, 2023 vide UTR-IN1ON230213013PG	22,500																									
Remaining fee paid on:																										
• November 03, 2023 vide UTR-IN1ON231103032JD	4,05,000																									
• November 03, 2023 vide UTR- IN1ON231103032JH	4,500																									
Net amount paid	4,32,000																									
12	Details of Net worth are not found in Annexure 24. Please clarify.	Separate CA certificate for Net-worth pre and post scheme of all entities, is issued and attached at Annexure-14 to the application filed on November 21, 2023. Hence CA has not mentioned again net worth details in the certificate for assets, liabilities and revenue.																								



Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.

Tel. : (91-22) 4324 4324

Fax : (91-22) 4324 4343

Website: www.sunpharma.com

Email: secretarial@sunpharma.com

CIN: L24230GJ1993PLC019050



Sr. No.	Additional documents/details	Company's remarks
13	Reasons along with relevant provisions of Companies Act, 2013 or applicable laws for proposed utilization of reserves viz. Capital Reserve, Capital Redemption Reserve, Securities premium, as a free reserve, certified by CA- to be submitted.	CA Certificate is attached at Annexure-9
14	Built up for reserves viz. Capital Reserve, Capital Redemption Reserve, Securities premium, Amalgamation reserve certified by CA.- to be submitted.	CA Certificate is attached at Annexure-10
15	Nature of reserves viz. Capital Reserve, Capital Redemption Reserve, whether they are notional and/or unrealized, certified by CA.- to be submitted.	
16	The built up of the accumulated losses over the years, certified by CA.- Please confirm if accumulated losses are present in the Company.	We hereby confirm that there are no accumulated losses carried forward over the years in the Company and presently no accumulated losses are present in the Company. CA certificate in this regard is attached at Annexure at Annexure-11
17	The Independent Director's recommendation and Auditor's certificate on the accounting treatment are silent about the reasons for losses. They are requested to provide their comments/opinion on the reasons for the losses.	The Transferor Companies are non-material wholly owned subsidiaries and mostly non-operating companies therefore no specific comments are made on the loss. Had the second part of the Scheme i.e. reclassification of general reserve of the Transferee Company to retained earnings, not been there, the merger of wholly owned subsidiary companies into the Transferee company would not warrant any such discussion.
18	The Company is requested to comment on the attached complaint received from the investor.	The Company has filed Action Taken Report against the complaint received from investor, with BSE and this complaint has also been closed by SEBI on November 22, 2023.



Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



We hereby request you to take on records and issue Observation letter/No-objection Letter.

Thanking you,

Yours truly,

For Sun Pharmaceutical Industries Limited

Anoop

(Anoop Deshpande)

Company Secretary & Compliance Officer

ICSI Membership No.: A23983

Encl.: As above.



Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



October 10, 2023

National Stock Exchange of India Ltd,

BSE Limited.,

NSE Code: SUNPHARMA

Stock Code: 524715

Dear Sir(s)/Madam(s),

Sub: Submission of Reconciliation of Share Capital Audit Report for the quarter ended September 30, 2023

Pursuant to Regulation 76 of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, please find enclosed herewith the Reconciliation of Share Capital Audit Report/ Certificate dated October 10, 2023, for the quarter ended September 30, 2023 issued by Mehta & Mehta, Practicing Company Secretaries.

This is for your information and record.

Thanking you,

Yours faithfully,

For Sun Pharmaceutical Industries Limited

ANOOP ANJANIKUMAR DESHPANDE
Digitally signed by ANOOP ANJANIKUMAR DESHPANDE
Date: 2023.10.10 17:13:13 +05'30'

(Anoop Deshpande)

Company Secretary & Compliance Officer

ICSI Membership No.: A23983



COMPANY SECRETARIES

201-206, Shiv Smriti Chambers, 2nd Floor, 49/A, Dr. Annie Besant Road, Above Corporation Bank, Worli, Mumbai-400 018
Tel.: +91-22-6611 9696. •E-mail: dipti@mehta-mehta.com. •Visit us: www.mehta-mehta.com

AUTHORISED AGENTS FOR TRADEMARK, COPYRIGHT AND PATENT

Date: 10th October, 2023

To,
The Board of Directors,
Sun Pharmaceutical Industries Limited
SPARC, Tandalja,
Vadodara,
Gujarat -390012

CERTIFICATE

We have examined the relevant books, registers, forms, documents and papers produced before us by **Sun Pharmaceutical Industries Limited** (hereinafter referred as 'the Company') and **Link Intime India Private Limited**, its R & T Agents for issuing this certificate, in respect of **Reconciliation of Share Capital Audit as per Regulation 76** of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. To the best of our knowledge and according to the information and explanations given to us and as shown by the records examined by us, we hereby certify the '**Reconciliation of Share Capital Audit Report**' for the quarter ended **30th September, 2023** as per **Annexure I**.

For Mehta & Mehta,
Unique Code No.: P1996MH007500
Company Secretaries,

Mehta



Partner
CS Monali Bhandari
UDIN: A027091E001244934



COMPANY SECRETARIES

Annexure – IREPORT ON RECONCILIATION OF SHARE CAPITAL AUDIT

1.	For Quarter Ended	30.09.2023
2.	ISIN	INE044A01036
3.	Face Value	Re. 1/-
4.	Name of the Company	Sun Pharmaceutical Industries Limited
5.	Registered Office Address	SPARC, Tandajja, Vadodara, Gujarat-390012
6.	Correspondence Address	Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (East), Mumbai - 400 063
7.	Telephone & Fax Nos.	Tel.: - (022) 4324 4324 Fax: - (022) 4324 4343
8.	Email Address	anoop.deshpande@sunpharma.com
9.	Names of the Stock Exchanges where the company's securities are listed :	<ul style="list-style-type: none"> • BSE Limited (BSE) • National Stock Exchange of India Limited (NSE)

		Number of Shares	% of Total Issued Capital
10.	Issued Capital	2,39,93,34,970	100.0000
11.	Listed Capital *(as per company records)	NSE	2,39,92,76,350
		BSE	2,39,92,76,350
12.	Held in dematerialised form in NSDL	1,82,58,12,151	76.0966
13.	Held in dematerialised form in CDSL	56,86,24,176	23.6992
14.	Physical	48,98,643	0.2042
15.	Total No. of shares (12+13+14)	2,39,93,34,970	100.0000

16.	Reasons for difference if any, between (10&11)	58,620 Equity shares issued and kept in abeyance with NSE
		58,620 Equity shares issued and kept in abeyance with BSE
	(10&15)	NIL
	(11&15)	58,620 Equity shares issued and kept in abeyance with NSE
		58,620 Equity shares issued and kept in abeyance with BSE





COMPANY SECRETARIES

As at the end of the Quarter, the reasons for difference between the issued Capital and the listed Capital are stated below: -

1. 15,120 Equity Shares are 'In Transit' with NSDL

We have been informed that as and when NSDL identifies the shareholder/s who are entitled to these shares and informs the Company, the Company will credit the shares to the respective dematerialized accounts and make necessary application for trading approval with BSE and NSE.

2. 20,890 Bonus Equity Shares issued in 2004, kept in abeyance

20,890 equity shares (Bonus 2004) yet to be listed as the same is kept in abeyance, we have been informed that as and when the dispute is resolved the Company will Credit/ dispatch the Bonus shares to the respective shareholders and make necessary application for trading approval with BSE and NSE.

3. 860 Equity shares allotted to shareholders of erstwhile Phlox Pharmaceuticals Limited, pursuant to a Scheme of Amalgamation are kept in abeyance.

In respect of remaining 860 Equity Shares kept in abeyance, we have been informed by the company that in terms of the Scheme of Amalgamation, on surrendering of the old share certificate by the shareholders of erstwhile Phlox Pharmaceuticals Ltd, the new share certificate would be released to them by necessary application for trading approval with NSE and BSE for the shares so released would be made.

4. 21,750 equity shares (20,890 (Bonus 2004) + 860 Phlox- Bonus Equity Shares 2013) kept in abeyance:

21,750 equity shares (20,890 (Bonus 2004) + 860 Phlox- Bonus Equity Shares 2013) yet to be listed as the same is kept in abeyance, we have been informed that as and when the dispute is resolved the Company will Credit/ dispatch the Bonus shares to the respective shareholders and make necessary application for trading approval with BSE and NSE.



Mehta & Mehta

COMPANY SECRETARIES

17. Certifying the details of changes in share capital during the quarter under consideration as per Table below: N.A.

Particulars	No. of shares	Applied / Not Applied for listing	Listed on Stock Exchanges	Whether intimated to CDSL	Whether intimated to NSDL	Is In-prin. appr. pending for SE

*** Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction Forfeiture, Any other (to specify):

18.	Register of Members is updated (Yes / No) If not, updated upto which date	Yes
19.	Reference of previous quarter with regards to excess dematerialized shares, if any.	NIL
20.	Has the company resolved the matter mentioned in point no.19 above in the current quarter? If not, reason why?	N. A.

21.	Mentioned the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:		
	Total No. of demat requests	No. of requests	No. of shares
	Confirmed after 21 Days	0	0
	Pending for more than 21 days	0	0
		N.A.	

22.	Name, Telephone & Fax No. of the Compliance Officer of the Co.	Mr. Anoop Deshpande Company Secretary & Compliance Officer Tel.: - (022) 4324 4324, Fax: (022) 4324 4343
23.	Name, Address, Tel. & Fax No., Regn. no. of the Auditor	Mehta & Mehta, 201-206, Shiv Smriti Chambers, 2nd Floor, 49/A, Dr. Annie Besant Road, Above Corporation Bank, Worli, Mumbai-400018, TEL No. :- (022) 6611 9696 CS Jagdish Patel -FCS 2613; Contact No. 9324545141 CS Atul Mehta -FCS 5782; Contact No. 9820223978 CS Monali Bhandari -ACS 27091; Contact No. 9320887217
24.	Appointment of common agency for share registry work if yes (name & address)	YES Link Intime India Private Limited C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West) Mumbai 400083, Maharashtra. SEBI Registration No.- INR000004058 Contact No.- 022-49186270; Fax No.- 022-49186060 Email id- rnt.helpdesk@linkintime.co.in ; www.linkintime.co.in
25.	Any other detail that the auditor may like to provide. (e.g. BIFR company, delisting from SE, company changed its name etc.)	NO

For Mehta & Mehta,
Unique Code No.: P1996MH007500
Company Secretaries,

Monali
Partner
CS Monali Bhandari



UDIN: A027091E001244934
Date: 10th October, 2023

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



December 07, 2023

BSE Limited,
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai - 400 001

Sub: Application under Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023, for the proposed Composite Scheme of Arrangement

Dear Sir/Madam,

In connection with the above application, we hereby confirm that:

- a) Upon the Scheme becoming effective, no shares of the Transferee Company shall be issued and allotted in lieu of shares held by it or its subsidiary companies in the Transferor Companies and the entire paid-up share capital of the Transferor Companies shall be cancelled and extinguished without any further act, deed or instrument as an integral part of this Scheme, there will be no change in the shareholding pattern of the Transferee Company. In view of the same, the requirement of valuation report is not applicable. Hence, confirmation that “no material event impacting the valuation has occurred during the intervening period of filing the scheme documents with Stock Exchange and period under consideration for valuation”, is not applicable; and
- b) There are no past defaults of listed debt obligations of the entities forming part of the scheme.

For **Sun Pharmaceutical Industries Limited**

Anoop D.

(Anoop Deshpande)
Company Secretary & Compliance Officer
ICSI Membership No.: A23983



Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Entity: Green Eco Development Centre Limited
2.	Scrip Code/Name of Scrip/Class of Security: Equity shares - Pre shareholding pattern
3.	Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg. 31(1)(b)/Reg.31(1)(c)
	a. If under 31(1)(b) then indicate the report for Quarter ending
	b. If under 31(1)(c) then indicate date of allotment/extinguishment
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-

	Yes*	No*
Particulars		
1 Whether the Listed Entity has issued any partly paid up shares?		No
2 Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
3 Whether the Listed Entity has any shares against which depository receipts are issued?		No
4 Whether the Listed Entity has any shares in locked-in?		No
5 Whether any shares held by promoters are pledge or otherwise encumbered?		No

* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding Convertible Securities/Warrants, depository receipts, locked-in shares, No of shares pledged or otherwise encumbered by promoters, as applicable, shall not be displayed at the time of dissemination on the Stock Exchange website. Also wherever there is 'No' declared by Listed Entity in above table the values will be considered as 'Zero' by default on submission of the format of holding of specified securities.




Table I - Summary Statement holding of specified securities

Category (I)	Category of shareholder (II)	Nos. of shareholders (III)	No. of fully paid up equity shares held (IV)	No. of Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Shareholding as a % of total no. of shares (calculated as per SCRR, 1957) (VIII) As a	Number of Voting Rights held in each class of securities (IX)			No. of Shares Underlying Outstanding convertible securities (including Warrants) share capital) (X)	Shareholding as a % assuming full conversion of convertible securities (as a percentage of diluted share capital) (XI)=	Number of Locked in shares (XII)		Number of Shares pledged or otherwise encumbered (XIII)		Number of equity shares held in dematerialised form (XIV)	
							Class eg: X	Class eg: y	Total (C)			Total as a % of (A+B+C)	No. (a)	No. (b)	As a % of total Shares held(b)		As a % of total dematerialised Shares
(A)	Promoter & Promoter Group	7	700000	0	0	100	700000	0	0	0	0	0	0	0	0	0	
(B)	Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
(C)	Non Promoter - Non Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
(C1)	Shares Underlying DRs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
(C2)	Shares Held By Employee Trust	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Total	7	700000	0	0	100	700000	0	0	0	0	0	0	0	0	0	



Table II - Statement showing shareholding pattern of the Promoter and Promoter Group

1	Category & Name of the shareholders (I)	Entity Type	PAN (II)	Nos. of shareholders (III)	No. of fully paid up equity shares held (IV)	Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Shareholding % calculated as per SCRR, 1957 As a % of (A+B+C2) (VIII) As	Number of Voting Rights held in each class of securities (IX)			No. of Shares Underlying Outstanding convertible securities (including Warrants) (X)	Shareholding, as a % assuming full conversion of convertible securities as a percentage of diluted share capital (XI) =	Number of Locked in shares (XII)		Number of Shares pledged or otherwise encumbered (XIII)	Number of equity shares held in dematerialised form (XIV)		
									Class eg: X	Class eg: y	Total			Total Voting Rights	Total as a % of Total Voting Rights			No. (a)	held(b)
(a)	Indian Individuals / Hindu Undivided Family Mr. Dilip Shangvi * (Jointly with Sun Pharmaceutical Industries Limited)		AMPPS4862F	6	6	0	0	6	0	0	0	0	0	0	0	0			
	Mr. Sailesh Desai * (Jointly with Sun Pharmaceutical Industries Limited)		ABCPDS074E	1	1	0	0	1	0	0	0	0	0	0	0	0			
	Mr. Dinesh Desai * (Jointly with Sun Pharmaceutical Industries Limited)		ADJPD6596P	1	1	0	0	1	0	0	0	0	0	0	0	0			
	Mr. Kedar nath Senapati * (Jointly with Sun Pharmaceutical Industries Limited)		AEXPS9231A	1	1	0	0	1	0	0	0	0	0	0	0	0			
	Mr. Ashok Bhuta * (Jointly with Sun Pharmaceutical Industries Limited)		ABFPB4466R	1	1	0	0	1	0	0	0	0	0	0	0	0			
	Mr. Sudhir Valia (Jointly with Sun Pharmaceutical Industries Limited)		AABPV2199J	1	1	0	0	1	0	0	0	0	0	0	0	0			
(b)	Central Government / State Government(s)			0	0	0	0	0	0	0	0	0	0	0	0	0			
(c)	Financial Institutions / Banks			0	0	0	0	0	0	0	0	0	0	0	0	0			
(d)	Any Other (Specify)			1	6,99,994	0	0	6,99,994	99.999	6,99,994	100	0	0	0	0	0			
	Bodies Corporate			1	6,99,994	0	0	6,99,994	99.999	6,99,994	100	0	0	0	0	0			
	Sun Pharmaceutical Industries Limited	Promoter	AADCS3124K	1	6,99,994	0	0	6,99,994	99.999	6,99,994	100	0	0	0	0	0			
	Sub Total (A)(1)			7	700000	0	0	700000	100.000	700000	100	0	0	0	0	0			
2	Foreign																		
(a)	Individuals (Non-Resident Individuals / Foreign Individuals)			0	0	0	0	0	0	0	0	0	0	0	0	0			
(b)	Government			0	0	0	0	0	0	0	0	0	0	0	0	0			
(c)	Institutions			0	0	0	0	0	0	0	0	0	0	0	0	0			
(d)	Foreign Portfolio Investor			0	0	0	0	0	0	0	0	0	0	0	0	0			
(e)	Any Other (Specify)			0	0	0	0	0	0	0	0	0	0	0	0	0			
	Sub Total (A)(2)			0	0	0	0	0	0	0	0	0	0	0	0	0			
	Total Shareholding Of Promoter And Promoter Group (A) = (A)(1)+(A)(2)			7	700000	0	0	700000	100	700000	100	0	0	0	0	0			

* Held for and on behalf of Sun Pharmaceutical Industries Limited as a nominee of Sun Pharmaceutical Industries Limited.



Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Entity: Green Eco Development Centre Limited
2.	Script Code/Name of Scrip/Class of Security: Equity shares - Post shareholding pattern
3.	Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg. 31(1)(b)/Reg.31(1)(c)
	a. If under 31(1)(b) then indicate the report for Quarter ending
	b. If under 31(1)(c) then indicate date of allotment/extinguishment
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-

	Particulars	Yes*	No*
1	Whether the Listed Entity has issued any partly paid up shares?		No
2	Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
3	Whether the Listed Entity has any shares against which depository receipts are issued?		No
4	Whether the Listed Entity has any shares in locked-in?		No
5	Whether any shares held by promoters are pledge or otherwise encumbered?		No

* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding

Post Shareholding- Not applicable as the Company shall be dissolved upon the scheme becoming effective.

For Green Eco Development Centre Limited



Rakeshchandra J. Sinha
 Director
 DIN: 07340998



ANNEX 5(A)

with PAN

Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Listed Entity: Sun Pharmaceutical Industries Limited		
2.	Scrip Code/Name of Scrip/Class of Security: 524715 - Pre shareholding pattern		
3.	Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg. 31(1)(b)/Reg.31(1)(c)		
	a. If under 31(1)(b) then indicate the report for Quarter ending: September 30, 2023		
	b. If under 31(1)(c) then indicate date of allotment/extinguishment		
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-		
	Particulars	Yes*	No*
1	Whether the Listed Entity has issued any partly paid up shares?		No
2	Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
3	Whether the Listed Entity has any shares against which depository receipts are issued?		No
4	Whether the Listed Entity has any shares in locked-in?		No
5	Whether any shares held by promoters are pledged or otherwise encumbered?	Yes	
	* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding Convertible Securities/Warrants, depository receipts, locked-in shares, No of shares pledged or otherwise encumbered by promoters, as applicable, shall not be displayed at the time of dissemination on the Stock Exchange website. Also wherever there is 'No' declared by Listed Entity in above table the values will be considered as 'Zero' by default on submission of the format of holding of specified securities.		

GENERATED ON : 07/10/2023

NSDL : 30/09/2023

CDSL : 30/09/2023



Sun Pharmaceutical Industries Limited

Table 1 - Summary Statement holding of specified securities

Category	Category of shareholder	Nos. of shareholders	No. of fully paid up equity shares held	No. of Partly paid-up equity shares held	No. of shares underlying Depository Receipts	Total nos. shares held	Shareholding as a % of total no. of shares (calculated as per SCRR, 1957)	Number of Voting Rights held in each class of securities		No. of Shares Underlying Outstanding convertible securities (including Warrants)	Shareholding as a % assuming full conversion of convertible securities (as a percentage of diluted share capital)	Number of Locked in shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialised form
								No of Voting Rights	Total as a % of (A+B+C)			No. (a)	As a % of total Shares held(b)	No. (a)	As a % of total Shares held(b)	
(I)	(II)	(III)	(IV)	(V)	(VI)	(VII) = (IV)+(V)+(VI)	(VIII) As a % of	(IX)	(X)	(XI) = (VI)+(X) As	(XII)	(XIII)	(XIV)			
(A)	Promoter & Promoter Group	14	1,307,134,535	-	-	1,307,134,535	54.48	1,307,134,535	54.48	54.48	-	31,930,000	2.44	1,307,122,535		
(B)	Public	616,574	1,092,200,435	-	-	1,092,200,435	45.52	1,092,200,435	45.52	45.52	-	NA	NA	1,087,313,792		
(C)	Non Promoter - Non Public	-	-	-	-	-	-	-	-	-	-	NA	NA	-		
(C1)	Shares Underlying DRs	-	-	-	-	-	-	-	-	-	-	NA	NA	-		
(C2)	Shares Held By Employee Trust	-	-	-	-	-	-	-	-	-	-	NA	NA	-		
	Total	616,588	2,399,334,970	-	-	2,399,334,970	100.00	2,399,334,970	100.00	100.00	-	31,930,000	1.33	2,394,436,327		

GENERATED ON : 07/10/2023 NSDL : 30/09/2023 CDSL : 30/09/2023



Table I - Statement showing shareholding pattern of the Promoter and Promoter Group.

Category & Name of the shareholders	Entity Type	PAN	Nos. of shareholders	Nos. of fully paid up equity shares held	Partly paid-up equity shares held	No. of shares underlying Depository Receipts	Total nos. shares held (VII) = (IV) + (V) + (VI)	Number of Voting Rights held in each class of securities (VIII) As a % of (A+B+C2)			Shareholding, as a % assuming full conversion of convertible securities (as a percentage of diluted share capital) (XI) = (VII) x (X) As a % of (X)	Number of Locked in shares (XII)	Number of Shares pledged or otherwise encumbered (XIII)	Number of equity shares held in dematerialised form (XIV)
								Weightage % as per SCRR, 1957 As a % of (A+B+C2)	No of Voting Rights (Class: X)	Total				
(a) Indian				(IV)	(V)	(VI)	(VII)	(VIII) As a % of (A+B+C2)	(IX)	(X)	(XI)	(XII)	(XIII)	(XIV)
Individuals / Hindu Undivided Family			6	259,370,161	-	-	259,370,161	10.91	259,370,161	10.91	-	100,000	0.04	259,370,161
Dhruj Shantilal Shanghvi	Promoter	AAJPN3862F	1	230,285,690	-	-	230,285,690	9.60	230,285,690	9.60	-	-	-	230,285,690
Sudhar Vrudhadas Valia	Promoter Group	AAJBPV2195J	1	14,345,019	-	-	14,345,019	0.60	14,345,019	0.60	-	-	-	14,345,019
Vibha Dhiru Shanghvi	Promoter Group	AAJPN2688P	1	8,840,280	-	-	8,840,280	0.37	8,840,280	0.37	-	-	-	8,840,280
Ashika Dhiru Shanghvi	Promoter Group	AAJPN2833P	1	2,872,280	-	-	2,872,280	0.12	2,872,280	0.12	-	-	-	2,872,280
Vidya Dhiru Shanghvi	Promoter Group	AAJPN2833P	1	2,872,280	-	-	2,872,280	0.12	2,872,280	0.12	-	-	-	2,872,280
Kansud Shantilal Shanghvi	Promoter Group	AAJPN2833P	1	199,465	-	-	199,465	0.01	199,465	0.01	-	-	-	199,465
(b) Central Government / State Government(s)			-	-	-	-	-	-	-	-	-	-	-	-
(c) Financial Institutions / Banks			-	-	-	-	-	-	-	-	-	-	-	-
(d) Promoter Trust			8	1,047,764,374	-	-	1,047,764,374	43.67	1,047,764,374	43.67	-	31,930,000	3.04	1,047,764,374
Shanghvi Family & Friends Benefit Trust	Promoter Trust	AAALN17896I	1	1,276,774	-	-	1,276,774	0.05	1,276,774	0.05	-	-	-	1,276,774
Persons Acting In Concert			2	39,231,202	-	-	39,231,202	1.64	39,231,202	1.64	-	26,690,000	68.03	39,231,202
Raksha Sudha Valia	Promoter Group	AAAPV2596F	1	28,830,352	-	-	28,830,352	1.20	28,830,352	1.20	-	-	-	28,830,352
United Investments Limited	Promoter Group	AAACU2065H	1	10,400,850	-	-	10,400,850	0.43	10,400,850	0.43	-	-	-	10,400,850
Radhika Corporation	Promoter Group	AAACS0963R	1	1,007,244,398	-	-	1,007,244,398	41.98	1,007,244,398	41.98	-	-	-	1,007,244,398
Shanghvi Investments Private Limited	Promoter Group	AAARCA0172I	1	967,051,732	-	-	967,051,732	40.30	967,051,732	40.30	-	-	-	967,051,732
Ashika Medicines Limited	Promoter Group	AAACU0445L	1	40,153,960	-	-	40,153,960	1.67	40,153,960	1.67	-	-	-	40,153,960
Flanbawer Finance Private Limited	Promoter Group	AAACU0445L	1	20,865	-	-	20,865	0.00	20,865	0.00	-	-	-	20,865
Shanghvi Properties Private Limited	Promoter Group	AAACS8603I	1	15,479	-	-	15,479	0.00	15,479	0.00	-	-	-	15,479
Gagan Sun Pharmaceutical Industries Pvt Ltd	Promoter Group	AAARCU4575G	1	14,302	-	-	14,302	0.00	14,302	0.00	-	-	-	14,302
Sub Total (A+D)			14	1,307,134,535	-	-	1,307,134,535	54.48	1,307,134,535	54.48	-	31,930,000	2.44	1,307,134,535
(e) Foreign			-	-	-	-	-	-	-	-	-	-	-	-
Individuals (Non-Resident Individuals / Foreign Individuals)			-	-	-	-	-	-	-	-	-	-	-	-
(f) Government			-	-	-	-	-	-	-	-	-	-	-	-
(g) Institutions			-	-	-	-	-	-	-	-	-	-	-	-
(h) Foreign Portfolio Investor			-	-	-	-	-	-	-	-	-	-	-	-
(i) Any Other Specified			-	-	-	-	-	-	-	-	-	-	-	-
Sub Total (A+D+G)			-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholding Of Promoter And Promoter Group (A+E+D+G)			14	1,307,134,535	-	-	1,307,134,535	54.48	1,307,134,535	54.48	-	31,930,000	2.44	1,307,134,535

Details of Shares which remain unclaimed may be given bear along with details such as number of shareholders, outstanding shares held in demat/unclaimed suspense account, voting rights which are frozen etc.



Note: (1) PAN would not be displayed on website of Stock Exchange(s) (2) The term 'Encumbrance' has the same meaning as assigned under regulation 28(C) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Table III - Statement showing shareholding pattern of the Public shareholder

Category & Name of the shareholders	PAN	Nos. of shareholder	No. of fully paid up equity shares held	Partly paid-up equity shares held	No. of shares underlying Depository Receipts	Total nos. shares held	Shareholding % as per SCRR, 1957 As a % of (A+B+C2)	Number of Voting Rights held in each class of securities			Shareholding as convertible securities (as a percentage of diluted share capital)	Number of Locked in shares	Number of Shares pledged or otherwise encumbered	Number of equity shares held in dematerialized form	Sub-categorization of shares				
								Class: X	Class: y	Total					(XII)	(XIII)	(XIV)	Sub-category(i)	Sub-category(ii)
(i)	(ii)	(iii)	(iv)	(v)	(vi)	(vii) As a % of (A+B+C2)	(viii) As a % of (A+B+C2)	(ix)			(x)	(xi)	(xii)	(xiii)	(xiv)	(xv)			
1. Institutions (Domestic)																			
(a) Mutual Fund		41	313,620,260	-	-	313,620,260	13.07	313,620,260	13.07	-	-	-	-	313,611,448	-	-	-	-	-
ICICI Prudential Value Discovery Fund	AAAAA0038F	1	82,594,109	-	-	82,594,109	3.44	82,594,109	3.44	-	-	-	-	82,594,109	-	-	-	-	-
SBI Mills 50 Etf	AAABT5047Q	1	57,068,134	-	-	57,068,134	2.38	57,068,134	2.38	-	-	-	-	57,068,134	-	-	-	-	-
(b) Venture Capital Funds		39	4,746,099	-	-	4,746,099	0.20	4,746,099	0.20	-	-	-	-	4,746,099	-	-	-	-	-
Banks		12	950,773	-	-	950,773	0.04	950,773	0.04	-	-	-	-	948,989	-	-	-	-	-
(c) Alternate Investment Funds		29	121,473,840	-	-	121,473,840	5.06	121,473,840	5.06	-	-	-	-	121,473,840	-	-	-	-	-
(d) Insurance Companies		1	69,798,696	-	-	69,798,696	2.91	69,798,696	2.91	-	-	-	-	69,798,696	-	-	-	-	-
(e) Life Insurance Corporation Of India	AAAAC10982H	1	27,107,234	-	-	27,107,234	1.13	27,107,234	1.13	-	-	-	-	27,107,234	-	-	-	-	-
(f) Provident Fund/Pension Funds		1	27,107,234	-	-	27,107,234	1.13	27,107,234	1.13	-	-	-	-	27,107,234	-	-	-	-	-
(g) Nps Trust-A/C Sbi Pension Fund Scheme - Stage (AA)B7N0649L		1	27,107,234	-	-	27,107,234	1.13	27,107,234	1.13	-	-	-	-	27,107,234	-	-	-	-	-
(h) Asset Reconstruction Companies		2	2,389,654	-	-	2,389,654	0.10	2,389,654	0.10	-	-	-	-	2,389,654	-	-	-	-	-
(i) Sovereign Wealth Funds		6	65,125	-	-	65,125	0.00	65,125	0.00	-	-	-	-	65,125	-	-	-	-	-
(j) NBFCs registered with RBI		3	1,553,584	-	-	1,553,584	0.06	1,553,584	0.06	-	-	-	-	1,553,584	-	-	-	-	-
(k) Other Financial Institutions		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(l) Any Other (Specify)		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(m) Sub Total (B)(1)		133	471,906,569	-	-	471,906,569	19.67	471,906,569	19.67	-	-	-	-	471,895,864	-	-	-	-	-
2. Institutions (Foreign)		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(a) Foreign Direct Investment		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(b) Foreign Venture Capital Investors		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(c) Sovereign Wealth Funds		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(d) Foreign Portfolio Investors Category I		835	386,397,535	-	-	386,397,535	16.10	386,397,535	16.10	-	-	-	-	386,397,535	-	-	-	-	-
(e) Government Of Singapore	AAAAG094R	1	28,689,081	-	-	28,689,081	1.20	28,689,081	1.20	-	-	-	-	28,689,081	-	-	-	-	-
(f) Government Pension Fund Global	AAACN1454E	1	24,700,324	-	-	24,700,324	1.03	24,700,324	1.03	-	-	-	-	24,700,324	-	-	-	-	-
(g) Overseas Portfolio Investors Category II (balancing figure)		67	16,399,908	-	-	16,399,908	0.68	16,399,908	0.68	-	-	-	-	16,399,908	-	-	-	-	-
(h) Overseas Depository/holding DRs (balancing figure)		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(i) Any Other (Specify)		13	18,509	-	-	18,509	0.00	18,509	0.00	-	-	-	-	18,509	-	-	-	-	-
(j) Foreign Institutional Investors		9	8,557	-	-	8,557	0.00	8,557	0.00	-	-	-	-	8,557	-	-	-	-	-
(k) Foreign Bank		4	9,952	-	-	9,952	0.00	9,952	0.00	-	-	-	-	9,952	-	-	-	-	-
(l) Sub Total (B)(2)		915	402,815,952	-	-	402,815,952	16.79	402,815,952	16.79	-	-	-	-	402,806,371	-	-	-	-	-
3. Central Government/ State Government(s)		3	9,576	-	-	9,576	0.00	9,576	0.00	-	-	-	-	9,576	-	-	-	-	-
(a) Central Government / President of India		1	3,340	-	-	3,340	0.00	3,340	0.00	-	-	-	-	3,340	-	-	-	-	-
(b) State Government / Governor		2	6,236	-	-	6,236	0.00	6,236	0.00	-	-	-	-	6,236	-	-	-	-	-
(c) Shareholding by Companies or Bodies Corporate where Central / State Government is a promoter		4	12,916	-	-	12,916	0.00	12,916	0.00	-	-	-	-	12,916	-	-	-	-	-
(d) Non-Institutions		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(e) Associate companies / Subsidiaries		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(f) Directors and their relatives (excluding Independent Directors and nominees Directors)		16	7,577,722	-	-	7,577,722	0.32	7,577,722	0.32	-	-	-	-	7,577,722	-	-	-	-	-
(g) Key Managerial Personnel		1	1	-	-	1	0.00	1	0.00	-	-	-	-	1	-	-	-	-	-
(h) Relatives of promoters (other than 'immediate relatives' of promoters disclosed under 'Promoter and Promoter Group' category)		3	558,811	-	-	558,811	0.02	558,811	0.02	-	-	-	-	558,811	-	-	-	-	-
(i) Trusts where any person belonging to 'Promoter and Promoter Group' category is 'trustee', 'beneficiary', or 'author of the trust'		2	5,830,913	-	-	5,830,913	0.24	5,830,913	0.24	-	-	-	-	5,830,913	-	-	-	-	-
(j) Investor Education and Protection Fund (IEPF)		1	2,488,629	-	-	2,488,629	0.10	2,488,629	0.10	-	-	-	-	2,488,629	-	-	-	-	-
(k) Resident Individual holding nominal share capital up to Rs. 2 lakhs		590,750	112,334,071	-	-	112,334,071	4.68	112,334,071	4.68	-	-	-	-	107,657,267	-	-	-	-	-



Sun Pharmaceutical Industries Limited
Table V - Statement showing details of significant beneficial owners

Sr. No.	Details of the significant beneficial owner (I)			Details of the registered owner (II)				Details of holding / exercise of right of the SBO in the reporting company, whether direct or indirect* (III)				(2) Date of creation / acquisition of significant beneficial interest# (IV)
	Name	PAN	Nationality	Name	PAN	Nationality	whether by virtue of:			Exercise of significant influence		
							Voting rights*	Rights on Dividend or any other distributable	Exercise of Control			
1	Dilip Shantilal Shanghvi	AMPPS4862F	Indian	Shanghvi Finance Private Limited ^s	AAACS6963R	Indian	40.30	40.30	No	No	No	13-06-2018
2	Dilip Shantilal Shanghvi	AMPPS4862F	Indian	Flamboyance Finance Private Limited	AAACF0545L	Indian	0.00	0.00	No	No	No	13-06-2018
3	Dilip Shantilal Shanghvi	AMPPS4862F	Indian	Sanghvi Properties Private Limited	AAACS5663E	Indian	0.00	0.00	No	No	No	13-06-2018
4	Dilip Shantilal Shanghvi	AMPPS4862F	Indian	Gujarat Sun Pharmaceutical Industries Pvt Ltd	AABCG4575G	Indian	0.00	0.00	No	No	No	13-06-2018
5	Dilip Shantilal Shanghvi	AMPPS4862F	Indian	Aditya Medisales Limited	AABCA9317J	Indian	1.67	1.67	No	No	No	13-06-2018
6	Dilip Shantilal Shanghvi	AMPPS4862F	Indian	Unimed Investments Limited	AAACU2965P	Indian	0.43	0.43	No	No	No	13-06-2018
7	Dilip Shantilal Shanghvi	AMPPS4862F	Indian	Shanghvi Family & Friends Benefit Trust (Kumud S. Shanghvi and Dilip S. Shanghvi)	AAATS0789G	Indian	0.05	0.05	No	No	No	13-06-2018

(1) For Disclosure w.r.t. SBO – Calculations for holdings / exercise of right of the SBO in the reporting company, has been done on the basis of the shareholding of the registered owner in the Company and not on proportionate basis.

(2) June 13, 2018, the date on which Section 90 of the Companies Act, 2013 as substituted by the Companies (Amendment) Act, 2017 relating to Significant Beneficial Owner was notified by the Ministry of Corporate Affairs, has been considered as the Date of creation / acquisition of significant beneficial interest for the purpose of this disclosure.

^sShanghvi Finance Private Limited ("SFPL") which is a part of the Promoter Group of the Company that, pursuant to Scheme of Amalgamation, erstwhile Asawari Investment and Finance Private Limited has inter alia got amalgamated w.e.f. 23.10.2018 with SFPL and thereby the shares held by Asawari in the Company stand transferred in name of SFPL. They also informed that they are in the process of getting the Demat account(s) transferred, which is presently in name of Asawari, to the name of SFPL and advised the Company to club the shareholding of aforementioned companies into the holdings of SFPL.

In view of the above, for the purpose of disclosure in Shareholding Pattern and disclosure w.r.t Significant Beneficial Owners (SBO), we have clubbed the shares held in such Demat account(s) with the shareholding of SFPL.



Note = * In case the nature of the holding/ exercise of the right of a SBO falls under multiple categories specified under (a) to (e) under Column III, multiple rows for the same SBO shall be inserted accordingly for each of the

Sun Pharmaceutical Industries Limited

Table VI - Statement showing foreign ownership limits

Particular	Approved limits (%)	Limits utilized (%)	
As on shareholding date	100	16.91	30-Sep
As on the end of previous 1st quarter	100	16.61	30-Jun
As on the end of previous 2nd quarter	100	17.01	31-Mar
As on the end of previous 3rd quarter	100	17.00	31-Dec
As on the end of previous 4th quarter	100	16.15	30-Sep

Notes :-

1) "Approved Limits (%)" means the limit approved by Board of Directors / shareholders of the Listed entity. In case the listed entity has no Board approved limit, provide details of sectoral / statutory cap prescribed by Government / Regulatory Authorities

2) Details of Foreign ownership includes foreign ownership / investments as specified in Rule 2(s) of the Foreign Exchange Management (Non-debt Instruments) Rules, 2019, made under the Foreign Exchange Management Act, 1999.

For Sun Pharmaceutical Industries Limited



(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983

Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Entity: Sun Pharmaceutical Industries Limited
2.	Scrip Code/Name of Scrip/Class of Security: Equity shares - Post shareholding pattern
3.	Share Holding Pattern Filed under: Reg. 31(D)(a)/Reg. 31(D)(b)/Reg.31(D)(c)
	a. If under 31(D)(b) then indicate the report for Quarter ending
	b. If under 31(D)(c) then indicate date of allotment/extinguishment
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-

	Particulars	Yes*	No*
1	Whether the Listed Entity has issued any partly paid up shares?		No
2	Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
3	Whether the Listed Entity has any shares against which depository receipts are issued?		No
4	Whether the Listed Entity has any shares in locked-in?		No
5	Whether any shares held by promoters are pledge or otherwise encumbered?		No

* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding

Post Shareholding- Post amalgamation there will be no change in shareholding pattern of the Transferee Company.

For Sun Pharmaceutical Industries Limited



Anoop

(Anoop Deshpande)
Company Secretary and Compliance Officer
 ICSI Membership No.: A23983

Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Entity: SUN PHARMACEUTICAL MEDICARE LIMITED
2.	Script Code/Name of Scrip/Class of Security: Equity shares - Pre shareholding pattern
3.	Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg. 31(1)(b)/Reg.31(1)(c)
	a. If under 31(1)(b) then indicate the report for Quarter ending
	b. If under 31(1)(c) then indicate date of allotment/extinguishment
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-

Particulars	Yes*	No*
1 Whether the Listed Entity has issued any partly paid up shares?		No
2 Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
3 Whether the Listed Entity has any shares against which depository receipts are issued?		No
4 Whether the Listed Entity has any shares in locked-in?		No
5 Whether any shares held by promoters are pledge or otherwise encumbered?		No

* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding Convertible Securities/Warrants, depository receipts, locked-in shares, No of shares pledged or otherwise encumbered by promoters, as applicable, shall not be displayed at the time of dissemination on the Stock Exchange website. Also wherever there is 'No' declared by Listed Entity in above table the values will be considered as 'Zero' by default on submission of the format of holding of specified securities.



Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Table I - Summary Statement holding of specified securities

(I) Category	(II) Category of shareholder	(III) Nos. of shareholders	(IV) No. of fully paid up equity shares held	(V) No. of Partly paid-up equity shares held	(VI) No. of shares underlying Depository Receipts	(VII) = Total shares held	(VIII) As calculated as per SCRR, 1957)	(IX) Shareholding as a % of total no. of shares	Number of Voting Rights held in each class of securities			No. of Shares Underlying Outstanding convertible securities (including Warrants)	Shareholding, as a % assuming full conversion of convertible securities (as a percentage of diluted share capital) (XI)= (VII)+(X)	Number of Locked in shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialised form (XIV)	
									No of Voting Rights Class eg: X	Class eg: Y	Total			As a % of total Shares held(b)	No. (a)	As a % of total Shares held(b)	No. (a)		(XIII)
(A)	Promoter & Promoter Group	7	250000	0	0	250000	100	100	250000	0	250000	100	0	0	0	0	0	0	0
(B)	Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C)	Non Promoter - Non Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C1)	Shares Underlying DRs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C2)	Shares Held By Employee Trust	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Total	7	250000	0	0	250000	100	100	250000	0	250000	100	0	0	0	0	0	0	0



Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Table II - Statement showing shareholding pattern of the Promoter and Promoter Group

Category & Name of the shareholders	Entity Type	PAN	Nos. of shareholders	No. of fully paid up equity shares held	Partly paid-up equity shares	No. of shares underlying Depository	Total nos. shares held (IV)+(V)+(VI)	Shareholding % calculated as per SCRR, a % of	Number of Voting Rights held in each class of securities			No. of Shares Outstanding	Shareholding as a % assuming full	Number of Locked in shares		Number of Shares pledged or otherwise	Number of equity shares held in demateriali
									Class	Total	% of			No. (a)	As a % of total		
(I)	(II)	(III)	(IV)	(V)	(VI)	(VII)	(VIII)	(IX)	(X)	(XI)	(XII)	(XIII)	(XIV)				
1	Indian																
(a)	Individuals / Hindu Undivided Family		6	6	0	0	6	6	0	0	0	0	0	0	0	0	0
	Mr. Sailesh Trambaklal Desai* (Jointly with Sun Pharma Laboratories Limited)	ABCPD5074E	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0
	Mr. Rakeshchandra Sinha * Jointly with Sun Pharma Laboratories Limited	ABHPS9259F	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0
	Mr. Kedarnath Senapati * Jointly with Sun Pharma Laboratories Limited	AEXPS9231A	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0
	Mr. Ashok I Bhuta * (Jointly with Sun Pharma Laboratories Limited)	ABFPP4466R	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0
	Mr. Anoop Deshpande * (Jointly with Sun Pharma Laboratories Limited)	ANGPD4865R	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0
	Ms. Meetal Sampat * (Jointly with Sun Pharma Laboratories Limited)	ARMPS4352A	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0
(b)	Central Government / State Government(s)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(c)	Financial Institutions / Banks		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(d)	Any Other (Specify)		1	2,49,994	0	0	2,49,994	99.998	2,49,994	0	2,49,994	0	99.998	0	0	0	0
	Bodies Corporate		1	2,49,994	0	0	2,49,994	99.998	2,49,994	0	2,49,994	0	99.998	0	0	0	0
	Promoter		1	2,49,994	0	0	2,49,994	99.998	2,49,994	0	2,49,994	0	99.998	0	0	0	0
	Sun Pharma Laboratories Limited	AACCS6163P	1	2,49,994	0	0	2,49,994	99.998	2,49,994	0	2,49,994	0	99.998	0	0	0	0
	Sub Total (A)(1)		7	2,50,000	0	0	2,50,000	100.000	2,50,000	0	2,50,000	0	100.000	0	0	0	0
2	Foreign																
(a)	Individuals (Non-Resident Individuals / Foreign Individuals)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(b)	Government		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(c)	Institutions		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(d)	Foreign Portfolio Investor		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(e)	Any Other (Specify)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sub Total (A)(2)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Total Shareholding Of Promoter And Promoter Group (A)=(A)(1)+(A)(2)		7	2,50,000	0	0	2,50,000	100	2,50,000	0	2,50,000	0	100	0	0	0	0

*Held for and on behalf of Sun Pharma Laboratories Limited (SPL) as a nominee of SPL.



Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Table III - Statement showing shareholding pattern of the Public shareholder

Category & Name of the shareholders	PAN	Nos. of shareholders	No. of fully paid up equity shares held	Partly paid-up equity shares held	shares underlying Depository Receipts held	Total nos. shares held	Weightage % calculated as per SCRR, 1957 As a % of Total Voting Rights	Number of Voting Rights		Total as a % of Voting Rights	Shares Underlying Outstanding	ing, as a % assuming full conversion	Number of Locked in Shares	As a % of total Shares held(b)	Number of Shares held(b)	As a % of shares held in dematerialised form	Sub-categorization of shares	
								No of Voting Rights	Class eg: X								(IX)	(X)
1																		
(a) Institutions (Domestic)																		
(a) Mutual Fund																		
(b) Venture Capital Funds																		
(c) Alternate Investment Funds																		
(d) Banks																		
(e) Insurance Companies																		
(f) Provident Funds/ Pension Funds																		
(g) Asset Reconstruction Companies																		
(h) Sovereign Wealth Funds																		
(i) NBFCs registered with RBI																		
(j) Other Financial Institutions																		
(k) Any Other (Specify)																		
2																		
(a) Sub Total (B)(1)																		
(a) Institutions (Foreign)																		
(b) Foreign Direct Investment																		
(c) Foreign Venture Capital Investors																		
(d) Sovereign Wealth Funds																		
(e) Foreign Portfolio Investors Category I																		
(f) Foreign Portfolio Investors Category II																		
(g) Overseas Depositories/holding DRs) (balancing figure)																		
(h) Any Other (Specify)																		
3																		
(a) Foreign Institutional Investors																		
(b) Foreign Bank																		
(c) Sub Total (B)(2)																		
(a) Central Government/ State Government(s)																		
(b) Central Government / President of India																		
(c) State Government / Governor																		
(C) Shareholding by Companies or Bodies Corporate where Central / State Government is a promoter																		
(C) Sub Total (B)(3)																		
4																		
(a) Non-Institutions																		
(a) Associate companies / Subsidiaries																		
(b) Directors and their relatives (excluding Independent Directors and nominee Directors)																		
(C) Key Managerial Personnel																		
(D) Relatives of promoters (other than 'immediate relatives' of promoters disclosed under 'Promoter and Promoter Group' category)																		
(E) Trusts where any person belonging to 'Promoter and Promoter Group' category is 'trustee', 'beneficiary', or 'author of the trust'																		
(F) Investor Education and Protection Fund (IEPF)																		
(g) i. Resident Individual holding nominal share capital up to Rs. 2 lakhs. ii. Resident individual holding nominal share capital in excess of Rs. 2 lakhs.																		
(h) Non Resident Indians (NRIs)																		
(j) Foreign Nationals																		
(k) Foreign Companies																		
(l) Bodies Corporate																		
(m) Any Other (Specify)																		
(n) Trusts																		
(o) Body Corp-Ltd Liability Partnership																		
(p) Hindu Undivided Family																		
(q) Clearing Member																		
(r) Overseas Bodies Corporates																		
(s) Sub Total (B)(4)																		
(t) Total Public Shareholding (B)= (B)(1)+(B)(2)+(B)(3)+(B)(4)																		



Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Table IV - Statement showing shareholding pattern of the Non Promoter- Non Public shareholder

Category & Name of the shareholders (I)	PAN (II)	Nos. of shareholders (III)	No. of fully paid up equity shares held (IV)	Partly paid up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Total nos. shares held (VII) = (IV) + (V) + (VI)	Shareholding % calculated as per SCRR, 1957 As a % of (A+B+C2) (VIII) As a % of (IX)	Number of Voting Rights held in each class of securities			No. of Shares Underlying Outstanding convertible securities (including Warrants) (X)	Shareholding, as % assuming full conversion of convertible securities (as a percentage of diluted share capital) (XI) = (VII)+(X)	Number of Locked in shares		Number of Shares pledged or otherwise encumbered (XIII) As a % of total Shares held (b) (XII)	Number of equity shares held in dematerialised form (XIV)	
								Total as a % of (A+B+C)		No. (a)			No. (b)	As a % of total Shares held (b) (XII)			As a % of total Shares held (b) (XIII)
								No. of Voting Rights	Total								
1 Custodian/DR Holder		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Employee Benefit Trust / Employee Welfare Trust under SEBI (Share based Employee Benefits and Sweat Equity) Regulations, 2021		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
2 Total Non-Promoter- Non Public Shareholding (C) = (X)+(X2)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Table V. Details of significant beneficial owners

Sr. No.	Name	Details of the SBO			Details of the registered owner			Details of holding/ exercise of right of the SBO in the			Date of creation / acquisition of significant beneficial interest	
		PAN	Passport No. in case of a foreign national	Nationality (Applicable in case of Any other is selected)	Nationality	Passport No. in case of a foreign national	Whether by virtue of:	Exercise of control	Exercise of significant influence	Exercise of significant beneficial interest		

Company is not listed

For Sun Pharmaceutical Medicare Limited



Rakeshchandra J. Sinha
Director
DIN: 073-0998



Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Entity: SUN PHARMACEUTICAL MEDICARE LIMITED
2.	Scrip Code/Name of Scrip/Class of Security: Equity shares - Post shareholding pattern
3.	Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg. 31(1)(b)/Reg.31(1)(c)
	a. If under 31(1)(b) then indicate the report for Quarter ending
	b. If under 31(1)(c) then indicate date of allotment/extinguishment
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-

	Particulars	Yes*	No*
1	Whether the Listed Entity has issued any partly paid up shares?		No
2	Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
3	Whether the Listed Entity has any shares against which depository receipts are issued?		No
4	Whether the Listed Entity has any shares in locked-in?		No
5	Whether any shares held by promoters are pledge or otherwise encumbered?		No

* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding Convertible

Post Shareholding- Not applicable as the Company shall be dissolved upon the scheme becoming effective.

For Sun Pharmaceutical Medicare Limited




Rakeshchandra J. Sinha
 Director
 DIN: 07340998

With PAN

Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Entity: Faststone Mercantile Company Private Limited
2.	Script Code/Name of Scrip/Class of Security: Equity shares - Pre shareholding pattern
3.	Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg. 31(1)(b)/Reg.31(1)(c) a. If under 31(1)(b) then indicate the report for Quarter ending b. If under 31(1)(c) then indicate date of allotment/extinguishment
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-

	Yes*	No*
1		No
2		No
3		No
4		No
5		No

* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding Convertible Securities/Warrants, depository receipts, locked-in shares, No of shares pledged or otherwise encumbered by promoters, as applicable, shall not be displayed at the time of dissemination on the Stock Exchange website. Also wherever there is 'No' declared by Listed Entity in above table the values will be considered as 'Zero' by default on submission of the format of holding of specified securities.



Faststone Mercantile Company Private Limited
Table I - Summary Statement holding of specified securities

Category (I)	Category of shareholder (II)	Nos. of shareholders	No. of fully paid up equity shares held (IV)	No. of Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Total nos. shares held (VII) = (IV) + (V) + (VI)	Shareholding as a % of total no. of shares (calculate as per SCRR, 1957) (VIII) As	Number of Voting Rights held in each class of securities (IX)			No. of Shares Underlying Outstanding convertible securities (including Warrants) (X)	Shareholding as a % assuming full conversion of convertible securities (as a percentage of diluted share capital) (XI) =	Number of Locked in shares (XII)		Number of Shares pledged or otherwise encumbered (XIII)		Number of equity shares held in dematerialised form (XIV)
								No of Voting Rights	Class eg: X	Class eg: y			Total (C)	No. (a)	As a % of total Shares held(b)	No. (a)	
(A)	Promoter & Promoter Group	7	10000	0	0	10000	100	10000	0	100	0	0	0	0	0	0	0
(B)	Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C)	Non Promoter - Non Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C1)	Shares Underlying DRs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C2)	Shares Held By Employee Trust	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Total	7	10000	0	0	10000	100	10000	0	10000	0	0	0	0	0	0	0



Faststone Mercantile Company Private Limited
Table II - Statement showing shareholding pattern of the Promoter and Promoter Group

Category & Name of the shareholders	Entity Type	PAN	(III)	(IV)	(V)	(VI)	(VII) = (V)+(VI)	(VIII) As a % of 1957 As a % of (A+B+C2)	Number of Voting Rights held in each class of securities			(IX) = Total Voting Rights	(X) = No. of Shares Underlying convertible securities (including Warrants)	Shareholding, as a % assuming full conversion of convertible securities as a percentage of diluted share		(XII) = No. (a) held(b) Shares of total Shares held(b)	(XIII) = No. (a) pledged or otherwise encumbered	(XIV) = Number of equity shares held in dematerialised form	
									No of Voting Rights		Total as a % of Total Voting Rights			No. of Shares Underlying convertible securities (including Warrants)	As a % of total Shares held(b)				As a % of total Shares held(b)
									Class X	Class Y									
1	Indian																		
(a)	Individuals / Hindu Undivided Family		6	6	0	0	6	0	6	0	0	0	0	0	0	0	0	0	
	Mr. Dilip Shangvi *																		
	(Jointly with Sun Pharmaceutical Industries Limited)	AMPPS4862F	1	1	0	0	1	0.01	1	0	0.01	0	0	0	0	0	0	0	
	Mr. Satish Desai *																		
	(Jointly with Sun Pharmaceutical Industries Limited)	ABCPD5074E	1	1	0	0	1	0.01	1	0	0.01	0	0	0	0	0	0	0	
	Mr. Dinesh Desai *																		
	(Jointly with Sun Pharmaceutical Industries Limited)	ADIPD6596P	1	1	0	0	1	0.01	1	0	0.01	0	0	0	0	0	0	0	
	Mr. Anoop Deshpande *																		
	(Jointly with Sun Pharmaceutical Industries Limited)	ANGPD4865R	1	1	0	0	1	0.01	1	0	0.01	0	0	0	0	0	0	0	
	Mr. Ashok Bhuta *																		
	(Jointly with Sun Pharmaceutical Industries Limited)	ABFPB4466R	1	1	0	0	1	0.01	1	0	0.01	0	0	0	0	0	0	0	
	Mr. Sudhir Valia *																		
	(Jointly with Sun Pharmaceutical Industries Limited)	AABPV2199J	1	1	0	0	1	0.01	1	0	0.01	0	0	0	0	0	0	0	
(b)	Central Government / State Government(s)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
(c)	Financial Institutions / Banks		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
(d)	Any Other (Specify)		1	9,994	0	0	9,994	99.94	9,994	0	9,994	99.94	0	0	0	0	0	0	
	Bodies Corporate		1	9,994	0	0	9,994	99.94	9,994	0	9,994	99.94	0	0	0	0	0	0	
	Promoter		1	9,994	0	0	9,994	99.94	9,994	0	9,994	99.94	0	0	0	0	0	0	
	Sun Pharmaceutical Industries Limited	AADCSS3124K	7	10000	0	0	10000	100.00	10000	0	10000	100.00	0	0	0	0	0	0	
	Sub Total (A)(1)																		
2	Foreign																		
(a)	Individuals (Non-Resident Individuals / Foreign Individuals)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
(b)	Government		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
(c)	Institutions		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
(d)	Foreign Portfolio Investor		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
(e)	Any Other (Specify)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sub Total (A)(2)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Total Shareholding Of Promoter And Promoter Group (A) = (A)(1)+(A)(2)		7	10000	0	0	10000	100.00	10000	0	10000	100.00	0	0	0	0	0	0	

*Held for and on behalf of Sun Pharmaceutical Industries Limited as a nominee of Sun Pharmaceutical Industries Limited



Table III - Statement showing shareholding pattern of the Public shareholder

Category & Name of the shareholders	PAN	Nos of shareholders	No. of fully paid up equity shares held	Partly paid-up equity shares held	No. of shares underlying Depository Receipts held	Shareholding % calculated as per SCRR, 1957 As a % of (A+B+C2)	Number of Voting Rights held in each class of securities			No. of Shares Underlying Outstanding convertible securities (including Warrants)	Shareholding as a % assuming full conversion of convertible securities (as percentage of diluted share capital)	Number of Locked in shares	Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialised form	Sub-categorization of shares	
							No of Voting Rights Class eg: X	Total Rights	Total Rights Class eg: Y				As a % of total Shares held(b)	No. (a)			As a % of total Shares held(b)
(I)	(II)	(III)	(IV)	(V)	(VI)	(VII)	(VIII)	(IX)	(X)	(XI)	(XII)	(XIII)	(XIV)	(XV)			
1																	
(a) Institutions (Domestic)																	
(a) Mutual Fund																	
(b) Venture Capital Funds																	
(c) Alternate Investment Funds																	
(d) Banks																	
(e) Insurance Companies																	
(f) Provident Funds/ Pension Funds																	
(G) Asset Reconstruction Companies																	
(h) Sovereign Wealth Funds																	
(i) NBFCs registered with RBI																	
(j) Other Financial Institutions																	
(k) Any Other (Specify)																	
Sub Total (B)(1)																	
2																	
(a) Institutions (Foreign)																	
(a) Foreign Direct Investment																	
(b) Foreign Venture Capital Investors																	
(c) Sovereign Wealth Funds																	
(d) Foreign Portfolio Investors Category I																	
(e) Foreign Portfolio Investors Category II																	
(f) Overseas Depositories(holding DRs) (balancing figure)																	
(g) Any Other (Specify)																	
Foreign Institutional Investors																	
Foreign Bank																	
Sub Total (B)(2)																	
3																	
(a) Central Government/ State Government(s)																	
(a) Central Government / President of India																	
(b) State Government / Governor																	
Shareholding by Companies or Bodies Corporate where Central / State Government is a promoter																	
Sub Total (B)(3)																	
4																	
(a) Non-Institutions																	
Associate companies / Subsidiaries																	
Directors and their relatives (excluding Independent Directors and nominee Directors)																	
(C) Key Managerial Personnel																	
Relatives of promoters (other than 'immediate relatives' of promoters disclosed under 'Promoter and Promoter Group' category)																	
(D)																	
Trusts where any person belonging to 'Promoter and Promoter Group' category is 'trustee', 'beneficiary', or 'author of the trust'																	
(E)																	
(F) Investor Education and Protection Fund (IEPF)																	
i. Resident Individual holding nominal share capital up to Rs. 2 lakhs.																	
ii. Resident individual holding nominal share capital in excess of Rs. 2 lakhs.																	
(f) Non Resident Indians (NRIs)																	
(f) Foreign Nationals																	
(k) Foreign Companies																	
(l) Bodies Corporate																	
(m) Any Other (Specify)																	
Trusts																	
Body Corp-Ltd Liability Partnership																	
Hindu Undivided Family																	
Clearing Member																	
Overseas Bodies Corporate																	
Sub Total (B)(4)																	
Total Public Shareholding / (R)=																	



Faststone Mercantile Company Private Limited

Table IV - Statement showing shareholding pattern of the Non Promoter- Non Public shareholder

Category & Name of the shareholders	PAN	(I)	(II)	(III)	(IV)	(V)	(VI)	(VII) = Total nos. shares held	(VIII)	Shareholding % calculated as per SCRR, 1957 As a % of (A+B+C2)	Number of Voting Rights held in each class of securities			Shares Underlying Outstanding convertible securities (including Warrants) (X)	Shareholding as a % assuming full conversion of convertible securities (as a percentage of diluted share capital) (XI)=	Number of Locked in shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialised form (XIV)			
											No of Voting Rights	Class eg: X	Total (C)			No. (a)	(XII)	No. (a)	(XIII)				
																					As a % of (A+B+C)	As a % of total Shares held(b)	As a % of total dematerialised Shares held(b)
1																							
Custodian/DR Holder																							
Employee Benefit Trust / Employee Welfare Trust under SEBI (Share based Employee Benefits and Sweat Equity) Regulations, 2021																							
2																							
Total Non-Promoter- Non Public Shareholding (C)= (C1)+(C2)																							

Faststone Mercantile Company Private Limited

Table V- Details of significant beneficial owners

Sr. No.	Details of the SBO				Details of the registered owner				Details of holding/ exercise of right of the SBO in the reporting company, whether direct or indirect*				Date of creation / acquisition of significant beneficial interest	
	Name	PAN	Passport No. in case of a foreign national	Nationality (Applicable in case of foreign national)	Name	PAN	Passport No. in case of foreign national	Nationality (Applicable in case of foreign national)	Shares	Voting rights	Rights on distributable dividend or any other distribution	Exercise of control		Exercise of significant influence

Company is not listed

For Faststone Mercantile Company Private Limited



[Handwritten Signature]

Rakeshchandra J. Sinha

Director

DIN: 07340998

Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Entity: Faststone Mercantile Company Private Limited
2.	Scrip Code/Name of Scrip/Class of Security: Equity shares - Post shareholding pattern
3.	Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg. 31(1)(b)/Reg.31(1)(c)
	a. If under 31(1)(b) then indicate the report for Quarter ending
	b. If under 31(1)(c) then indicate date of allotment/extinguishment
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-

	Particulars	Yes*	No*
1	Whether the Listed Entity has issued any partly paid up shares?		No
2	Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
3	Whether the Listed Entity has any shares against which depository receipts are issued?		No
4	Whether the Listed Entity has any shares in locked-in?		No
5	Whether any shares held by promoters are pledge or otherwise encumbered?		No

* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding

Post Shareholding- Not applicable as the Company shall be dissolved upon the scheme becoming effective.

For Faststone Mercantile Company Private Limited



Rakeshchandra J. Sinha

Rakeshchandra J. Sinha
 Director
 DIN: 07340998

With PAN

Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Listed Entity: Realstone Multitrade Private Limited
2.	Scrip Code/Name of Scrip/Class of Security: Equity shares - Pre shareholding pattern
3.	Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg. 31(1)(b)/Reg.31(1)(c) a. If under 31(1)(b) then indicate the report for Quarter ending b. If under 31(1)(c) then indicate date of allotment/extinguishment
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-

Particulars	Yes*	No*
1 Whether the Listed Entity has issued any partly paid up shares?		No
2 Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
3 Whether the Listed Entity has any shares against which depository receipts are issued?		No
4 Whether the Listed Entity has any shares in locked-in?		No
5 Whether any shares held by promoters are pledge or otherwise encumbered?		No

* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding Convertible Securities/Warrants, depository receipts, locked-in shares, No of shares pledged or otherwise encumbered by promoters, as applicable, shall not be displayed at the time of dissemination on the Stock Exchange website. Also wherever there is 'No' declared by Listed Entity in above table the values will be considered as 'Zero' by default on submission of the format of holding of specified securities.



Table I - Summary Statement holding of specified securities

Category (I)	Category of shareholder (II)	Nos. of shareholders (III)	No. of fully paid up equity shares held (IV)	No. of Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Total nos. shares held (VII) = (IV) + (V) + (VI)	Shareholding as a % of total no. of shares (calculated as per SCRR, 1957) (VIII) As a	Number of Voting Rights held in each class of securities (IX)			No. of Shares Underlying convertible securities (including Warrants) (X)	Shareholding, as a % assuming full conversion of convertible securities (XI) =	Number of Locked in shares (XII)		Number of Shares pledged or otherwise encumbered (XIII)		Number of equity shares held in dematerialised form (XIV)
								No of Voting Rights (Class eg: Y)	Total	Total			No. (a)	As a % of total Shares held (b)	No. (a)	As a % of total Shares held (b)	
(A)	Promoter & Promoter Group	7	10000	0	0	10000	100	10000	0	10000	0	0	0	0	0	0	0
(B)	Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C)	Non Promoter - Non Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C1)	Shares Underlying DRs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C2)	Shares Held By Employee Trust	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Total	7	10000	0	0	10000	100	10000	0	10000	0	0	0	0	0	0	0



Table II - Statement showing shareholding pattern of the Promoter and Promoter Group.

Category & Name of the shareholders	Entity Type	PAN	(I)	(II)	(III)	(IV)	(V)	(VI)	(VII) = Total nos. shares held	(VIII) As a % of 1987 As a % of (A+B+C2)	Number of Voting Rights held in each class of securities			No. of Shares Underlying Outstanding convertible securities (including Warrants)	Shareholding, as a % assuming full conversion of convertible securities (as a percentage of diluted share capital)	Number of Locked in shares		Number of Shares pledged or otherwise encumbered	Number of equity shares held in dematerialised form		
											Total Rights					No. (a)	As a % of total Shares held(b)			No. (a)	As a % of total Shares held(b)
											No. of Voting Rights	Class e.g. X	Total								
(IX)	(X)	(XI)	(XII)	(XIII)	(XIV)																
1	Indian																				
(a)	Individuals / Hindu Undivided Family																				
	Mr. Datta Shingari *		6						6												
	(Jointly with Sun Pharmaceutical Industries Limited)																				
	Mr. Siddhar Vaid *	AAMPS482F	1						1												
	(Jointly with Sun Pharmaceutical Industries Limited)																				
	Mr. Subish Desai *	AABPV219J	1						1												
	(Jointly with Sun Pharmaceutical Industries Limited)																				
	Mr. Dinesh Desai *	ABCPD5074E	1						1												
	(Jointly with Sun Pharmaceutical Industries Limited)																				
	Mr. Ashok Bhatia *	ADIPD5496P	1						1												
	(Jointly with Sun Pharmaceutical Industries Limited)																				
	Mr. Meenal Shreed Sanyal *	ABFPB4466R	1						1												
	(Jointly with Sun Pharmaceutical Industries Limited)																				
(b)	Central Government / State Government(s)																				
(c)	Financial Institutions / Banks																				
(d)	Any Other (Specify)		9,994						9,994	99.94			9,994								
	Bodhis Corporate		1						9,994	99.94			9,994								
	Sun Pharmaceutical Industries (Promoter) AADCS3124K		1						9,994	99.94			9,994								
	Sub Total (A)(1)		7						10000	100.00			10000								
2	Foreign																				
(a)	Individuals (Non-Resident Individuals / Foreign)																				
(b)	Government																				
(c)	Institutions																				
(d)	Foreign Portfolio Investor																				
(e)	Any Other (Specify)																				
	Sub Total (A)(2)																				
	Total Shareholding Of Promoter And Promoter Group (A) = (A)(1)+(A)(2)		7						10000	100			10000								

*Held for and on behalf of Sun Pharmaceutical Industries Limited as a nominee of Sun Pharmaceutical Industries Limited



Table III - Statement showing shareholding pattern of the Public shareholder

Category & Name of the shareholders	PAN	Nos. of shareholders	No. of fully paid up equity shares held	Partly paid-up equity shares held	No. of shares underlying Depository Receipts	Total shares held	Shareholding % calculated as per SCRR, 1957 As a % of (A+B+C2)	Number of Voting Rights		Underlying Outstanding convertible securities (including Warrants)	Surrendering, as a % assuming full conversion of	Number of		Number of		Sub-categorization of Shareholding (No. of shares)		
								Class	Total			No. (a)	As a % of total Shares held(b)	No. (a)	As a % of total Shares held(b)	(i)	(ii)	(iii)
	(II)	(III)	(IV)	(V)	(VI)	(VII)	(VIII) As a %	(IX)	(X)	(XI)=	(XII)	(XIII)	(XIV)	(XV)	(i)	(ii)	(iii)	
1 Institutions (Domestic)																		
(a) Mutual Fund																		
(b) Venture Capital Funds																		
(c) Alternate Investment Funds																		
(d) Banks																		
(e) Insurance Companies																		
(f) Provident Funds/ Pension Funds																		
(g) Asset Reconstruction Companies																		
(h) Sovereign Wealth Funds																		
(i) NBFCs registered with RBI																		
(j) Other Financial Institutions																		
(k) Any Other (Specify)																		
Sub Total (B)(1)																		
2 Institutions (Foreign)																		
(a) Foreign Direct Investment																		
(b) Foreign Venture Capital Investors																		
(c) Sovereign Wealth Funds																		
(d) Foreign Portfolio Investors Category I																		
(e) Foreign Portfolio Investors Category II																		
(f) Overseas Depositories (holding DRs) (balancing figure)																		
(g) Any Other (Specify)																		
Foreign Institutional Investors																		
Foreign Bank																		
Sub Total (B)(2)																		
3 Central Government/ State Government(s)																		
(a) Central Government / President of India																		
(b) State Government / Governor																		
Shareholding by Companies or Bodies Corporate where Central / State Government is a promoter																		
Sub Total (B)(3)																		
4 Non-Institutions																		
(a) Associate companies / Subsidiaries																		
(b) Directors and their relatives (excluding Independent Directors and nominee Directors)																		
(c) Key Managerial Personnel																		
Relatives of promoters other than 'immediate relatives' of promoters disclosed under 'Promoter and Promoter Group' category																		
Trusts where any person belonging to 'Promoter and Promoter Group' category is 'trustee', 'beneficiary', or 'author of the trust'																		
(f) Investor Education and Protection Fund (IEPF)																		
(g) i. Resident individual holding nominal share capital up to Rs. 2 lakhs. ii. Resident individual holding nominal share capital in excess of Rs. 2 lakhs.																		
(h) Non Resident Indians (NRIs)																		
(i) Foreign Nationals																		
(k) Foreign Companies																		
(l) Bodies Corporate																		
(m) Any Other (Specify)																		
Trusts																		
Body Corp-Ltd Liability Partnership																		
Hindu Undivided Family																		
Clearing Member																		
Overseas Bodies Corporates																		
Sub Total (B)(4)																		
Total Public Shareholding (B)=																		



Realstone Multitrade Private Limited

Table IV - Statement showing shareholding pattern of the Non Promoter- Non Public shareholder

Sr. No.	Category & Name of the shareholders	PAN (I)	Nos. of shareholders held	No. of fully paid up equity shares held (IV)	Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Total nos. shares held (VII) = (IV) + (V) + (VI)	Shareholding % calculated as per SCRR, 1957 As a % of (A+B+C) (VIII)	Number of Voting Rights held in each class of securities			Total No. of Voting Rights (IX)	Shareholding as a % assuming full conversion of convertible securities (including (X))	Number of Locked in shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialised form (XIV)
									Class eg: X	Class eg: Y	Total (C)			No. (a) held(b)	As a % of total Shares held(b)	No. (a) held(b)	As a % of total Shares held(b)	
1	Custodian/DR Holder		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
2	Employee Benefit Trust / Employee Welfare Trust under SEBI (Share based Employee Benefits and Sweat Equity) Regulations, 2021 Total Non-Promoter- Non Public Shareholding (C)= (C)(1)+(C)(2)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Realstone Multitrade Private Limited

Table V- Details of significant beneficial owners

Sr. No.	Name	PAN	Passport No. in case of a foreign national	Nationality (Applicable in case of Any other is selected)	PAN	Name	Passport No. in case of a foreign national	Nationality (Applicable in case of Any other is selected)	Details of the registered owner			Details of holding/ exercise of right of the SBO in the reporting company, whether direct or indirect*:		Date of creation / acquisition of significant beneficial interest			
									Nationality (Applicable in case of Any other is selected)	Passport No. in case of a foreign national	Nationality (Applicable in case of Any other is selected)	Shares	Voting rights		Whether by virtue of:		
															Rights on distributable dividend or any other distribution	Exercise of control	Exercise of significant influence

Company is not listed

For Realstone Multitrade Private Limited



Prince Kalarickal Elias

Director

DIN: 07292533



Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Entity: Realstone Multitrade Private Limited
2.	Scrip Code/Name of Scrip/Class of Security: Equity shares - Post shareholding pattern
3.	Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg. 31(1)(b)/Reg.31(1)(c)
	a. If under 31(1)(b) then indicate the report for Quarter ending
	b. If under 31(1)(c) then indicate date of allotment/extinguishment
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-

	Particulars	Yes*	No*
1	Whether the Listed Entity has issued any partly paid up shares?		No
2	Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
3	Whether the Listed Entity has any shares against which depository receipts are issued?		No
4	Whether the Listed Entity has any shares in locked-in?		No
5	Whether any shares held by promoters are pledge or otherwise encumbered?		No

* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding

Post Shareholding- Not applicable as the Company shall be dissolved upon the scheme becoming effective.

For Realstone Multitrade Private Limited



Prince Kalarickal Elias

Director

DIN: 07292533

With PAN.

Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Entity: Skisen Labs Private Limited
2.	Scrip Code/Name of Scrip/Class of Security: Equity shares - Pre shareholding pattern
3.	Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg. 31(1)(b)/Reg.31(1)(c) a. If under 31(1)(b) then indicate the report for Quarter ending b. If under 31(1)(c) then indicate date of allotment/extinguishment
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-

Particulars	Yes*	No*
1 Whether the Listed Entity has issued any partly paid up shares?		No
2 Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
3 Whether the Listed Entity has any shares against which depository receipts are issued?		No
4 Whether the Listed Entity has any shares in locked-in?		No
5 Whether any shares held by promoters are pledge or otherwise encumbered?		No

* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding Convertible Securities/Warrants, depository receipts, locked-in shares, No of shares pledged or otherwise encumbered by promoters, as applicable, shall not be displayed at the time of dissemination on the Stock Exchange website. Also wherever there is 'No' declared by Listed Entity in above table the values will be considered as 'Zero' by default on submission of the format of holding of specified securities.



Table I - Summary Statement holding of specified securities

Category	(I)	(II)	(III)	(IV)	(V)	(VI)	(VII) = Total nos. held	(VIII) As	Number of Voting Rights held in each class of securities			No. of Shares Underlying convertible securities (including Warrants)	Shareholding, as a % assuming conversion of convertible securities (as a percentage of diluted share capital)	Number of Locked in shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialised form (XIV)					
									No. of fully paid up equity shares held	No. of Partly paid-up equity shares held	No. of shares underlying Depository Receipts			Shareholding as a % of total no. of shares (calculate as per SCRR, 1957)	Class eg: X	Class eg: y	Total		Total as a % of (A+B+C)	No. (a)	No. (b)	No. (a)	No. (b)
(A)	Promoter & Promoter Group	7	16360000	0	0	0	16360000	100	16360000	0	16360000	100	0	0	0	0	0	0					
(B)	Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
(C)	Non Promoter - Non Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
(C1)	Shares Underlying DRs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
(C2)	Shares Held By Employee Trust	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0					
	Total	7	16360000	0	0	0	16360000	100	16360000	0	16360000	100	0	0	0	0	0	0					



Table III - Statement showing shareholding pattern of the Public shareholder

Category & Name of the shareholders (I)	PAN (II)	Nos. of shareholders (III)	No. of fully paid up equity shares held (IV)	Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts held (VI)	Shareholding calculated as per SCRR, 1957 As a % of (A+B+C2) (VIII) As (VII) =	Number of Voting Rights held in each class of securities (IX)			Total as a % of Total Voting Rights (including Warrants) (X)	Shareholding, as a % assuming full conversion of convertible securities (as a percentage of diluted share capital) (XI) = (VII)+(X)	Number of Shares pledged or otherwise (XIII)		Number of equity shares held in demat form (XIV)	Sub-categorization of equity shares (XV)				
							No of Voting Rights Class eg: X	Class eg: Y	Total			As a % of total Shares held(b)	No. (a)		As a % of total Shares held(b)	No. (a)	SUB- category (i)	SUB- category (ii)	SUB- category (iii)
1																			
(a) Institutions (Domestic)																			
(a) Mutual Fund																			
(b) Venture Capital Funds																			
(c) Alternate Investment Funds																			
(d) Banks																			
(e) Insurance Companies																			
(f) Provident Funds/ Pension Funds																			
(G) Asset Reconstruction Companies																			
(h) Sovereign Wealth Funds																			
(i) NBFCs registered with RBI																			
(j) Other Financial Institutions																			
(k) Any Other (Specify)																			
(k) Sub Total (B)(1)																			
2																			
(a) Institutions (Foreign)																			
(a) Foreign Direct Investment																			
(b) Foreign Venture Capital Investors																			
(c) Sovereign Wealth Funds																			
(d) Foreign Portfolio Investors Category I																			
(e) Foreign Portfolio Investors Category II																			
(f) Overseas Depositories(holding DRs) (balancing figure)																			
(g) Any Other (Specify)																			
(g) Foreign Institutional Investors																			
(g) Foreign Bank																			
(g) Sub Total (B)(2)																			
3																			
(a) Central Government/ State Government(s)																			
(b) Central Government / President of India																			
(b) State Government / Governor																			
(C) Shareholding by Companies or Bodies Corporate where Central / State Government is a promoter																			
(C) Sub Total (B)(3)																			
4																			
(a) Non-Institutions																			
(a) Associate companies / Subsidiaries																			
(b) Directors and their relatives (excluding Independent Directors and nominee Directors)																			
(C) Key Managerial Personnel																			
Relatives of promoters (other than 'immediate relatives' of promoters disclosed under 'Promoter and Promoter Group' category)																			
(D) Trusts where any person belonging to 'Promoter and Promoter Group' category is 'trustee', beneficiary', or 'author of the trust'																			
(E) Investor Education and Protection Fund (IEPF)																			
(F) i. Resident individual holding nominal share capital up to Rs. 2 lakhs.																			
(g) ii. Resident individual holding nominal share capital in excess of Rs. 2 lakhs.																			
(h) Non Resident Indians (NRIs)																			
(i) Foreign Nationals																			
(j) Foreign Companies																			
(k) Bodies Corporate																			
(l) Any Other (Specify)																			
(m) Trusts																			
Body Corp-Ltd Liability Partnership																			
Hindu Undivided Family																			
Clearing Member																			
Overseas Bodies Corporates																			
Sub Total (B)(4)																			



Table IV - Statement showing shareholding pattern of the Non Promoter- Non Public shareholder


Category & Name of the shareholders	PAN	Nos. of shareholders held	No. of fully paid up equity shares held	Partly paid-up equity shares held	No. of shares underlying Depository Receipts	Shareholding % calculated as per SCRR, 1957 As a % of (A+B+C2)	Number of Voting Rights held in each class of securities		Shares Underlying Outstanding convertible securities (including Warrants)	Locking of shares	Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialised form
							No of Voting Rights Class X eg: y	Total Class C			As a % of total Shares held(b) No. (a)	As a % of total dematerialised Shares held(b) No. (a)	
(I)	(II)	(III)	(IV)	(V)	(VI)	(VII)	(IX)	(X)	(XI)	(XII)	(XIII)	(XIV)	
Custodian/DR Holder		0	0	0	0	0	0	0	0	0	0	0	
Employee Benefit Trust / Employee Welfare Trust under SEBI (Share based Employee Benefits and Sweat Equity) Regulations, 2021		0	0	0	0	0	0	0	0	0	0	0	
Total Non-Promoter- Non Public Shareholding (C)= (C1)+(C2)		0	0	0	0	0	0	0	0	0	0	0	

Skisen Labs Private Limited

Table V - Details of significant beneficial owners

Sr. No.	Name	Details of the SBO		Details of the registered owner			Details of holding/ exercise of right of			Date of creation / acquisition of significant beneficial interest	
		PAN	Passport No. in case of a foreign national	Nationality (Applicable in case of Any other is selected)	Passport No. in case of a foreign national	Nationality (Applicable in case of Any other is selected)	Shares	Whether by virtue of:	Exercise of significant influence		
		PAN									

Company is not listed



For Skisen Labs Private Limited

(Signature)

Prince Kalarickal Elias

Director

DIN: 07292533

Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Entity: Skisen Labs Private Limited
2.	Scrip Code/Name of Scrip/Class of Security: Equity shares - Post shareholding pattern
3.	Share Holding Pattern Filled under: Reg. 31(1)(a)/Reg. 31(1)(b)/Reg.31(1)(c) a. If under 31(1)(b) then indicate the report for Quarter ending b. If under 31(1)(c) then indicate date of allotment/extinguishment
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-

Particulars	Yes*	No*
1. Whether the Listed Entity has issued any partly paid up shares?		No
2. Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
3. Whether the Listed Entity has any shares against which depository receipts are issued?		No
4. Whether the Listed Entity has any shares in locked-in?		No
5. Whether any shares held by promoters are pledge or otherwise encumbered?		No

* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding

Post Shareholding- Not applicable as the Company shall be dissolved upon the scheme becoming effective.

For Skisen Labs Private Limited



Prince Kalarickal Elias

Director

DIN: 07292533



Without PAN

Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Entity: Green Eco Development Centre Limited
2.	Scrip Code/Name of Scrip/Class of Security: Equity shares - Pre shareholding pattern
3.	Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg. 31(1)(b)/Reg.31(1)(c) a. If under 31(1)(b) then indicate the report for Quarter ending b. If under 31(1)(c) then indicate date of allotment/extinguishment
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-

	Particulars	Yes*	No*
1	Whether the Listed Entity has issued any partly paid up shares?		No
2	Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
3	Whether the Listed Entity has any shares against which depository receipts are issued?		No
4	Whether the Listed Entity has any shares in locked-in?		No
5	Whether any shares held by promoters are pledged or otherwise encumbered?		No

* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding Convertible Securities/Warrants, depository receipts, locked-in shares, No of shares pledged or otherwise encumbered by promoters, as applicable, shall not be displayed at the time of dissemination on the Stock Exchange website. Also wherever there is 'No' declared by Listed Entity in above table the values will be considered as 'Zero' by default on submission of the format of holding of specified securities.



Green Eco Development Centre Limited

Table I - Summary Statement holding of specified securities

Category	Category of shareholder	Nos. of shareholders	No. of fully paid up equity shares held	No. of Partly paid-up equity shares held	No. of shares underlying Depository Receipts	Shareholding as a % of total no. of shares (calculated as per SCRR, 1957)	Number of Voting Rights held in each class of securities			No. of Shares Underlying Outstanding convertible securities (including Warrants)	Shareholding, as a % assuming full conversion of convertible securities (as a percentage of diluted share capital)	Number of Locked in shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialised form
							No of Voting Rights	Class eg: X	Class eg: y			Total	As a % of total Shares held(b)	No. (a) held(b)	As a % of total Shares held(b)	
(I)	(II)	(III)	(IV)	(V)	(VI)	(VII)	(VIII)	(IX)	(X)	(XI)	(XII)	(XIII)	(XIV)			
(A)	Promoter & Promoter Group	7	700000	0	0	700000	100	700000	0	0	0	0	0	0	0	0
(B)	Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C)	Non Promoter - Non Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C1)	Shares Underlying DRs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C2)	Shares Held By Employee Trust	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Total	7	700000	0	0	700000	100	700000	0	0	0	0	0	0	0	0



Table II - Statement showing shareholding pattern of the Promoter and Promoter Group

Category & Name of the shareholders	Entity Type	PAN	(II)	(III)	(IV)	(V)	(VI)	(VII) = Total shares held	(VIII) As % of (A+B+C2)	Number of Voting Rights held in each class of securities			(IX)	(X)	Shareholding, as a % assuming full conversion of convertible securities (including Warrants)	Number of Locked in shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialised form (XIV)							
										No. of shareholders	Nos. of fully paid up equity shares held	Partly paid-up equity shares held				No. of shares underlying Depository Receipts	Shareholding % calculated as per SCRR, 1957 As a % of (A+B+C2)	Class eg: y	X		Total	Total Voting Rights	Total as a % of Total Voting Rights	No. (a)	No. (b)	No. (a)	No. (b)
1																											
(a)	Indian Individuals / Hindu Undivided Family																										
	Mr. Dilip Shanghvi *																										
	(Jointly with Sun Pharmaceutical Industries Limited)																										
	Mr. Sailesh Desai *																										
	(Jointly with Sun Pharmaceutical Industries Limited)																										
	Mr. Dinesh Desai *																										
	(Jointly with Sun Pharmaceutical Industries Limited)																										
	Mr. Kedar nath Senapati *																										
	(Jointly with Sun Pharmaceutical Industries Limited)																										
	Mr. Ashok Bhuta *																										
	(Jointly with Sun Pharmaceutical Industries Limited)																										
	Mr. Sudhir Valia																										
	(Jointly with Sun Pharmaceutical Industries Limited)																										
(b)	Central Government / State Government(s)																										
(c)	Financial Institutions / Banks																										
(d)	Any Other (Specify)																										
	Bodies Corporate																										
	Sun Pharmaceutical Industries Limited	Promoter																									
	Sub Total (A)(1)																										
	Foreign																										
	Individuals (Non-Resident Individuals / Foreign Individuals)																										
(a)	Government																										
(b)	Institutions																										
(c)	Foreign Portfolio Investor																										
(d)	Any Other (Specify)																										
(e)	Sub Total (A)(2)																										
	Total Shareholding Of Promoter And Promoter Group (A) = (A)(1)+(A)(2)																										

* Held for and on behalf of Sun Pharmaceutical Industries Limited as a nominee of Sun Pharmaceutical Industries Limited.



Table III - Statement showing shareholding pattern of the Public shareholder

Category & Name of the shareholders (I)	PAN (II)	Nos. of shareholders (III)	No. of fully paid-up equity shares held (IV)	Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts held (VI)	Shareholding % calculated as per SCRR, 1957 As a % of (A+B+C2) X (VII) = (VIII) As a %	Number of Voting Rights held in each class of securities (IX)			No. of Shares Underlying Outstanding convertible securities (including Warrants) (X)	Shareholding, as a % assuming full conversion of convertible securities (as a percentage of diluted share capital) (XI) = (VIII) + (X) As a %	Number of Locked in shares (XII)		Number of Shares pledged or otherwise encumbered (XIII)		Sub-categorization of shares (XIV)				
							Class eg: X	Class eg: Y	Total			No. of Locked in shares (XII)	As a % of total Shares held (b)	No. of Shares pledged or otherwise encumbered (XIII)	As a % of total Shares held (b)	Sub-category (i)	Sub-category (ii)	Sub-category (iii)		
																			No. of Voting Rights	Total % of Total Voting Rights
1																				
(a) Institutions (Domestic)																				
(b) Mutual Fund																				
(c) Venture Capital Funds																				
(d) Alternate Investment Funds																				
(e) Banks																				
(f) Insurance Companies																				
(g) Provident Funds/ Pension Funds																				
(h) Asset Reconstruction Companies																				
(i) Sovereign Wealth Funds																				
(j) NBFCs registered with RBI																				
(k) Other Financial Institutions																				
(l) Any Other (Specify)																				
(m) Sub Total (B)(1)																				
2																				
(a) Institutions (Foreign)																				
(b) Foreign Direct Investment																				
(c) Foreign Venture Capital Investors																				
(d) Sovereign Wealth Funds																				
(e) Foreign Portfolio Investors Category I																				
(f) Foreign Portfolio Investors Category II																				
(g) Overseas Depositories (holding DRs) (balancing figure)																				
(h) Any Other (Specify)																				
(i) Foreign Institutional Investors																				
(j) Foreign Bank																				
(k) Sub Total (B)(2)																				
3																				
(a) Central Government/ State Government(s)																				
(b) Central Government/ President of India																				
(c) State Government/ Governor																				
(d) Shareholding by Companies or Bodies Corporate where Central/ State Government is a promoter																				
(e) Sub Total (B)(3)																				
4																				
(a) Non-Institutions																				
(b) Associate companies/ Subsidiaries																				
(c) Directors and their relatives (excluding Independent Directors and non-Independent Directors)																				
(d) Key Managerial Personnel																				
(e) Relatives of promoters (other than 'immediate relatives' of promoters disclosed under 'Promoter and Promoter Group' category)																				
(f) Trusts where any person belonging to 'Promoter and Promoter Group' category is 'trustee', 'beneficiary', or 'author of the trust'																				
(g) Investor Education and Protection Fund (IEPF)																				
(h) i. Resident individual holding nominal share capital up to Rs. 2 lakhs.																				
ii. Resident individual holding nominal share capital in excess of Rs. 2 lakhs.																				
(i) Non Resident Indians (NRIs)																				
(j) Foreign Nationals																				
(k) Foreign Companies																				
(l) Bodies Corporate																				
(m) Any Other (Specify)																				
(n) Trusts																				
(o) Body Corp-Ltd Liability Partnership																				
(p) Hindu Undivided Family																				
(q) Clearing Member																				
(r) Overseas Bodies Corporate																				
(s) Sub Total (B)(4)																				
(t) Total Public Shareholding (B) = (B)(1)+(B)(2)+(B)(3)+(B)(4)																				



Green Eco Development Centre Limited

Table IV - Statement showing shareholding pattern of the Non Promoter- Non Public shareholder

Sr. No.	Category & Name of the shareholders	PAN	Nos. of share holders	No. of fully paid up equity shares held	Partly paid-up equity shares held	No. of shares underlying Depository Receipts	Total nos. shares held	Shareholding % calculated as per SCRR, 1957 As a % of (A+B+C2)	Number of Voting Rights held in each class of securities			No. of Shares Underlying convertible securities (including Warrants)	Shareholding, as a % assuming full conversion of convertible securities (as a percentage of diluted share capital)	Number of Locked in shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialised form
									No of Voting Rights Class X eg: Y	Class	Total			No. (a) held(b)	As a % of total Shares held(b)	No. (a) held(b)	As a % of total Shares held(b)	
	(I)	(II)	(III)	(IV)	(V)	(VI)	(VII)	(VIII) As a	(IX)			(X)	(XI)=	(XII)	(XIII)	(XIV)		
1	Custodian/DR Holder		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Employee Benefit Trust / Employee Welfare Trust under SEBI (Share based Employee Benefits and Sweat Equity) Regulations, 2021		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
2	Total Non-Promoter- Non Public Shareholding (C)= (C1)+(C2)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Green Eco Development Centre Limited

Table V- Details of significant beneficial owners

Sr. No.	Details of the SBO				Details of the registered owner				Details of holding/ exercise of right of the SBO in the reporting company, whether direct or indirect*:				Date of creation / acquisition of significant beneficial interest	
	Name	PAN	Passport No. in case of a foreign national	Nationality (Applicable in case of Any other)	Name	PAN	Passport No. in case of a foreign national	Nationality (Applicable in case of Any other)	Voting rights	Shares	Rights on distributable dividend or any other distribution	Exercise of control		Exercise of significant influence

Company is not listed.

For Green Eco Development Centre Limited



Rakeshchandra J. Sinha
Director
DIN: 07340998

Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Entity: Green Eco Development Centre Limited
2.	Scrip Code/Name of Scrip/Class of Security: Equity shares - Post shareholding pattern
3.	Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg. 31(1)(b)/Reg.31(1)(c)
	a. If under 31(1)(b) then indicate the report for Quarter ending
	b. If under 31(1)(c) then indicate date of allotment/extinguishment
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-

Particulars	Yes*	No*
1 Whether the Listed Entity has issued any partly paid up shares?		No
2 Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
3 Whether the Listed Entity has any shares against which depository receipts are issued?		No
4 Whether the Listed Entity has any shares in locked-in?		No
5 Whether any shares held by promoters are pledge or otherwise encumbered?		No

* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding

Post Shareholding- Not applicable as the Company shall be dissolved upon the scheme becoming effective.

For Green Eco Development Centre Limited



Rakeshchandra J. Sinha
 Director
 DIN: 07340998

Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Listed Entity: Sun Pharmaceutical Industries Limited		
2.	Scrip Code/Name of Scrip/Class of Security: 524715 - Pre shareholding pattern		
3.	Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg. 31(1)(b)/Reg.31(1)(c)		
	a. If under 31(1)(b) then indicate the report for Quarter ending: September 30, 2023		
	b. If under 31(1)(c) then indicate date of allotment/extinguishment		
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-		
	Particulars	Yes*	No*
1	Whether the Listed Entity has issued any partly paid up shares?		No
2	Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
3	Whether the Listed Entity has any shares against which depository receipts are issued?		No
4	Whether the Listed Entity has any shares in locked-in?		No
5	Whether any shares held by promoters are pledge or otherwise encumbered?	Yes	
	* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding Convertible Securities/Warrants, depository receipts, locked-in shares, No of shares pledged or otherwise encumbered by promoters, as applicable, shall not be displayed at the time of dissemination on the Stock Exchange website. Also wherever there is 'No' declared by Listed Entity in above table the values will be considered as 'Zero' by default on submission of the format of holding of specified securities.		

GENERATED ON : 07/10/2023

NSDL : 30/09/2023

CDSL : 30/09/2023



Sun Pharmaceutical Industries Limited

Table I - Summary Statement holding of specified securities

Category	Category of shareholder	Nos. of shareholders	No. of fully paid up equity shares held	No. of Partly paid-up equity shares held	No. of shares underlying Depository Receipts	Total nos. shares held	Shareholding as a % of total shares (calculated as per SCRR, 1957)	Number of Voting Rights held in each class of securities		No. of Shares Underlying Outstanding convertible securities (including Warrants)	Shareholding as a % assuming full conversion of convertible securities as a percentage of diluted share capital	Number of Locked in shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialised form	
								No of Voting Rights	Total as a % of (A+B+C)			No. (a)	As a % of total Shares held(b)	No. (a)	As a % of total Shares held(b)		
(I)	(II)	(III)	(IV)	(V)	(VI)	(VII) = (VI)+(V)+ (IV)	(VIII) As a % of	(IX)	(X)	(XI) As a % of	(XII)	(XIII)	(XIV)	(XV)	(XVI)	(XVII)	(XVIII)
(A)	Promoter & Promoter Group	14	1,307,134,535	54.48	-	1,307,134,535	54.48	-	1,307,134,535	54.48	54.48	-	-	31,930,000	2.44	1,307,122,535	
(B)	Public	616,574	1,092,200,435	45.52	-	1,092,200,435	45.52	-	1,092,200,435	45.52	45.52	-	-	NA	NA	1,087,313,792	
(C)	Non Promoter - Non Public	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	-	
(C1)	Shares Underlying DRs	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	-	
(C2)	Shares Held By Employee Trust	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	-	
	Total	616,588	2,399,334,970	100.00	-	2,399,334,970	100.00	-	2,399,334,970	100.00	100.00	-	-	31,930,000	1.33	2,394,436,327	



Sun Pharmaceutical Industries Limited

Table II - Statement showing shareholding pattern of the Promoter and Promoter Group

Category & Name of the shareholders	Entity Type	Nos. of shareholders	No. of fully paid up equity shares held	Partly paid-up equity shares held	No. of shares underlying Depository Receipts	Total nos. shares held (VII) = (IV)+(V)+(VI)	Shareholding % as per SCRR, 1957 As a % of (A+B+C2)	Number of Voting Rights held in each class of securities			No. of Shares Underlying Outstanding convertible securities (as a percentage of diluted share capital)	Shareholding, as a % convertible securities (as a percentage of diluted share capital) (XII) = (VII)/(X) As a % of (A+B+C2)	Number of Locked in shares		Number of Shares pledged or otherwise encumbered	Number of equity shares held in dematerialised form
								No of Voting Rights Class eg: X	Class eg: Y	Total			(IX)	(XIII)		
(a) Indian																
Individuals / Hindu Undivided Family																
Dilip Shantilal Shanghui	Promoters	6	259,370,161	-	-	259,370,161	10.81	259,370,161	10.81	-	-	-	-	100,000	0.04	259,370,161
Sudhir Yrundaevandas Valia	Promoter Group	1	230,285,690	-	-	230,285,690	9.60	230,285,690	9.60	-	-	-	-	-	-	230,285,690
Vibha Dip Shanghui	Promoter Group	1	14,345,019	-	-	14,345,019	0.60	14,345,019	0.60	-	-	-	-	-	-	14,345,019
Alak Dilip Shanghui	Promoter Group	1	8,840,280	-	-	8,840,280	0.37	8,840,280	0.37	-	-	-	-	-	-	8,840,280
Vedhi Dilip Shanghui	Promoter Group	1	2,877,280	-	-	2,877,280	0.12	2,877,280	0.12	-	-	-	-	-	-	2,877,280
Kumud Shantilal Shanghui	Promoter Group	1	2,822,427	-	-	2,822,427	0.12	2,822,427	0.12	-	-	-	-	-	-	2,822,427
(b) Central Government / State Government(s)																
Financial Institutions / Banks																
Any Other (Specify)																
Promoter Trust		8	1,047,764,374	-	-	1,047,764,374	43.67	1,047,764,374	43.67	-	-	-	-	31,830,000	3.04	1,047,764,374
Shanghui Family & Friends Benefit Trust	Promoter Group	1	1,276,774	-	-	1,276,774	0.05	1,276,774	0.05	-	-	-	-	-	-	1,276,774
Persons Acting In Concert		2	39,231,202	-	-	39,231,202	1.64	39,231,202	1.64	-	-	-	-	26,690,000	68.03	39,231,202
Raksha Sudhir Valia	Promoter Group	1	28,830,352	-	-	28,830,352	1.20	28,830,352	1.20	-	-	-	-	26,690,000	92.59	28,830,352
Unimed Investments Limited	Promoter Group	1	10,400,850	-	-	10,400,850	0.43	10,400,850	0.43	-	-	-	-	-	-	10,400,850
Bodles Corporate	Promoter Group	5	1,007,256,398	-	-	1,007,256,398	41.98	1,007,256,398	41.98	-	-	-	-	5,140,000	0.51	1,007,256,398
Shanghui Finance Private Limited	Promoter Group	1	967,051,732	-	-	967,051,732	40.30	967,051,732	40.30	-	-	-	-	-	-	967,051,732
Adhya Mediasies Limited	Promoter Group	1	40,153,960	-	-	40,153,960	1.67	40,153,960	1.67	-	-	-	-	5,140,000	12.80	40,153,960
Flamboyance Finance Private Limited	Promoter Group	1	20,865	-	-	20,865	0.00	20,865	0.00	-	-	-	-	-	-	20,865
Sanghui Properties Private Limited	Promoter Group	1	15,479	-	-	15,479	0.00	15,479	0.00	-	-	-	-	-	-	15,479
Gujarat Sun Pharmaceutical Industries Pvt Ltd	Promoter Group	1	14,362	-	-	14,362	0.00	14,362	0.00	-	-	-	-	-	-	14,362
Sub Total (A)(1)		14	1,307,134,535	-	-	1,307,134,535	54.48	1,307,134,535	54.48	-	-	-	-	31,930,000	2.44	1,307,134,535
Foreign																
Individuals (Non-Resident Individuals / Foreign Individuals)																
Government																
Institutions																
Foreign Portfolio Investor																
Any Other (Specify)																
Sub Total (A)(2)																
Total Shareholding Of Promoter And Promoter Group (A) = (A)(1)+(A)(2)		14	1,307,134,535	-	-	1,307,134,535	54.48	1,307,134,535	54.48	-	-	-	-	31,930,000	2.44	1,307,134,535

Details of Shares which remain unclaimed may be given hear along with details such as number of shareholders, outstanding shares held in demat/unclaimed suspense account, voting rights which are frozen etc.

Note : (1) PAN would not be displayed on website of Stock Exchange(s)

(2) The term 'Encumbrance' has the same meaning as assigned under regulation 28(3) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.



Sun Pharmaceutical Industries Limited

Table IV - Statement showing shareholding pattern of the Non Promoter- Non Public shareholder

Category & Name of the shareholders	PAN	Nos. of shareholders	No. of fully paid up equity shares held	Party paid-up equity shares held	No. of shares underlying Depository Receipts	Shareholding % as per SCRR, 1957 As a % of (A+B+C2)	Number of Voting Rights held in each class of securities			Shares Underlying Outstanding convertible securities (including securities held by)	ing, as a % assuming full conversion of convertible securities (XII)=	Number of Locked in shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialised form (XIV)
							No. of Voting Rights	Class eg: X	Total % of (A+B+C)			No. (a)	As a % of total Shares held(b)	No. (a)	As a % of total Shares held(b)	
1 Custodian/DR Holder Employee Benefit Trust / Employee Welfare Trust under SEBI (Share based Employee Benefits and Sweat Equity) Regulations, 2021		(i)	(IV)	(V)	(VI)	(VII) =	(IX)	(X)	(XI)=	(XII)	(XIII)	(XIV)				
2 Total Non-Promoter- Non Public Shareholding (C)= (C1)+(C2)																

Note :

- (1) PAN would not be displayed on website of Stock Exchange(s).
- (2) The above format needs to be disclosed along with the names of the shareholders holding 1% or more than 1% of shares of the listed entity. Column no.(XIII) is not applicable in the above format.
- (3) W.r.t. the information pertaining to Depository Receipts, the same may be disclosed in the respective columns to the extent information available.



Sun Pharmaceutical Industries Limited
Table V - Statement showing details of significant beneficial owners

Sr. No.	Details of the significant beneficial owner		Details of the registered owner (II)		(I) Details of holdings / exercise of right of the SBO in the whether by virtue of:					(2) Date of creation / acquisition of significant beneficial interest# (IV)
	Name	Nationality	Name	Nationality	Shares*	Voting rights*	Rights on Distributable Dividend or any other distribution [†]	Exercise of Control	Exercise of significant influence	
1	Dilip Shantilal Shanghvi	Indian	Shanghvi Finance Private Limited [§]	Indian	40.30	40.30	40.30	No	No	13-06-2018
2	Dilip Shantilal Shanghvi	Indian	Flamboyance Finance Private Limited	Indian	0.00	0.00	0.00	No	No	13-06-2018
3	Dilip Shantilal Shanghvi	Indian	Sanghvi Properties Private Limited	Indian	0.00	0.00	0.00	No	No	13-06-2018
4	Dilip Shantilal Shanghvi	Indian	Gujarat Sun Pharmaceutical Industries Pvt Ltd	Indian	0.00	0.00	0.00	No	No	13-06-2018
5	Dilip Shantilal Shanghvi	Indian	Aditya Medisales Limited	Indian	1.67	1.67	1.67	No	No	13-06-2018
6	Dilip Shantilal Shanghvi	Indian	Unimed Investments Limited	Indian	0.43	0.43	0.43	No	No	13-06-2018
7	Dilip Shantilal Shanghvi	Indian	Shanghvi Family & Friends Benefit Trust (Kumud S. Shanghvi and Dilip S. Shanghvi)	Indian	0.05	0.05	0.05	No	No	13-06-2018

(1) For Disclosure w.r.t. SBO – Calculations for holdings / exercise of right of the SBO in the reporting company, has been done on the basis of the shareholding of the registered owner in the Company and not on proportionate basis.

(2) June 13, 2018, the date on which Section 90 of the Companies Act, 2013 as substituted by the Companies (Amendment) Act, 2017 relating to Significant Beneficial Owner was notified by the Ministry of Corporate Affairs, has been considered as the Date of creation / acquisition of significant beneficial interest for the purpose of this disclosure.

[§]Shanghvi Finance Private Limited ("SFPL") which is a part of the Promoter Group of the Company has informed the Company that, pursuant to Scheme of Amalgamation, erstwhile Asawari Investment and Finance Private Limited has inter alia got amalgamated w.e.f. 23.10.2018 with SFPL and thereby the shares held by Asawari in the Company stand transferred in name of SFPL. They also informed that they are in the process of getting the Demat account(s) transferred, which is presently in name of Asawari, to the name of SFPL and advised the Company to club the shareholding of aforementioned companies into the holdings of SFPL.

In view of the above, for the purpose of disclosure in Shareholding Pattern and disclosure w.r.t. Significant Beneficial Owners (SBO), we have clubbed the shares held in such Demat account(s) with the shareholding of SFPL.



Sun Pharmaceutical Industries Limited

Table VI - Statement showing foreign ownership limits

Particular	Approved limits (%)	Limits utilized (%)	
As on shareholding date	100	16.91	30-Sep
As on the end of previous 1st quarter	100	16.61	30-Jun
As on the end of previous 2nd quarter	100	17.01	31-Mar
As on the end of previous 3rd quarter	100	17.00	31-Dec
As on the end of previous 4th quarter	100	16.15	30-Sep

Notes :-

1) "Approved Limits (%)" means the limit approved by Board of Directors / shareholders of the Listed entity. In case the listed entity has no Board approved limit, provide details of sectoral / statutory cap prescribed by Government / Regulatory Authorities

2) Details of Foreign ownership includes foreign ownership / investments as specified in Rule 2(s) of the Foreign Exchange Management (Non-debt Instruments) Rules, 2019, made under the Foreign Exchange Management Act, 1999.

For Sun Pharmaceutical Industries Limited



Anoop D

(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983

Without PAN

Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Entity: SUN PHARMACEUTICAL MEDICARE LIMITED
2.	Scrip Code/Name of Scrip/Class of Security: Equity shares - Pre shareholding pattern
3.	Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg. 31(1)(b)/Reg.31(1)(c) a. If under 31(1)(b) then indicate the report for Quarter ending b. If under 31(1)(c) then indicate date of allotment/extinguishment
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-

	Particulars	Yes*	No*
1	Whether the Listed Entity has issued any partly paid up shares?		No
2	Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
3	Whether the Listed Entity has any shares against which depository receipts are issued?		No
4	Whether the Listed Entity has any shares in locked-in?		No
5	Whether any shares held by promoters are pledged or otherwise encumbered?		No

* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding Convertible Securities/Warrants, depository receipts, locked-in shares, No of shares pledged or otherwise encumbered by promoters, as applicable, shall not be displayed at the time of dissemination on the Stock Exchange website. Also wherever there is 'No' declared by Listed Entity in above table the values will be considered as 'Zero' by default on submission of the format of holding of specified securities.



Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
 Table 1 - Summary Statement holding of specified securities

Category (I)	Category of shareholder (II)	Nos. of shareholders (III)	No. of fully paid up equity shares held (IV)	No. of Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Shareholding as a % of total no. of shares (calculated as per SCRR, 1957) (VIII) As	Number of Voting Rights held in each class of securities (IX)			No. of Shares Underlying Outstanding convertible securities (including Warrants) (X)	Shareholding, as a % assuming full conversion of convertible securities (as a percentage of diluted share capital) (XD) = (VII)+(X)	Number of Locked in shares (XII)		Number of Shares pledged or otherwise encumbered (XIII)		Number of equity shares held in dematerialised form (XIV)
							Class eg: X	Class eg: Y	Total			No. (a)	As a % of total Shares held(b)	No. (a)	As a % of total Shares held(b)	
(A)	Promoter & Promoter Group	7	250000	0	0	100	250000	0	250000	100	0	0	0	0	0	0
(B)	Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C)	Non Promoter - Non Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C1)	Shares Underlying DRs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C2)	Shares Held By Employee Trust	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Total	7	250000	0	0	100	250000	0	250000	100	0	0	0	0	0	0



(Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Table II - Statement showing shareholding pattern of the Promoter and Promoter Group

Category & Name of the shareholders (I)	Entity Type (II)	Nos. of share holders (III)	No. of fully paid up equity shares held (IV)	Partly paid-up equity shares (V)	No. of shares underlying Depository (VI)	Total nos. shares held (IV)+(V)+(VI)	Shareholding % calculate as per SCRR, a % of (VII)	Number of Voting Rights held in each class of securities (IX)			No. of Shares Underlying Outstanding (X)	Shareholding as a % assuming full (VII)+(X)	Number of Locked in shares (XII)		Number of Shares pledged or otherwise (XIII)		Number of equity shares held in demat (XIV)
								Class	Total	Total as a % of			No. (a)	As a % of total (b)	No. (a)	As a % of total (b)	
1																	
(a)	Indian Individuals / Hindu Undivided Family		6	6	0	6	6	0	6	0	0	0	0	0	0	0	0
	Mr. Sailesh Trambaklal Desai* (Jointly with Sun Pharma Laboratories Limited)		1	1	0	1	1	0	1	0	0	0	0	0	0	0	0
	Mr. Rakeshchandra Sinha * Jointly with Sun Pharma Laboratories Limited		1	1	0	1	1	0	1	0	0	0	0	0	0	0	0
	Mr. Kedarnath Senapati * Jointly with Sun Pharma Laboratories Limited		1	1	0	1	1	0	1	0	0	0	0	0	0	0	0
	Mr. Ashok I Bhuta * (Jointly with Sun Pharma Laboratories Limited)		1	1	0	1	1	0	1	0	0	0	0	0	0	0	0
	Mr. Anoop Deshpande * (Jointly with Sun Pharma Laboratories Limited)		1	1	0	1	1	0	1	0	0	0	0	0	0	0	0
(b)	Ms. Meetal Sampat * (Jointly with Sun Pharma Laboratories Limited)		1	1	0	1	1	0	1	0	0	0	0	0	0	0	0
(c)	Central Government / State Government(s)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(d)	Financial Institutions / Banks Any Other (Specify)		1	2,49,994	0	2,49,994	99.998	0	2,49,994	99.998	0	0	0	0	0	0	0
	Bodies Corporate		1	2,49,994	0	2,49,994	99.998	0	2,49,994	99.998	0	0	0	0	0	0	0
	Sun Pharma Laboratories Limited	Promoter	1	2,49,994	0	2,49,994	99.998	0	2,49,994	99.998	0	0	0	0	0	0	0
	Sub Total (A)(1)		7	2,50,000	0	2,50,000	100.000	0	2,50,000	100.000	0	0	0	0	0	0	0
2	Foreign Individuals (Non-Resident Individuals / Foreign Individuals) Government Institutions Foreign Portfolio Investor Any Other (Specify)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(a)			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(b)			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(c)			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(d)			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(e)			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sub Total (A)(2)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Total Shareholding Of Promoter And Promoter Group (A)=(A)(1)+(A)(2)		7	2,50,000	0	2,50,000	100	0	2,50,000	100	0	0	0	0	0	0	0

*Held for and on behalf of Sun Pharma Laboratories Limited (SPLL) as a nominee of SPLL.



Table III - Statement showing shareholding pattern of the Public shareholder

Category & Name of the shareholders	PAN	Nos. of shareholders	No. of fully paid up equity shares held	Partly paid-up equity shares held	shares underlying Depositor Receipts	Total nos. shares held	Weighted average cost per share (WACS) as per SCRR, 1957 As a % of face value	Number of Voting Rights held in each class			Total as a % of Voting Rights	Shares Underlying Outstanding	Assuming full conversion	Number of Locked In		As a % of total Shares held(b)	Number of shares held in dematerialised form	Sub-categorization of shares		
								No of Voting Rights	Class eg: X	Class eg: Y				Total	(X)			(XI)=	(XII)	(XIII)
1																				
(a) Institutions (Domestic)																				
(a) Mutual Fund																				
(b) Venture Capital Funds																				
(c) Alternate Investment Funds																				
(d) Banks																				
(e) Insurance Companies																				
(f) Provident Funds/Pension Funds																				
(G) Asset Reconstruction Companies																				
(h) Sovereign Wealth Funds																				
(i) NBFCs registered with RBI																				
(j) Other Financial Institutions																				
(k) Any Other (Specify)																				
(k) Sub Total (B)(1)																				
2																				
(a) Institutions (Foreign)																				
(a) Foreign Direct Investment																				
(b) Foreign Venture Capital Investors																				
(c) Sovereign Wealth Funds																				
(d) Foreign Portfolio Investors Category I																				
(e) Foreign Portfolio Investors Category II																				
(f) Overseas Depositor(s) (holding DRs) (balancing figure)																				
(g) Any Other (Specify)																				
(g) Foreign Institutional Investors																				
(h) Foreign Bank																				
(h) Sub Total (B)(2)																				
3																				
(a) Central Government/State Government(s)																				
(b) Central Government / President of India																				
(b) State Government / Governor																				
(c) Shareholding by Companies or Bodies Corporate where Central / State Government is a promoter																				
(c) Sub Total (B)(3)																				
4																				
(a) Non-Institutions																				
(a) Associate companies / Subsidiaries																				
(b) Directors and their relatives (excluding Independent Directors and non-Executive Directors)																				
(c) Key Managerial Personnel																				
(c) Relatives of promoters (other than 'immediate relatives' of promoters disclosed under 'Promoter and Promoter Group' category)																				
(d) Trusts where any person belonging to 'Promoter and Promoter Group' category is 'trustee', 'beneficiary', or 'author of the trust'																				
(e) Investor Education and Protection Fund (IEPF)																				
(e) i. Resident Individual holding nominal share capital up to Rs. 2 lakhs.																				
(e) ii. Resident individual holding nominal share capital in excess of Rs. 2 lakhs.																				
(f) Non Resident Indians (NRIs)																				
(g) Foreign Nationals																				
(h) Foreign Companies																				
(i) Bodies Corporate																				
(im) Any Other (Specify)																				
(i) Trusts																				
(i) Body Corp-Ltd Liability Partnership																				
(i) Hindu Undivided Family																				
(i) Clearing Member																				
(i) Overseas Bodies Corporate																				
(i) Sub Total (B)(4)																				
(i) Total Public Shareholding (B)= (B)(1)+(B)(2)+(B)(3)+(B)(4)																				



Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Table IV - Statement showing shareholding pattern of the Non Promoter- Non Public shareholder

Category & Name of the shareholders (I)	PAN (II)	Nos. of shareholders (III)	No. of fully paid up equity shares held (IV)	Partly paid up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Shareholding % calculated as per SCRR, 1957 As a % of (A+B+C2) (VII) As a %	Number of Voting Rights held in each class of securities		No. of Shares Underlying Outstanding convertible securities (including Warrants) (X)	Shareholding, as a % assuming full conversion of convertible securities (as a percentage of diluted share capital) (XI)=(VII)+(X)	Number of Locked in shares		Number of Shares pledged or otherwise encumbered (XIII)	Number of equity shares held in dematerialized form (XIV)
							No. of Voting Rights (IX)	Total % of (A+B+C)			No. (a)	As a % of total Shares held(b) (XII)		
1 Custodian/DR Holder Employee Benefit Trust / Employee Welfare Trust under SEBI (Share based Employee Benefits and Sweat Equity) Regulations, 2021 Total Non-Promoter- Non Public Shareholding (C)=(C1)+(C2)		0	0	0	0	0	0	0	0	0	0	0	0	0
2		0	0	0	0	0	0	0	0	0	0	0	0	0

Table V - Details of significant beneficial owners

Sr. No.	Name	Details of the SBO			Details of the registered owner			Details of holding/ exercise of right of the SBO in the				Date of creation / acquisition of significant beneficial interest		
		PAN	Passport No. in case of a foreign national	Nationality (Applicable in case of Any other is selected)	Name	PAN	Passport No. in case of a foreign national	Nationality (Applicable in case of Any other is selected)	Whether by virtue of:	Voting rights	Rights on distributable dividend or any other distribution		Exercise of control	Exercise of significant influence

Company is not listed

For Sun Pharmaceutical Medicare Limited



Rakeshchandra J. Sinha
Director
DIN: 07340998



Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Entity: SUN PHARMACEUTICAL MEDICARE LIMITED
2.	Scrip Code/Name of Scrip/Class of Security: Equity shares - Post shareholding pattern
3.	Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg. 31(1)(b)/Reg.31(1)(c)
	a. If under 31(1)(b) then indicate the report for Quarter ending
	b. If under 31(1)(c) then indicate date of allotment/extinguishment
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-

	Particulars	Yes*	No*
1	Whether the Listed Entity has issued any partly paid up shares?		No
2	Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
3	Whether the Listed Entity has any shares against which depository receipts are issued?		No
4	Whether the Listed Entity has any shares in locked-in?		No
5	Whether any shares held by promoters are pledge or otherwise encumbered?		No

* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding Convertible

Post Shareholding- Not applicable as the Company shall be dissolved upon the scheme becoming effective.

For Sun Pharmaceutical Medicare Limited



Rakeshchandra J. Sinha

Director

DIN: 07340998



Without PAN

Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Entity: Faststone Mercantile Company Private Limited
2.	Scrip Code/Name of Scrip/Class of Security: Equity shares - Pre shareholding pattern
3.	Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg. 31(1)(b)/Reg.31(1)(c) a. If under 31(1)(b) then indicate the report for Quarter ending b. If under 31(1)(c) then indicate date of allotment/extinguishment
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-

	Particulars	Yes*	No*
1	Whether the Listed Entity has issued any partly paid up shares?		No
2	Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
3	Whether the Listed Entity has any shares against which depository receipts are issued?		No
4	Whether the Listed Entity has any shares in locked-in?		No
5	Whether any shares held by promoters are pledge or otherwise encumbered?		No

* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding Convertible Securities/Warrants, depository receipts, locked-in shares, No of shares pledged or otherwise encumbered by promoters, as applicable, shall not be displayed at the time of dissemination on the Stock Exchange website. Also wherever there is 'No' declared by Listed Entity in above table the values will be considered as 'Zero' by default on submission of the format of holding of specified securities.



Faststone Mercantile Company Private Limited

Table I - Summary Statement holding of specified securities

Category	(I) Category of shareholder	(II) Nos. of share holders	(IV) No. of fully paid up equity shares held	(V) No. of Parity paid-up equity shares held	(VI) No. of shares underlying Depository Receipts	(VII) Total nos. shares held	(VIII) As calculated as per SCRR, 1957	(IX) Number of Voting Rights held in each class of securities			(X) No. of Shares Underlying Outstanding convertible securities (including Warrants)	(XI) Shareholding, as a % assuming full conversion of convertible securities (as a percentage of diluted share capital)	(XII) Number of Locked in shares		(XIII) Number of Shares pledged or otherwise encumbered		(XIV) Number of equity shares held in dematerialised form
								Class eg: X	Class eg: Y	Total			No. (a)	% of total Shares held(b)	No. (a)	% of total Shares held(b)	
(A)	Promoter & Promoter Group	7	10000	0	0	10000	100	10000	0	10000	100	0	0	0	0	0	0
(B)	Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C)	Non Promoter - Non Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C1)	Shares Underlying DRs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C2)	Shares Held By Employee Trust	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Total	7	10000	0	0	10000	100	10000	0	10000	100	0	0	0	0	0	0



Faststone Mercantile Company Private Limited
Table II - Statement showing shareholding pattern of the Promoter and Promoter Group

Category & Name of the shareholders (I)	Entity Type	PAN (II)	Nos. of share holders (III)	No. of fully paid up equity shares held (IV)	Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Shareholding % as per SCRR, 1957 As a % of (A+B+C2) (VIII) As a	Number of Voting Rights held in each class of securities (IX)			No. of Shares Underlying convertible securities (including Warrants) (X)	Shareholding, as a % assuming full conversion of convertible securities as a percentage of diluted share (XI)=	Number of Locked in shares (XII)		Number of Shares pledged or otherwise encumbered (XIII)		Number of equity shares held in dematerialised form (XIV)
								No. of Voting Rights	Class eg: X	Total Voting Rights			No. (a)	held(b)	No. (a)	held(b)	
1	Indian																
(a)	Individuals / Hindu Undivided Family		6	6	0	0	6	0	6	0	0	0	0	0	0	0	0
	Mr. Dilip Shrivastava * (Jointly with Sun Pharmaceutical Industries Limited)		1	1	0	0	0.01	1	0	1	0.01	0	0	0	0	0	0
	Mr. Sailesh Desai * (Jointly with Sun Pharmaceutical Industries Limited)		1	1	0	0	0.01	1	0	1	0.01	0	0	0	0	0	0
	Mr. Dinesh Desai * (Jointly with Sun Pharmaceutical Industries Limited)		1	1	0	0	0.01	1	0	1	0.01	0	0	0	0	0	0
	Mr. Anoop Deshpande * (Jointly with Sun Pharmaceutical Industries Limited)		1	1	0	0	0.01	1	0	1	0.01	0	0	0	0	0	0
	Mr. Ashok Bhuta * (Jointly with Sun Pharmaceutical Industries Limited)		1	1	0	0	0.01	1	0	1	0.01	0	0	0	0	0	0
	Mr. Sudhir Valia * (Jointly with Sun Pharmaceutical Industries Limited)		1	1	0	0	0.01	1	0	1	0.01	0	0	0	0	0	0
(b)	Central Government / State Government(s)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(c)	Financial Institutions / Banks		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(d)	Any Other (Specify)		1	9,994	0	0	99.94	9,994	0	9,994	99.94	0	0	0	0	0	0
	Bodies Corporate		1	9,994	0	0	99.94	9,994	0	9,994	99.94	0	0	0	0	0	0
	Sun Pharmaceutical Industries Limited	Promoter	1	9,994	0	0	99.94	9,994	0	9,994	99.94	0	0	0	0	0	0
	Sub Total (A)(1)		7	10000	0	0	100.00	10000	0	10000	100.00	0	0	0	0	0	0
2	Foreign																
(a)	Individuals (Non-Resident Individuals / Foreign Individuals)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(b)	Government		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(c)	Institutions		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(d)	Foreign Portfolio Investor		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(e)	Any Other (Specify)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sub Total (A)(2)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Total Shareholding Of Promoter And Promoter Group (A)= (A)(1)+(A)(2)		7	10000	0	0	100.00	10000	0	10000	100.00	0	0	0	0	0	0

*Held for and on behalf of Sun Pharmaceutical Industries Limited as a nominee of Sun Pharmaceutical Industries Limited



Table III - Statement showing shareholding pattern of the Public shareholder

Category & Name of the shareholders	PAN	Nos. of shareholders	No. of fully paid up equity shares held	Partly paid-up equity shares held	No. of shares underlying Depository Receipts	Shareholding % calculated as per SCRR, 1957 As amended (A+B+C2)	Number of Voting Rights held in each class of securities			No. of Shares Underlying convertible securities (including Warrants)	Shareholding, as a % assuming full conversion of convertible securities (as a percentage of diluted share capital)	Number of Locked in shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialised form	Sub-categorization of shares	
							No of Voting Rights Class eg: X, Y, Z					Total Rights	As a % of Total Shares held(b)	As a % of total Shares held(b)	As a % of total Shares held(b)			Sub-category
							Class eg: X	Class eg: Y	Class eg: Z									
1																		
(a) Institutions (Domestic)																		
(a) Mutual Fund																		
(b) Venture Capital Funds																		
(c) Alternate Investment Funds																		
(d) Banks																		
(e) Insurance Companies																		
(f) Provident Funds/ Pension Funds																		
(g) Asset Reconstruction Companies																		
(h) Sovereign Wealth Funds																		
(i) NBFCs registered with RBI																		
(j) Other Financial Institutions																		
(k) Any Other (Specify)																		
(l) Sub Total (B)(1)																		
2																		
(a) Institutions (Foreign)																		
(a) Foreign Direct Investment																		
(b) Foreign Venture Capital Investors																		
(c) Sovereign Wealth Funds																		
(d) Foreign Portfolio Investors Category I																		
(e) Foreign Portfolio Investors Category II																		
(f) Overseas Depositories(holding DRs) (balancing figure)																		
(g) Any Other (Specify)																		
(h) Foreign Institutional Investors																		
(i) Foreign Bank																		
(j) Sub Total (B)(2)																		
3																		
(a) Central Government/ State Government(s)																		
(b) Central Government / President of India																		
(c) State Government / Governor																		
(d) Shareholding by Companies or Bodies Corporate where Central / State Government is a promoter																		
(e) Sub Total (B)(3)																		
4																		
(a) Associate companies / Subsidiaries																		
(b) Directors and their relatives (excluding Independent Directors and nominee Directors)																		
(c) Key Managerial Personnel																		
(d) Relatives of promoters (other than 'immediate relatives' of promoters disclosed under 'Promoter and Promoter Group' category)																		
(e) Promoter Group' category is 'trustee', beneficiary', or 'author of the trust'																		
(f) Investor Education and Protection Fund (IEPF)																		
(g) i. Resident individual holding nominal share capital up to Rs. 2 lakhs.																		
ii. Resident individual holding nominal share capital in excess of Rs. 2 lakhs.																		
(h) Non Resident Indians (NRIs)																		
(i) Foreign Nationals																		
(j) Foreign Companies																		
(k) Bodies Corporate																		
(l) Any Other (Specify)																		
(m) Trusts																		
(n) Body Corp-Ltd Liability Partnership																		
(o) Hindu Undivided Family																		
(p) Clearing Member																		
(q) Overseas Bodies Corporate																		
(r) Sub Total (B)(4)																		
Total Public Shareholder (R)=																		



Faststone Mercantile Company Private Limited

Table IV - Statement showing shareholding pattern of the Non Promoter- Non Public shareholder

Category & Name of the shareholders	PAN	No. of equity shares held		No. of shares under Depository Receipts	Shareholding % calculated as per SCRR, 1957 As a % of (A+B+C2)	Number of Voting Rights held in each class of securities			Shares Underlying Outstanding convertible securities (including Warrants) (X)	Shareholding as a % assuming full conversion of securities (as a percentage of diluted share capital) (XI)=	Number of Locked in shares		Number of Shares pledged or otherwise encumbered		
		Nos. of shareholders (III)	Partly paid-up equity shares held (IV)			No of Voting Rights	Class eg: X	Class eg: Y			Total of (A+B+C)	No. (a)	No. (b)	No. (a)	No. (b)
1 Custodian/DR Holder		0	0	0	0	0	0	0	0	0	0	0	0	0	
2 Employee Benefit Trust / Employee Welfare Trust under SEBI (Share based Employee Benefits and Sweat Equity) Regulations, 2021 Total Non-Promoter- Non Public Shareholding (C)= (C1)+(C2)		0	0	0	0	0	0	0	0	0	0	0	0	0	

Faststone Mercantile Company Private Limited
Table V- Details of significant beneficial owners

Sr. No.	Details of the SBO				Details of the registered owner				Details of holding/ exercise of right of the SBO in the reporting company, whether direct or indirect*				Date of acquisition of significant beneficial interest	
	Name	PAN	Passport No. in case of a foreign national	Nationality (Applicable in case of Any other is)	Name	PAN	Passport No. in case of a foreign national	Nationality (Applicable in case of Any other is)	Whether by virtue of:					
									Shares	Voting rights	Exercise of control	Exercise of significant influence		Exercise of significant beneficial interest

Company is not listed

For Faststone Mercantile Company Private Limited



(Signature)

Rakeshchandra J. Sinha

Director

DIN: 07340998

Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Entity: Faststone Mercantile Company Private Limited
2.	Scrip Code/Name of Scrip/Class of Security: Equity shares - Post shareholding pattern
3.	Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg. 31(1)(b)/Reg.31(1)(c)
	a. If under 31(1)(b) then indicate the report for Quarter ending
	b. If under 31(1)(c) then indicate date of allotment/extinguishment
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-

	Particulars	Yes*	No*
1	Whether the Listed Entity has issued any partly paid up shares?		No
2	Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
3	Whether the Listed Entity has any shares against which depository receipts are issued?		No
4	Whether the Listed Entity has any shares in locked-in?		No
5	Whether any shares held by promoters are pledge or otherwise encumbered?		No

* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding

Post Shareholding- Not applicable as the Company shall be dissolved upon the scheme becoming effective.

For Faststone Mercantile Company Private Limited



(Handwritten Signature)

Rakeshchandra J. Sinha
 Director
 DIN: 07340998

Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Listed Entity: Realstone Multitrade Private Limited
2.	Scrip Code/Name of Scrip/Class of Security: Equity shares - Pre shareholding pattern
3.	Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg. 31(1)(b)/Reg.31(1)(c)
	a. If under 31(1)(b) then indicate the report for Quarter ending
	b. If under 31(1)(c) then indicate date of allotment/extinguishment
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-

Particulars	Yes*	No*
1 Whether the Listed Entity has issued any partly paid up shares?		No
2 Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
3 Whether the Listed Entity has any shares against which depository receipts are issued?		No
4 Whether the Listed Entity has any shares in locked-in?		No
5 Whether any shares held by promoters are pledge or otherwise encumbered?		No


* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding Convertible Securities/Warrants, depository receipts, locked-in shares, No of shares pledged or otherwise encumbered by promoters, as applicable, shall not be displayed at the time of dissemination on the Stock Exchange website. Also wherever there is 'No' declared by Listed Entity in above table the values will be considered as 'Zero' by default on submission of the format of holding of specified securities.



Realstone Multitrade Private Limited

Table 1 - Summary Statement holding of specified securities

Category (I)	Category of shareholder (II)	Nos. of shareholders (III)	No. of fully paid up equity shares held (IV)	No. of Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Total nos. shares held (VII) = (IV) + (V) + (VI)	Shareholding as a % of total no. of shares (calculated as per SCRR, 1957) (VIII) As a	Number of Voting Rights held in each class of securities (IX)			No. of Shares Underlying convertible securities (including Warrants) (X)	Shareholding as a % assuming full conversion of convertible securities (XI) =	Number of Locked in shares (XII)		Number of Shares pledged or otherwise encumbered (XIII)		Number of equity shares held in dematerialised form (XIV)
								No of Voting Rights (Class eg: X)	Class eg: Y	Total			No. (a)	As a % of total Shares held(b)	No. (a)	As a % of total Shares held(b)	
(A)	Promoter & Promoter Group	7	10000	0	0	10000	100	10000	0	10000	100	0	0	0	0	0	0
(B)	Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C)	Non Promoter - Non Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C1)	Shares Underlying DRs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C2)	Shares Held By Employee Trust	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Total	7	10000	0	0	10000	100	10000	0	10000	100	0	0	0	0	0	0



Realstone Multitrade Private Limited

Table II - Statement showing shareholding pattern of the Promoter and Promoter Group.

Category & Name of the shareholders	Entity Type	PAN	(II)	(III)	(IV)	(V)	(VI)	(VII) = Total nos. shares held	(VIII) As a % of (A+B+C2)	Number of Voting Rights held in each class of securities			No. of Shares Underlying convertible securities (including Warrants)	Shareholding, as a % assuming full conversion of convertible securities (as a percentage of diluted share capital)	Number of Locked in shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialised form
										Total as a % of Total Voting Rights					No. (a)	As a % of total Shares held	No. (a)	As a % of total Shares held	
										Class: X	Class: Y	Total							
1	Indian Individuals / Hindu Undivided Family																		
(a)	Mr. Dip Singhvi * (Jointly with Sun Pharmaceutical Industries Limited)			6	6	6	6	6	6	0	0	0	0	0	0	0	0	0	0
	Mr. Sudhir Vaia * (Jointly with Sun Pharmaceutical Industries Limited)			1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	Mr. Suresh Desai * (Jointly with Sun Pharmaceutical Industries Limited)			1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	Mr. Dinesh Desai * (Jointly with Sun Pharmaceutical Industries Limited)			1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	Mr. Ashok Bhatnagar * (Jointly with Sun Pharmaceutical Industries Limited)			1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	Mr. Meenal Sharda Sumpal * (Jointly with Sun Pharmaceutical Industries Limited)			1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
(b)	Central Government / State Government(s)			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(c)	Financial Institutions / Banks			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(d)	Any Other (Specific)			9,994	9,994	9,994	9,994	9,994	9,994	0	0	0	0	0	0	0	0	0	0
	Bodies Corporate			1	9,994	9,994	9,994	9,994	9,994	0	0	0	0	0	0	0	0	0	0
	Sun Pharmaceutical Industries L Promoter			1	9,994	9,994	9,994	9,994	9,994	0	0	0	0	0	0	0	0	0	0
	Sub Total (A)(1)			7	10000	10000	10000	10000	10000	0	0	0	0	0	0	0	0	0	0
2	Foreign Individuals (Non-Resident)																		
(a)	Individuals			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(b)	Government			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(c)	Institutions			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(d)	Foreign Portfolio Investor			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(e)	Any Other (Specific)			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sub Total (A)(2)			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Total Shareholding Of Promoter And Promoter Group (A) = (A)(1)+(A)(2)			7	10000	10000	10000	10000	10000	0	0	0	0	0	0	0	0	0	0

*Held for and on behalf of Sun Pharmaceutical Industries Limited as a nominee of Sun Pharmaceutical Industries Limited




Table IV - Statement showing shareholding pattern of the Non Promoter- Non Public shareholder


Category & Name of the shareholders (I)	PAN (II)	Nos. of share holders (III)	No. of fully paid up equity shares held (IV)	Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Total shares held (VII) = (IV)+(V)+(VI)	Shareholding % calculated as per SCRR, 1957 As a % of (A+B+C)	Number of Voting Rights held in each class of securities		No. of Voting Rights (IX) = (X)+(XI)+(XII)	No. of Shares Underlying Outstanding convertible securities (including (XIII))	Number of Locked in shares		Number of Shares pledged or otherwise encumbered	Number of equity shares held in dematerialised form (XIV)
								No. of Voting Rights in each class of securities (A)	Class eg: X			As a % of total Shares held(b)	As a % of total Shares held(b)		
1 Custodian/DR Holder		0	0	0	0	0	0	0	0	0	0	0	0	0	0
Employee Benefit Trust / Employee Welfare Trust under SEBI (Share based Employee Benefits and Sweat Equity) Regulations, 2021		0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Non-Promoter- Non Public Shareholding (C)= (C)(1)+(C)(2)		0	0	0	0	0	0	0	0	0	0	0	0	0	0

Table V- Details of significant beneficial owners

Sr. No.	Details of the SBO		Details of the registered owner				Details of holding/ exercise of right of the SBO in the reporting company, whether direct or indirect*			Date of creation / acquisition of significant beneficial interest
	Name	PAN	Passport No. in case of foreign national	Nation ality	Nation ality (Applicable in case of Any other is selected)	Passport No. in case of a foreign national	Nation ality (Applicable in case of Any other is selected)	Whether by virtue of: Voting rights, Rights on distributable dividend or any other distribution	Exercise of significant influence	
..										

Company is not listed

For Realstone Multitrade Private Limited



Signature

Prince Kalarickal Elias
Director
DIN: 07292533

Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Entity: Realstone Multitrade Private Limited
2.	Scrip Code/Name of Scrip/Class of Security: Equity shares - Post shareholding pattern
3.	Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg. 31(1)(b)/Reg.31(1)(c)
	a. If under 31(1)(b) then indicate the report for Quarter ending
	b. If under 31(1)(c) then indicate date of allotment/extinguishment
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-

	Particulars	Yes*	No*
1	Whether the Listed Entity has issued any partly paid up shares?		No
2	Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
3	Whether the Listed Entity has any shares against which depository receipts are issued?		No
4	Whether the Listed Entity has any shares in locked-in?		No
5	Whether any shares held by promoters are pledge or otherwise encumbered?		No

* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding

Post Shareholding- Not applicable as the Company shall be dissolved upon the scheme becoming effective.

For Realstone Multitrade Private Limited



(Handwritten Signature)

Prince Kalarickal Elias

Director

DIN: 07292533

Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Entity: Skisen Labs Private Limited
2.	Scrip Code/Name of Scrip/Class of Security: Equity shares - Pre shareholding pattern
3.	Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg. 31(1)(b)/Reg.31(1)(c)
	a. If under 31(1)(b) then indicate the report for Quarter ending
	b. If under 31(1)(c) then indicate date of allotment/extinguishment
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-

Particulars	Yes*	No*
1. Whether the Listed Entity has issued any partly paid up shares?		No
2. Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
3. Whether the Listed Entity has any shares against which depository receipts are issued?		No
4. Whether the Listed Entity has any shares in locked-in?		No
5. Whether any shares held by promoters are pledged or otherwise encumbered?		No

* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding Convertible Securities/Warrants, depository receipts, locked-in shares, No of shares pledged or otherwise encumbered by promoters, as applicable, shall not be displayed at the time of dissemination on the Stock Exchange website. Also wherever there is 'No' declared by Listed Entity in above table the values will be considered as 'Zero' by default on submission of the format of holding of specified securities.



Table I - Summary Statement holding of specified securities

Category (I)	Category of shareholder (II)	Nos. of shareholders (III)	No. of fully paid up equity shares held (IV)	No. of Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Total nos. shares held (VII) = (IV) + (V) + (VI)	Shareholding as a % of total no. of shares (calculated as per SCRR, 1957) (VIII) As	Number of Voting Rights held in each class of securities (IX)			No. of Shares Underlying Outstanding convertible securities (including Warrants) (X)	Shareholding, as a % assuming full conversion of convertible securities (as a percentage of diluted share capital) (XI) =	Number of Locked in shares (XII)		Number of Shares pledged or otherwise encumbered (XIII)		Number of equity shares held in dematerialised form (XIV)
								No of Voting Rights X	Class eg: y Class eg: y	Total Total			No. (a) No. (a)	As a % of total Shares As a % of total	No. (b) No. (b)	As a % of total Shares As a % of total	
(A)	Promoter & Promoter Group	7	16360000	0	0	16360000	100	16360000	0	16360000	100	0	0	0	0	0	0
(B)	Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C)	Non Promoter - Non Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C1)	Shares Underlying DRs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(C2)	Shares Held By Employee Trust	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Total	7	16360000	0	0	16360000	100	16360000	0	16360000	100	0	0	0	0	0	0



Table II - Statement showing shareholding pattern of the Promoter and Promoter Group

I	Category & Name of the shareholders (I)	Entity Type	PAN (II)	Nos. of shareholders (III)	No. of fully paid up equity shares held (IV)	Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Shareholding % as per SCRR, 1957 As a % of (A+B+C2) (VIII) As a	Number of Voting Rights held in each class of securities (IX)			No. of Shares Underlying Outstanding convertible securities (including Warrants) (X)	Shareholding % as a % assuming full conversion of convertible securities (XI) =	Number of Locked in shares (XII)		Number of Shares pledged or otherwise encumbered (XIII)		Number of equity shares held in dematerialised form (XIV)	
									Total nos. shares held (VII) =	No of Voting Rights (Class eg: X, Class eg: Y)				As a % of total Shares held (b)	No. (a) held (b)	As a % of total Shares held (b)	No. (a) held (b)		As a % of total Shares held (b)
										Total	Class								
(a)	Indian Individuals / Hindu Undivided Family			6	6	0	0	6	0	0	0	0	0	0	0	0	0	0	
	Mr. Dilip Shanghvi * (Jointly with Sun Pharmaceutical Industries Limited)			1	1	0	0	1	0	1	0	0	0	0	0	0	0	0	
	Mr. Sudhir Valia * (Jointly with Sun Pharmaceutical Industries Limited)			1	1	0	0	1	0	1	0	0	0	0	0	0	0	0	
	Mr. Suresh Desai * (Jointly with Sun Pharmaceutical Industries Limited)			1	1	0	0	1	0	1	0	0	0	0	0	0	0	0	
	Mr. Dinesh Desai * (Jointly with Sun Pharmaceutical Industries Limited)			1	1	0	0	1	0	1	0	0	0	0	0	0	0	0	
	Mr. Ashok Bhuta * (Jointly with Sun Pharmaceutical Industries Limited)			1	1	0	0	1	0	1	0	0	0	0	0	0	0	0	
	Mr. Anoop Deshpande * (Jointly with Sun Pharmaceutical Industries Limited)			1	1	0	0	1	0	1	0	0	0	0	0	0	0	0	
(b)	Central Government / State Government(s)			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
(c)	Financial Institutions / Banks			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
(d)	Any Other (Specify)			1	1,63,59,994	0	0	1,63,59,994	99.99996	1,63,59,994	0	1,63,59,994	99.99996	0	0	0	0	0	
	Bodies Corporate			1	1,63,59,994	0	0	1,63,59,994	99.99996	1,63,59,994	0	1,63,59,994	99.99996	0	0	0	0	0	
	Promoter			1	1,63,59,994	0	0	1,63,59,994	99.99996	1,63,59,994	0	1,63,59,994	99.99996	0	0	0	0	0	
	Sun Pharmaceutical Industries Limited			7	1,63,60,000	0	0	1,63,60,000	100.00000	1,63,60,000	0	1,63,60,000	100.00000	0	0	0	0	0	
2	Foreign Individuals (Non-Resident Individuals / Foreign Individuals)			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
(a)	Government			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
(b)	Institutions			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
(c)	Foreign Portfolio Investor			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
(d)	Any Other (Specify)			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
(e)	Sub Total (A)(2)			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Total Shareholding Of Promoter And Promoter Group (A) = (A)(1)+(A)(2)			7	1,63,60,000	0	0	1,63,60,000	100	1,63,60,000	0	1,63,60,000	100	0	0	0	0	0	



*Held for and on behalf of Sun Pharmaceutical Industries Limited as a nominee of Sun Pharmaceutical Industries Limited

Table III - Statement showing shareholding pattern of the Public shareholder

Sl. No.	Category & Name of the shareholders (I)	Nos. of shareholders (II)	No. of fully paid up equity shares held (IV)	Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Shareholding % calculated as per SCRR, 1957 As a % of (A+B+C2) (VIII) As (VII) =	Number of Voting Rights held in each class of securities (IX)			No. of Shares Underlying convertible securities (including Warrants) (X)	Shareholding, as a % assuming full conversion of convertible securities (as a percentage of diluted share capital) (XI) = (VII)+(X)	Number of Shares pledged or otherwise (XIII)		Sub-categorization of shares under SIP- category (ii) (iii) (XV)					
							Total as a % of Total Voting Rights		No. (a)			As a % of total Shares held (b)	No. (a)	As a % of total Shares held (b)	SIP- category (ii)	SIP- category (iii)			
							No. of Class e.g. Y	Class e.g. X									Locked in shares No. (a)	As a % of total Shares held (b)	Number of equity shares held in dematerialised form (i)
1	Institutions (Domestic)																		
(a)	Mutual Fund																		
(b)	Venture Capital Funds																		
(c)	Alternate Investment Funds																		
(d)	Banks																		
(e)	Insurance Companies																		
(f)	Provident Funds/ Pension Funds																		
(g)	Asset Reconstruction Companies																		
(h)	Sovereign Wealth Funds																		
(i)	NBFCs registered with RBI																		
(j)	Other Financial Institutions																		
(k)	Any Other (Specify)																		
(l)	Sub Total (B)(1)																		
2	Institutions (Foreign)																		
(a)	Foreign Direct Investment																		
(b)	Foreign Venture Capital Investors																		
(c)	Sovereign Wealth Funds																		
(d)	Foreign Portfolio Investors Category I																		
(e)	Foreign Portfolio Investors Category II																		
(f)	Overseas Depositories/holding (DRs) (balancing figure)																		
(g)	Any Other (Specify)																		
(h)	Foreign Institutional Investors																		
(i)	Foreign Bank																		
(j)	Sub Total (B)(2)																		
3	Central Government/ State Government(s)																		
(a)	Central Government / President of India																		
(b)	State Government / Governor																		
(c)	Shareholding by Companies or Bodies Corporate where Central / State Government is a promoter																		
(d)	Sub Total (B)(3)																		
4	Non-Institutions																		
(a)	Associate companies / Subsidiaries																		
(b)	Directors and their relatives (excluding Independent Directors and nominee Directors)																		
(c)	Key Managerial Personnel																		
(d)	Relatives of promoters (other than 'immediate relatives' of promoters disclosed under 'Promoter and Promoter Group' category)																		
(e)	Trusts where any person belonging to 'Promoter and Promoter Group' category is 'trustee', 'beneficiary', or 'author of the trust'																		
(f)	Investor Education and Protection Fund (IEPF)																		
(g)	i. Resident Individual holding nominal share capital up to Rs. 2 lakhs.																		
(h)	ii. Resident individual holding nominal share capital in excess of Rs. 2 lakhs.																		
(i)	Non Resident Indians (NRIs)																		
(j)	Foreign Nationals																		
(k)	Foreign Companies																		
(l)	Bodies Corporate																		
(m)	Any Other (Specify)																		
(n)	Trusts																		
(o)	Body Corp-Ltd Liability Partnership																		
(p)	Hindu Undivided Family																		
(q)	Clearing Member																		
(r)	Overseas Bodies Corporates																		
(s)	Sub Total (B)(4)																		



Table IV - Statement showing shareholding pattern of the Non Promoter- Non Public shareholder

Sr. No.	Category & Name of the shareholders	PAN	Nos. of shareholders (III)	No. of fully paid up equity shares held (IV)	Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Shareholding % calculated as per SCRR, 1957 As a % of (A+B+C2)	Number of Voting Rights held in each class of securities			Shares Underlying Outstanding convertible securities (including Warrants) (X)	Holding, as a % assuming full conversion of convertible securities (as a % of total Shares held(b) (XI)= (X)/(XI)=	Number of Locked in shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialised form (XIV)
								No of Voting Rights	Class eg: X	Total (IX)			No. (a)	As a % of total Shares held(b) (XII)	No. (a)	As a % of total Shares held(b) (XIII)	
1	Custodian/DR Holder	(II)	0	0	0	0	(VII) = (VIII) As	0	0	0	0	0	0	0	0	0	0
2	Employee Benefit Trust / Employee Welfare Trust under SEBI (Share based Employee Benefits and Sweat Equity) Regulations, 2021		0	0	0	0		0	0	0	0	0	0	0	0	0	0
	Total Non-Promoter- Non Public Shareholding (C)= (C)(1)+(C)(2)		0	0	0	0		0	0	0	0	0	0	0	0	0	0

Table V- Details of significant beneficial owners

Sr. No.	Name	Details of the SBO		Details of the registered owner			Details of holding/ exercise of right of			Date of creation / acquisition of significant beneficial interest	
		PAN	Passport No. in case of a foreign national	Nationality	Passport No. in case of a foreign national	Nationality (Applicable in case of other is selected)	Shares	Voting rights	Whether by virtue of:		Exercise of significant influence
		PAN									

Company is not listed

For Skisen Labs Private Limited



Prince Kalarickal Elias

Director

DIN: 07292533

Shareholding Pattern under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1.	Name of Entity: Skisen Labs Private Limited
2.	Scrip Code/Name of Scrip/Class of Security: Equity shares - Post shareholding pattern
3.	Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg. 31(1)(b)/Reg.31(1)(c) a. If under 31(1)(b) then indicate the report for Quarter ending b. If under 31(1)(c) then indicate date of allotment/extinguishment
4.	Declaration: The Listed entity is required to submit the following declaration to the extent of submission of information:-

Particulars	Yes*	No*
1 Whether the Listed Entity has issued any partly paid up shares?		No
2 Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
3 Whether the Listed Entity has any shares against which depository receipts are issued?		No
4 Whether the Listed Entity has any shares in locked-in?		No
5 Whether any shares held by promoters are pledge or otherwise encumbered?		No

* If the Listed Entity selects the option 'No' for the questions above, the columns for the partly paid up shares, Outstanding

Post Shareholding- Not applicable as the Company shall be dissolved upon the scheme becoming effective.

For Skisen Labs Private Limited



Prince Kalarickal Elias

Prince Kalarickal Elias

Director

DIN: 07292533

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050

**Compliance Report to be submitted along with the draft scheme**

It is hereby certified that the draft Composite Scheme of Arrangement involving (a) Amalgamation of Wholly-owned subsidiary companies viz. Sun Pharmaceutical Medicare Limited, Green Eco Development Centre Limited, Faststone Mercantile Company Private Limited, Realstone Multitrade Private Limited, Skisen Labs Private Limited with Sun Pharmaceutical Industries Limited (“Company”), and (b) Reclassification of General Reserves of the Company to Retained Earnings, does not, in any way violate, override or limit the provisions of securities laws or requirements of the Stock Exchange(s) and the same is in compliance with the applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and this circular, including the following:

Sr. No.	Reference	Particulars	Whether complied or not
1	Regulations 17 to 27 of LODR Regulations	Corporate governance requirements	Complied
2	Regulation 11 of LODR Regulations	Compliance with securities laws	Complied
Requirements of the SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20 2023			
(a)	Para (A)(2) of Part-I	Submission of documents to Stock Exchanges	Complied
(b)	Para (A)(3) of Part-I	Conditions for schemes of arrangement involving unlisted entities	Complied to the extent applicable.
(c)	Para (A)(4)(a) of Part-I	Submission of Valuation Report	Not Applicable, as the Transferor Companies are Wholly-owned Subsidiary Companies of the Transferee Company, hence no consideration in form of shares or otherwise is envisaged pursuant to the Scheme.
(d)	Para (A)(5) of Part-I	Auditors certificate regarding compliance with Accounting Standards	Complied

Registered Office: SPARC, Tandajja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



(e)	Para (A)(10) of Part-I	Provision of approval of public shareholders through e-voting	Not Applicable
-----	------------------------	---	----------------

(Anoop Deshpande)
Company Secretary & Compliance Officer
ICSI Membership No.: A23983

(Dilip Shanghvi)
Managing Director
DIN-00005588

Certified that the transactions/ accounting treatment provided in the draft Composite Scheme of Arrangement involving (a) Amalgamation of Wholly-owned subsidiary companies viz. Sun Pharmaceutical Medicare Limited, Green Eco Development Centre Limited, Faststone Mercantile Company Private Limited, Realstone Multitrade Private Limited, Skisen Labs Private Limited with the Company, and (b) Reclassification of General Reserves of the Company to Retained Earnings, are in compliance with all the Accounting Standards applicable to a listed entity.

(C. S. Muralidharan)
Chief Financial Officer

(Dilip Shanghvi)
Managing Director
DIN-00005588

Date: November 30, 2023



Sun Pharmaceutical Industries Limited
 Sun House, Plot No. 201 B/1,
 Western Express Highway, Goregaon (E),
 Mumbai – 400 063, Maharashtra, INDIA.
 Tel. : (91-22) 4324 4324
 Fax : (91-22) 4324 4343
 Website: www.sunpharma.com
 Email: secretarial@sunpharma.com
 CIN: L24230GJ1993PLC019050

Brief particulars of the transferee and transferor companies

Particulars	Transferee/ Resulting Company	Transferor Companies				
		Transferor Company No. 1	Transferor Company No. 2	Transferor Company No. 3	Transferor Company No. 4	Transferor Company No. 5
Name of the company	Sun Pharmaceutical Industries Limited	Sun Pharmaceutical Medicare Limited	Green Eco Development Centre Limited	Faststone Mercantile Company Private Limited	Realstone Multitrade Private Limited	Skisen Labs Private Limited
Date of Incorporation & details of name changes, if any	March 01, 1993	January 16, 2017	November 12, 2010	January 25, 2006	January 16, 2006	January 13, 2005
Registered Office	SPARC, Tandajla, Vadodara - 390012, Gujarat, India	SPARC, Tandajla, Vadodara – 390012, Gujarat, India	Plot No. 4708, GIDC Estate Ankleshwar Bharuch - 393002, Gujarat, India	SPARC, Tandajla, Vadodara – 390012, Gujarat, India	SPARC, Tandajla, Vadodara – 390012, Gujarat, India	SPARC, Tandajla, Vadodara – 390012, Gujarat, India
Brief particulars of the scheme	Composite Scheme of Arrangement (“Scheme”) covering: 1. Amalgamation of Sun Pharmaceutical Medicare Limited, Green Eco Development Centre Limited, Faststone Mercantile Company Private Limited, Realstone Multitrade Private Limited and Skisen Labs Private Limited [hereinafter referred to as “Transferor Companies”] with Sun Pharmaceutical Industries Limited [hereinafter referred to as “Transferee Company”]; and 2. Reclassification of General Reserve of Transferee Company to the Retained Earnings of the Transferee Company.					



Registered Office: SPARC, Tandajla, Vadodara – 390 012, Gujarat, INDIA.
 Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited
 Sun House, Plot No. 201 B/1,
 Western Express Highway, Goregaon (E),
 Mumbai – 400 063, Maharashtra, INDIA.
 Tel. : (91-22) 4324 4324
 Fax : (91-22) 4324 4343
 Website: www.sunpharma.com
 Email: secretarial@sunpharma.com
 CIN: L24230GJ1993PLC019050



Rationale for the scheme	1. Rationale for Amalgamation of Transferor Companies with Transferee Company All Transferor Companies are wholly-owned subsidiaries of the Transferee Company. The amalgamation of Transferor Companies with Transferee Company would <i>inter alia</i> have the following benefits: (a) Greater efficiency in overall combined business including economies of scale, efficiency of operations, efficient cash flow management eliminating inter-corporate dependencies. (a) Optimum utilisation of resources by pooling in the managerial, technical and administrative resources and efforts. (b) Reduction in legal and regulatory compliance enabling better compliance efficiency at the consolidated level. (c) Certain pharmaceutical products manufactured by one of the transferor company i.e. SPML are sold in the regulated markets are exported through Transferee Company and this amalgamation would further help in consolidation of exports.	2. Rationale for reclassification and transfer of the General Reserve of the Transferee Company to Retained Earnings	Over the years, the Transferee Company has built up significant reserves through transfer of profits to the general reserve in accordance with provisions of the erstwhile Companies Act, 1956 and erstwhile rules notified thereunder, namely, the Companies (Transfer of Profits to Reserves) Rules, 1975. While the excess reserves can be profitably utilized for the Company's overall growth strategy, the Board of Directors of the Transferee Company is of the view that even after considering the foreseeable investments required for such opportunities over the next few years, the fund represented by the General Reserve are in excess of the Transferee Company's current and anticipated operational needs.
Date of resolution passed by the Board of Director of the company approving the scheme	November 1, 2023	October 30, 2023	October 30, 2023
Date of meeting of the Audit Committee in which the draft scheme has been approved	October 31, 2023	NA	NA
	NA	NA	NA
	NA	NA	NA
	NA	NA	NA
	NA	NA	NA
	NA	NA	NA
	NA	NA	NA
	NA	NA	NA
	NA	NA	NA
	NA	NA	NA



Registered Office: SPARC, Tandaija, Vadodara – 390 012, Gujarat, INDIA.
 Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited
 Sun House, Plot No. 201 B/1,
 Western Express Highway, Goregaon (E),
 Mumbai – 400 063, Maharashtra, INDIA.
 Tel. : (91-22) 4324 4324
 Fax : (91-22) 4324 4343
 Website: www.sunpharma.com
 Email: secretarial@sunpharma.com
 CIN: L24230GJ1993PLC019050



Appointed Date		April 1, 2023					
Name of Exchanges where securities of the company are listed	1- National Stock Exchange of India Limited 2- BSE Limited	NA	NA	NA	NA	NA	NA
Nature of Business/main objects	It is engaged in the business of development, manufacture, marketing, sale, trading and export of various pharmaceutical products.	It is primarily engaged in the business of manufacturing and marketing of pharmaceutical products.	The main objects of the Company are to carry out the business of disposal of industrial wastes.	The main objects of the Company are to carry out the business of trading in various products.	The main objects of the Company are to carry out the business of trading in various products.	The main objects of the Company are to carry out the business of trading in various products.	The main objects of the Company are to carry out R&D for pharmaceutical business.
Capital before the scheme (No. of equity shares as well as capital in rupees)	2,399,334,970 fully-paid up equity shares of face value of INR 1/- each	250,000 equity shares of face value of INR 10/- each	700,000 equity shares of face value of INR 10/- each	10,000 equity shares of face value of INR 10/- each	10,000 equity shares of face value of INR 10/- each	10,000 equity shares of face value of INR 10/- each	16,360,000 fully-paid up equity shares of face value of INR 10/- each
No. of shares to be issued	NIL						
Cancellation of shares on account of cross holding, if any	The investments in the shares of the Transferor Companies appearing in the books of accounts of the Transferee Company or other subsidiary companies of the Transferee Company shall, without any further act, deed or instrument, stand cancelled.						



Registered Office: SPARC, Tandajia, Vadodara – 390 012, Gujarat, INDIA.
 Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited
 Sun House, Plot No. 201 B/1,
 Western Express Highway, Goregaon (E),
 Mumbai – 400 063, Maharashtra, INDIA.
 Tel. : (91-22) 4324 4324
 Fax : (91-22) 4324 4343
 Website: www.sunpharma.com
 Email: secretarial@sunpharma.com
 CIN: L24230GJ1993PLC019050



Capital after the scheme (No. of equity shares as well as capital in rupees)	2,399,334,970 fully-paid up equity shares of face value of INR 1/- each amounting to Rs. 2,399,334,970 (There will be no change in shareholding post Scheme)	Nil	Nil	Nil	Nil	Nil
Net Worth (Standalone)	(Rs. in Million)	(Rs. in Million)	(Rs. in Million)	(Rs. in Million)	(Rs. in Million)	(Rs. in Million)
Pre	193,617.2	(3,382.0)	1.3	3.3	2.3	(0.5)
Post	190,231.9	Nil	Nil	Nil	Nil	Nil
Valuation independent Chartered Accountant – Name of the valuer/valuer firm and Regn no.	Upon the Scheme becoming effective, no shares of the Transferee Company shall be issued and allotted in lieu of shares held by it or its subsidiary companies in the Transferor Companies and the entire paid-up share capital of the Transferor Companies shall be cancelled and extinguished without any further act, deed or instrument as an integral part of this Scheme, there will be no change in the shareholding pattern of the Transferee Company. In view of the same, the valuation report from a Registered Valuer in terms of Para (A)(4)(b) of Part-I of the SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023 and fairness opinion by Merchant Banker are not applicable to the Scheme referred above.					
Methods of valuation and value per share arrived under each method with weight given to each method, if any.	NA					



Registered Office: SPARC, Tandajia, Vadodara – 390 012, Gujarat, INDIA.
 Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited
 Sun House, Plot No. 201 B/1,
 Western Express Highway, Goregaon (E),
 Mumbai – 400 063, Maharashtra, INDIA.
 Tel. : (91-22) 4324 4324
 Fax : (91-22) 4324 4343
 Website: www.sunpharma.com
 Email: secretarial@sunpharma.com
 CIN: L24230GJ1993PLC019050



Fair value per shares	NA		
Exchange ratio	NA		
Name of Merchant Banker giving fairness opinion	NA		
Shareholding pattern	Pre	Post	% of holding
	No. of Shares	No. of Shares	
Promoter	As per the annexure-5(b)		
Public			
Custodian			
TOTAL			
No of shareholders			
Names of the Promoters (with PAN nos.)	As per annexure - 13		
Names of the Board of Directors (with DIN and PAN nos.)	As per Annexure - 13		
Please specify relation among the companies involved in the scheme, if any	The Transferor Companies are Wholly-owned Subsidiaries of the Transferee Company		



Registered Office: SPARC, Tandaija, Vadodara – 390 012, Gujarat, INDIA.
 Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited
Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



Details regarding change in management control in listed or resulting company seeking listing if any

None

For Sun Pharmaceutical Industries Limited



Anoop

(Anoop Deshpande)

Company Secretary and Compliance Officer

ICSI Membership No. A23983

December 07, 2023

(e)	Any Others	6	0	6	0	6	0	6	0	6	0	40507976	1.69	40507976	1.69
	Sub Total(A)(1)	250,000	100	700000	100	10000	100	10000	100	16360000	100	1307134535	54.48	1307134535	54.48
2	Foreign														
(a)	Individuals (Non-Residents Individuals/ Foreign Individuals)	0	0	0	0	0	0	0	0	0	0				
(b)	Bodies Corporate	0	0	0	0	0	0	0	0	0	0				
(c)	Institutions	0	0	0	0	0	0	0	0	0	0				
(d)	Any Others	0	0	0	0	0	0	0	0	0	0				
	Sub Total(A)(2)	0	0	0	0	0	0	0	0	0	0				
	Total Shareholding of Promoter and Promoter Group (A)= (A)(1)+(A)(2)	250,000	100	700000	100	10000	100	10000	100	16360000	100	1307134535	54.48	1307134535	54.48
(B)	Public shareholding														
1	Institutions														
(a)	Mutual Funds/ UTI	0	0	0	0	0	0	0	0	0	0	313620260	13.07	313620260	13.07
(b)	Financial Institutions / Banks	0	0	0	0	0	0	0	0	0	0	2569482	0.11	2569482	0.11
(c)	Central Government/ State Government(s)	0	0	0	0	0	0	0	0	0	0	12916	0	12916	0

(d)	Venture Capital Funds	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(e)	Insurance Companies	0	0	0	0	0	0	0	0	0	0	121473840	5.06	121473840	5.06
(f)	Foreign Institutional Investors	0	0	0	0	0	0	0	0	0	0	402806000	16.79	402806000	16.79
(g)	Foreign Venture Capital Investors	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(h)	Any Other	0	0	0	0	0	0	0	0	0	0	342522939	1.43	342522939	1.43
	Sub-Total (B)(1)	0	0	0	0	0	0	0	0	0	0	748005530	36.46	748005530	36.46
2	Non-institutions														
(a)	Bodies Corporate	0	0	0	0	0	0	0	0	0	0	51640746	2.15	51640746	2.15
(b)	Individuals	0	0	0	0	0	0	0	0	0	0	0	0	0	0
I	Individuals -i. Individual shareholders holding nominal share capital up to Rs 2 lakh	0	0	0	0	0	0	0	0	0	0	112334071	4.68	112334071	4.68
II	ii. Individual shareholders holding nominal share capital in excess of Rs. 2 lakh.	0	0	0	0	0	0	0	0	0	0	20958889	0.87	20958889	0.87
(c)	Any Other	0	0	0	0	0	0	0	0	0	0	32531292	1.36	32531292	1.36

	Sub-Total (B)(2)	0	0	0	0	0	0	0	0	0	0	217464998	9.06	217464998	9.06
(B)	Total Public Shareholding (B)= (B)(1)+(B)(2)	0	0	0	0	0	0	0	0	0	0	1092212435	45.52	1092212435	45.52
	TOTAL (A)+(B)	250,000	100	700000	100	10000	100	10000	100	1636000	100	2399334970	100.00	2399334970	100.00
(C)	Shares held by Custodians and against which DRs have been issued	0	0	0	0	0	0	0	0	0	0	0		0	
	GRAND TOTAL (A)+(B)+(C)	250,000	100	700000	100	10000	100	10000	100	1636000	100	2399334970	100.00	2399334970	100.00

For Sun Pharmaceutical Industries Limited

Anoop D.



(Anoop Deshpande)
Company Secretary & Compliance Officer
 ICSI Membership No.: A23983

Encl above:

Sun Pharmaceutical Medicare Limited

Registered Office. SPARC, Tandalja,
Vadodara-390 012, India.
CIN U36900GJ2017PLC095132
Tel : 0265-6615500
Fax : 0265-2354897

**LIST OF EQUITY SHAREHOLDERS AS ON MARCH 31, 2023**

SR. NO.	NAME OF SHAREHOLDER	NUMBER OF SHARES	TOTAL AMOUNT	%HOLDING
1	Sun Pharma Laboratories Limited	249994	2499940	100.00
2	Mr. Sailesh Trambaklal Desai Jointly with and as a nominee of Sun Pharma Laboratories Limited	1	10	0.00
3	Mr. Rakeshchandra Sinha Jointly with and as a nominee of Sun Pharma Laboratories Limited	1	10	0.00
4	Mr. Kedarnath Senapati Jointly with and as a nominee of Sun Pharma Laboratories Limited	1	10	0.00
5	Mr. Ashok I Bhuta Jointly with and as a nominee of Sun Pharma Laboratories Limited	1	10	0.00
6	Mr. Anoop Deshpande Jointly with and as a nominee of Sun Pharma Laboratories Limited	1	10	0.00
7	Ms. Meetal Sampat Jointly with and as a nominee of Sun Pharma Laboratories Limited	1	10	0.00
Total		250000	2500000	100.00

For Sun Pharmaceutical Medicare Limited

A handwritten signature in black ink, appearing to read "A I Bhuta".

Ashok I. Bhuta
Director
DIN:00065307




Registered Office:
Plot No.: 4708, G.I.D.C. Estate,
Ankleshwar, Bharuch - 393002, Gujarat.
CIN: U90009GJ2010PLC062892

List of Equity Shareholders of Green Eco development Centre Limited as on March 31, 2023

Sr. No	Name of the Shareholder	No. of shares held	Total Amount	% of holding
1.	Sun Pharmaceutical Industries Limited	6,99,994	6,99,9940	100.00
2.	Dilip S. Shanghvi* jointly with Sun Pharmaceutical Industries Limited	1.00	10	0.00
3.	Sailesh T. Desai* jointly with Sun Pharmaceutical Industries Limited	1.00	10	0.00
4.	Dinesh Desai* jointly with Sun Pharmaceutical Industries Limited	1.00	10	0.00
5.	Kedarnath Senapati* jointly with Sun Pharmaceutical Industries Limited	1.00	10	0.00
6.	Ashok Bhuta* jointly with Sun Pharmaceutical Industries Limited	1.00	10	0.00
7.	Sudhir Valia* jointly with Sun Pharmaceutical Industries Limited	1.00	10	0.00
	Total	7,00,000.00	70,00,000	100.00

*Held for and on behalf of Sun Pharmaceutical Industries Limited as a nominee of Sun Pharmaceutical Industries Limited

For **Green Eco Development Centre Limited**


Rakeshchandra Sinha
Director
DIN: 07340998

Correspondence Address: Plot No. 24/2 & 25, Phase IV, G.I.D.C., Panoli - 394116,
Dist. Bharuch, Gujarat.
Tel.: +91-2646-272363 / 272534. Fax: +91 - 2646-272541.

FASTSTONE MERCANTILE COMPANY PRIVATE LIMITED

Regd office: Sun Pharma Advanced Research Centre (SPARC), Tandalja, Vadodara, Gujarat, India, 390 012
CIN - U51900GJ2006PTC133844, Tel.: 0265-6615500

LIST OF EQUITY SHAREHOLDERS AS ON MARCH 31, 2023

SR. NO.	NAME	NUMBER OF SHARES	TOTAL AMOUNT	%HOLDING
1	Sun Pharmaceutical Industries Ltd.	9994	99940	99.94%
2	Dilip Shanghvi* jointly with Sun Pharmaceutical Industries Ltd.	1	10	0.01%
3	Sailesh Desai* jointly with Sun Pharmaceutical Industries Ltd.	1	10	0.01%
4	Dinesh Desai* jointly with Sun Pharmaceutical Industries Ltd.	1	10	0.01%
5	Anoop Deshpande* jointly with Sun Pharmaceutical Industries Ltd.	1	10	0.01%
6	Ashok Bhuta* jointly with Sun Pharmaceutical Industries Ltd.	1	10	0.01%
7	Sudhir Valia* jointly with Sun Pharmaceutical Industries Ltd.	1	10	0.01%
		10000	100000	100.00%

Note : *Held for and on behalf of Sun Pharmaceutical Industries Limited as a nominee of Sun Pharmaceutical Industries Limited.

For Faststone Mercantile Company Private Limited



Rakesh Sinha
Director
DIN:07340998

REALSTONE MULTITRADE PRIVATE LIMITED

Regd. office: Sun Pharma Advanced Research Centre (SPARC), Tandalja, Vadodara - 390012, Gujarat
CIN - U51900GJ2006PTC133238, Tel No.: 0265-6615500/600/700

LIST OF EQUITY SHAREHOLDERS OF REALSTONE MULTITRADE PRIVATE LIMITED AS ON 31ST MARCH, 2023

Sr. No.	Name of Equity Shareholders	Number of Shares of Rs. 10 each held	Total Amount	% Holding
1	Sun Pharmaceutical Industries Ltd.	9,994	99,940	99.94
2	Dilip Shanghvi* Jointly with Sun Pharmaceutical Industries Ltd.	1	10	0.01
3	Sudhir Valia* Jointly with Sun Pharmaceutical Industries Ltd.	1	10	0.01
4	Sailesh Desai* Jointly with Sun Pharmaceutical Industries Ltd.	1	10	0.01
5	Dinesh Desai* Jointly with Sun Pharmaceutical Industries Ltd.	1	10	0.01
6	Ashok Bhuta* Jointly with Sun Pharmaceutical Industries Ltd.	1	10	0.01
7	Meetal Sharad Sampat* Jointly with Sun Pharmaceutical Industries Ltd.	1	10	0.01
	Total	10,000	100,000	100.00

*Held for and on behalf of Sun Pharmaceutical Industries Limited as a nominee of Sun Pharmaceutical Industries Limited.



SKISEN LABS PRIVATE LIMITED

Regd. office: Acme Plaza, Andheri-Kurla Road, Andheri (East), Mumbai – 400 059, Maharashtra
CIN - U73100MH2005PTC150606, Tel No.: 022-42244224

LIST OF EQUITY SHAREHOLDERS OF SKISEN LABS PRIVATE LIMITED AS ON 31ST MARCH, 2023

Sr. No.	Name of Equity Shareholders	Number of Shares of Rs.10 each held	Total Amount	% Holding
1	Sun Pharmaceutical Industries Ltd.	1,63,59,994	16,35,99,940	100.00
2	Dilip Shanghvi* Jointly with Sun Pharmaceutical Industries Ltd.	1	10	0.00
3	Sudhir Valia* Jointly with Sun Pharmaceutical Industries Ltd.	1	10	0.00
4	Sailesh Desai* Jointly with Sun Pharmaceutical Industries Ltd.	1	10	0.00
5	Dinesh Desai* Jointly with Sun Pharmaceutical Industries Ltd.	1	10	0.00
6	Ashok Bhuta* Jointly with Sun Pharmaceutical Industries Ltd.	1	10	0.00
7	Anoop Deshpande * Jointly with Sun Pharmaceutical Industries Ltd.	1	10	0.00
	TOTAL	1,63,60,000	16,36,00,000	100.00

**Held for and on behalf of Sun Pharmaceutical Industries Limited as a nominee of Sun Pharmaceutical Industries Limited.*



Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



December 7, 2023

BSE Limited,
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai - 400 001.

Dear Sir / Madam,

Sub: Application under Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023, for the proposed Composite Scheme of Arrangement

With reference to the above application, please find below the detailed note in respect of the scheme is beneficial for the stakeholders of the Company:

The Composite Scheme of Arrangement (herein after referred to as “Scheme of Arrangement” or “Scheme”), involving:

- a) Amalgamation of Wholly-owned subsidiary companies viz. Sun Pharmaceutical Medicare Limited, Green Eco Development Centre Limited, Faststone Mercantile Company Private Limited, Realstone Multitrade Private Limited, Skisen Labs Private Limited (“Transferor Companies”) with Sun Pharmaceutical Industries Limited (“Transferee Company” or “the Company”), and
- b) Reclassification of General Reserve of the Company to Retained Earnings.

Rationale for the Scheme

1. Rationale for Amalgamation of Transferor Companies with Transferee Company

All Transferor Companies are wholly-owned subsidiaries of the Transferee Company. The amalgamation of Transferor Companies with Transferee Company would *inter alia* have the following benefits:

- (a) Greater efficiency in overall combined business including economies of scale, efficiency of operations, efficient cash flow management eliminating inter-corporate dependencies.
- (b) Optimum utilisation of resources by pooling in the managerial, technical and administrative resources and efforts.
- (c) Reduction in legal and regulatory compliance enabling better compliance efficiency at the consolidated level.



Registered Office: SPARC, Tandalja, Vadodra - 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



- (d) Certain pharmaceutical products manufactured by one of the transferor company i.e. SPML are sold in the regulated markets are exported through Transferee Company and this amalgamation would further help in consolidation of exports.

The amalgamation of the Transferor Companies with the Transferee Company will combine the business, activities and operations of the Transferor Companies and the Transferee Company into a single company with effect from the Appointed Date and shall be in accordance with the provisions of the Income Tax Act, 1961, and rules framed thereunder including Section 2(1B) thereof or any amendments thereto.

2. Rationale for reclassification and transfer of the General Reserve of the Transferee Company to Retained Earnings

Over the years, the Transferee Company has built up significant reserves through transfer of profits to the general reserve in accordance with provisions of the erstwhile Companies Act, 1956 and erstwhile rules notified thereunder, namely, the Companies (Transfer of Profits to Reserves) Rules, 1975. While the excess reserves can be profitably utilized for the Company's overall growth strategy, the Board of Directors of the Transferee Company is of the view that even after considering the foreseeable investments required for such opportunities over the next few years, the fund represented by the General Reserve are in excess of the Transferee Company's current and anticipated operational needs.

Scheme is not detrimental to the interest of the Shareholders of the Company

1. The Scheme involves amalgamation of Wholly-owned Subsidiaries into the Holding Company and reclassification of General Reserve of Transferee Company to Retained Earnings as such it does not involved any issuance of shares or any outflow of funds as there is not consideration involved.
2. Even if net worth is reducing marginally, it remains to be strongly positive not having any adverse impact on any of the stakeholders. This together with the benefits enumerated under the rationale above results into scheme is being beneficial to the stakeholders.
3. The second part of the proposed Scheme is an arrangement between the Company and its shareholders. Pursuant to this Scheme, the entire amount of Rs. 51,435.0 million standing to the credit of the General Reserve of the Transferee Company, as on March 31, 2023 shall be reclassified, transferred to and shall form part of the 'Retained Earnings'.
4. As you are aware, Section 205(2A) of the Companies Act, 1956 read with the Companies (Transfer of Profits to Reserves) Rules 1975, mandated every company to transfer, in any financial year, a specific portion out of the profits of the company for that year arrived at, after

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA

Reaching People. Touching Lives.



Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



providing for depreciation, to the general reserves account of the company, before declaring any dividend to the shareholders.

5. With introduction of the Companies Act, 2013 ("Act, 2013"), the requirement of mandatory transfer to reserves is done away with considering the changing economic and regulatory scenario. This change suggests that the profits of the Company are fully distributable without having to create any reserves and the Board of Directors and the shareholders are allowed to exercise their own judgement on maintenance of general reserves, if any.
6. We would like to bring to your kind attention that even during the existence of the Companies Act, 1956 and Rules framed thereunder, in Nestle India Limited (C.P No. 141/ 2007, High Court of Delhi) it was permitted to transfer the amounts standing to the credit of general reserve account to retained earnings account pursuant to a scheme of arrangement with the shareholders. In the said scheme, the grounds for such transfer was to create shareholder value and that the amounts transferred are nothing but accumulated profits of the company which are required to be utilized for the shareholders to create value for them.
7. Pursuant to the proposed Scheme, the Company believes that reclassification of general reserve to retained earnings will provide greater flexibility to enable the Company, among other things, distribution of profits to the shareholders. The Board of Directors of the Company believes that such a transfer would not only be in the interest of shareholders and create higher shareholder value, but also not be prejudicial to the interest of any stakeholders.
8. Even, under the corresponding provisions of Sections 230 to 232 of the Act, 2013, the Securities and Exchange Board of India and the various Benches of the National Company Law Tribunal ("NCLT") have permitted companies like Hindustan Unilever Limited (TCSP No. 151 of 2017, NCL T, Mumbai Bench), International Paper APPM Limited (CP No. 416 of 2016, NCLT, Hyderabad Bench), Prime Securities Limited (CP.CAA No. 1084 of 2020, NCLT, Mumbai Bench), The Tata Power Company Limited (CP. CAA No. 42 of 2021, NCLT, Mumbai Bench), Nestle India Limited (CA.CAA.30/230-232/ND/2022, NCLT, New Delhi Bench) etc. to undertake such a transfer through a scheme of arrangement whereby amounts standing to the credit of the general reserves account were transferred to the retained earnings account.
9. It is important to note that the reserves created upon declaration of dividend were created by way of a Board approval as it was a statutory requirement. As there is not provision mandating or prohibiting reclassification of general reserve, it can be said that the general reserve can be brought back to retained earnings only by passing a Board resolution. However, the Company has proposed to do it by way of a Scheme of Arrangement as it endeavours to follow best corporate governance practices where the Scheme will not only be approved by the shareholders at an NCLT directed meeting (convened pursuant to the requirements of Section 230 to 232 of the Act, 2013), but will also go through the scrutiny of various regulatory authorities before NCLT approves it.

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA

Reaching People. Touching Lives.



Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



10. It may be noted that while transfer of amounts standing to credit of the general reserve account to retained earnings account is being proposed and once the Scheme if approved by NCLT, the utilisation of the amounts from the retained earnings account will be undertaken as may be permissible under the relevant provisions of the Act, 2013. The selection of method to reward the shareholders of the Company is dependent upon various external and internal factors like overall business environment of the Indian economy, financial position of the Company etc., which would be quite difficult for the Company to ascertain at this stage. However, kindly note that the Company will duly follow requisite provisions of the Act, 2013 while determining the exact method to reward its shareholders.
11. In terms of provisions of Sections 230 to 232 of Act, 2013, the Board of Directors of the Company, at their meeting held on November 01, 2023, had inter alia unanimously approved the Scheme of Arrangement taking on record that the Scheme is not detrimental to the interests of any of the stakeholders of the Company.

We hereby request you to take the above on records and issue Observation letter/No-objection Letter.

Thanking you,

Yours truly,

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)

Company Secretary & Compliance Officer

ICSI Membership No.: A23983



Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



December 7, 2023

To,
The General Manager,
Department of Corporate Services,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400 001.

Dear Sir / Madam,

Sub: Application under Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the proposed Composite Scheme of Arrangement

In connection with the above application, we hereby confirm that:

- a) The proposed Composite Scheme of Arrangement to be presented to any Court or Tribunal does not in any way violate or override or circumscribe the provisions of the SEBI Act, 1992, the Securities Contracts (Regulation) Act, 1956, securities contract (Regulations) Rules, 1957, RBI Act, The Depositories Act, 1996, Companies Act, 2013, the rules, regulations and guidelines made under these Acts, the provisions as explained in Regulation 11 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 and the requirements of SEBI circulars and BSE Limited.
- b) In the explanatory statement to be forwarded by the company to the shareholders u/s 230 of the Companies Act 2013, it shall disclose:
 - i) the pre and post-arrangement or amalgamation (expected) capital structure and shareholding pattern and
 - ii) Information about unlisted companies involved in the scheme as per the format provided for abridged prospectus of the SEBI ICDR Regulations: Not Applicable
 - iii) The Complaint report; and
 - iv) The observation letter issued by the stock exchanges
- c) The draft Composite Scheme of Arrangement together with all documents mentioned in Part-I(A)(8)(a) of SEBI Master Circular no. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023 has been disseminated on company's website at <https://sunpharma.com/investors-statutory-communications/>
- d) The company shall disclose the observation letter of the stock exchange on its website within 24 hours of receiving the same.
- e) The approval from the shareholders through e-voting, as required under Para (I)(A)(10)(a) of SEBI Circular SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023 is not applicable, therefore as required under Para (I)(A)(10)(c) of said SEBI circular, an undertaking certified by the auditors clearly stating the reasons for non-applicability of Para 10(a).

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.




Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



- f) The documents filed by the Company with the Exchange are same/ similar/ identical in all respect, which have been filed by the Company with Registrar of Companies/SEBI/Reserve Bank of India, wherever applicable.
- g) There will be no alteration in the Share Capital of the unlisted transferor company from the one given in the draft composite scheme arrangement.
- h) None of the promoters or directors of the companies involved in the scheme is a fugitive economic offender.

For Sun Pharmaceutical Industries Limited


(Anoop Deshpande)

Company Secretary & Compliance Officer
ICSI Membership No.: A23983



Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



The Scheme related documents as mentioned in Part - I(A)(8)(a) of SEBI Master Circular no. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023 has been disseminated on company's website at <https://sunpharma.com/investors-statutory-communications/>

As desired please find below a snapshot of the scheme related documents submitted on the website of the Company:

**For Sun Pharmaceutical Industries Limited**

Anoop D.

(Anoop Deshpande)

Company Secretary & Compliance Officer
ICSI Membership No.: A23983



Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.



MIRAL ZATAKIA & ASSOCIATES

34, Dattani Gram no. 2, Iraniwadi No. 3,
Kandivali West, Mumbai 400067

M. No. 7666822205

Mail: mlzatakia@gmail.com

To,
Sun Pharmaceutical Industries Limited,
SPARC, Tandalja,
Vadodara – 390 012

Dear Sir(s)/ Madam

In the matter of Composite Scheme of Arrangement (herein after referred to as “Scheme of Arrangement” or “Scheme”), involving (a) amalgamation of Wholly-owned subsidiary companies viz. Sun Pharmaceutical Medicare Limited, Green Eco Development Centre Limited, Faststone Mercantile Company Private Limited, Realstone Multitrade Private Limited, Skisen Labs Private Limited (“Transferor Companies”) with Sun Pharmaceutical Industries Limited (“Transferee Company” or “the Company”), and (b) Reclassification of General Reserve of the Company to Retained Earnings, pursuant to the provisions of Sections 230 to 232 of the Companies Act, 2013, and on the basis of our evaluation of the relevant documents and according to the information and explanations given to us by the management of the Company, we hereby certify that,

- A) The Scheme does not involve utilisation of reserves as no shares of the Transferee Company shall be issued and allotted in lieu of shares held by it or its subsidiary companies in the Transferor Companies and the entire paid-up share capital of the Transferor Companies shall be cancelled and extinguished without any further act, deed or instrument as an integral part of this Scheme; and
- B) As per Part C of the Scheme, the entire amount of Rs. 51,435.0 million standing to the credit of the General Reserve of the Transferee Company, as on March 31, 2023 shall be reclassified, transferred to and shall form part of the ‘Retained Earnings’ of the Transferee Company. This is only a reclassification and does not amount to utilisation of reserves.

For Miral Zatakia & Associates
Chartered Accountants
FRN : 0142715W

M D Zatakia

CA Miral Zatakia
Proprietor

M. No. 168489

UDIN: 23168489BGVQUF8552

Date: 04/12/2023

Place: Mumbai





To,
Sun Pharmaceutical Industries Limited,
SPARC, Tandalja,
Vadodara – 390 012

Dear Sir(s)/ Madam

In the matter of Composite Scheme of Arrangement (herein after referred to as “Scheme of Arrangement” or “Scheme”), involving (a) amalgamation of Wholly-owned subsidiary companies viz. Sun Pharmaceutical Medicare Limited, Green Eco Development Centre Limited, Faststone Mercantile Company Private Limited, Realstone Multitrade Private Limited, Skisen Labs Private Limited (“Transferor Companies”) with Sun Pharmaceutical Industries Limited (“Transferee Company” or “the Company”), and (b) Reclassification of General Reserve of the Company to Retained Earnings, pursuant to the provisions of Sections 230 to 232 of the Companies Act, 2013, and on the basis of our evaluation of the relevant documents and according to the information and explanations given to us by the management of the Company, we hereby certify that the built-up for reserves and Nature of reserves of the companies involved in the Scheme as at March 31, 2023, are as follows:

Built up for reserves and Nature of reserves

1. SUN PHARMACEUTICAL INDUSTRIES LIMITED

Particulars	Rs. in Million		
	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
Capital reserve	22,258.5	22,258.5	22,258.5
Securities premium	11,874.1	11,874.1	11,874.1
Capital redemption reserve	7.5	7.5	7.5
Total	34,140.1	34,140.1	34,140.1

Nature of reserves:

Capital reserve - During amalgamation / merger / acquisition, the excess of net assets taken, over the consideration paid, if any, is treated as capital reserve.

Securities premium - The amount received in excess of face value of the equity shares is recognised in securities premium. In case of equity-settled share-based payment transactions, the difference between fair value on grant date and nominal value of share is accounted as securities premium. It is utilised in accordance with the provisions of the Companies Act, 2013.

Capital redemption reserve - The Company has recognised capital redemption reserve on buyback of equity shares from its retained earnings. The amount in capital redemption reserve is equal to nominal amount of the equity shares bought back.





MIRAL ZATAKIA & ASSOCIATES

34, Dattani Gram no. 2, Iraniwadi No. 3,

Kandivali West, Mumbai 400067

M. No. 7666822205

Mail: mlzatakia@gmail.com

2. Sun Pharmaceutical Medicare Limited

Rs. in Million

Particulars	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
Capital reserve	-	-	-
Securities premium	-	-	-
Capital redemption reserve	-	-	-
Total	-	-	-

3. Green Eco Development Centre Limited

Rs. in Million

Particulars	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
Capital reserve	-	-	-
Securities premium	-	-	-
Capital redemption reserve	-	-	-
Total	-	-	-

4. Faststone Mercantile Company Private Limited

Rs. in Million

Particulars	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
Capital reserve	-	-	-
Securities premium	-	-	-
Capital redemption reserve	-	-	-
Total	-	-	-





MIRAL ZATAKIA & ASSOCIATES

34, Dattani Gram no. 2, Iraniwadi No. 3,

Kandivali West, Mumbai 400067

M. No. 7666822205

Mail: mlzatakia@gmail.com

5. Realstone Multitrade Private Limited

Rs. in Million

Particulars	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
Capital reserve	-	-	-
Securities premium	-	-	-
Capital redemption reserve	-	-	-
Total	-	-	-

6. Skisen Labs Private Limited

Rs. in Million

Particulars	As at March 31, 2023	As at March 31, 2022	As at March 31, 2021
Capital reserve	-	-	-
Securities premium	-	-	-
Capital redemption reserve	-	-	-
Total	-	-	-

For Miral Zatakia & Associates

Chartered Accountants

FRN : 0142715W

M D Zatakia



CA Miral Zatakia

Proprietor

M. No. 168489

UDIN: 23168489BGVQUE6363

Date: 04/12/2023

Place: Mumbai



MIRAL ZATAKIA & ASSOCIATES

34, Dattani Gram no. 2, Iraniwadi No. 3,
Kandivali West, Mumbai 400067

M. No. 7666822205

Mail: mlzatakia@gmail.com

To,
Sun Pharmaceutical Industries Limited,
SPARC, Tandalja,
Vadodara – 390 012

Dear Sir(s)/ Madam

In the matter of Composite Scheme of Arrangement (herein after referred to as “Scheme of Arrangement” or “Scheme”), involving (a) amalgamation of Wholly-owned subsidiary companies viz. Sun Pharmaceutical Medicare Limited, Green Eco Development Centre Limited, Faststone Mercantile Company Private Limited, Realstone Multitrade Private Limited, Skisen Labs Private Limited (“Transferor Companies”) with Sun Pharmaceutical Industries Limited (“Transferee Company” or “the Company”), and (b) Reclassification of General Reserve of the Company to Retained Earnings, pursuant to the provisions of Sections 230 to 232 of the Companies Act, 2013, and on the basis of our evaluation of the relevant documents and according to the information and explanations given to us by the management of the Company, we hereby certify that there are no accumulated losses carried forward over the years in the Company and presently no accumulated losses are present in the Company.

For Miral Zatakia & Associates
Chartered Accountants
FRN : 0142715W

M D Zatakia



CA Miral Zatakia
Proprietor
M. No. 168489
UDIN: 23168489BGVQUG4675
Date: 04/12/2023
Place: Mumbai

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



December 15, 2023

BSE Limited

Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai - 400 001

Dear Sir/ Madam,

Sub: Application under Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023, for the proposed Composite Scheme of Arrangement

With reference to the above application, please find below the additional documents /information as requested by your good office on December 08, 2023:

Sr. No.	Additional documents/details	Company's remarks
1	An undertaking from the Company clearly stating the reasons for non-applicability of Para 10(a) of SEBI circular dated 20.06.2023 is not certified by the auditor. Further, kindly elaborate the applicability of all 5 exemptions and resubmit the same. - to be submitted.	An undertaking from the Company certified by the Auditors clearly stating the reasons for non-applicability of Paragraph A(10)(b) read with Paragraph A(10)(a) of Part I of the SEBI Master Circular no. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023, is enclosed at Annexure-1 .
2	Confirmation by the Managing Director/ Company Secretary as per format enclosed as Annexure XI.: a) how point b) iii) is not applicable?	Reason for non-applicability is mentioned at point no. b) ii) in the enclosed confirmation issued by the Company Secretary of the Company at Annexure-2 .

We hereby request you to take on records and issue Observation letter/No-objection Letter.

Thanking you,

Yours truly,

For Sun Pharmaceutical Industries Limited


(Anoop Deshpande)

Company Secretary & Compliance Officer

ICSI Membership No.: A23983

Encl.: As above.



Registered Office: SPARC, Tandajja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Auditors' Certificate of even date on non-applicability of Para (A)(10)(a) read with Para (A)(10)(b) of Part I of Circular no. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023 issued by the Securities Exchange Board of India ("SEBI")

The Board of Directors,
Sun Pharmaceutical Industries Limited
Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai - 400 063, Maharashtra

1. This Certificate is issued in accordance with the terms of the Master Engagement Agreement (the "MEA") dated October 24, 2022.
2. The accompanying undertaking approved by the Board of Directors in its meeting held on November 01, 2023 (the "undertaking") stating the reasons for non-applicability of Para (A)(10)(a) read with Para (A)(10)(b) of Part I of circular no. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023 issued by the Securities Exchange Board of India ("SEBI") (hereinafter referred to as "Circular") has been prepared by management of Sun Pharmaceutical Industries Limited (the "Company") pursuant to the requirements of Para (A)(10)(c) of Part I of the circular in connection with its proposed Composite Scheme of Arrangement (hereinafter referred to as "Scheme of Arrangement" or "Scheme"), involving (a) Amalgamation of Wholly-owned subsidiary companies viz. Sun Pharmaceutical Medicare Limited, Green Eco Development Centre Limited, Faststone Mercantile Company Private Limited, Realstone Multitrade Private Limited, Skisen Labs Private Limited (Hereinafter referred to as "Transferor companies") with Sun Pharmaceutical Industries Limited (Hereinafter referred to as "Transferee Company" or "Company"), and (b) Reclassification of General Reserve of the Transferee Company to Retained Earnings.
3. The attached undertaking is prepared by the Company and is required to be submitted by the Company to Securities and Exchange Board of India, BSE Limited, National Stock Exchange of India Limited, National Company Law Tribunal, Reserve Bank of India, Registrar of Companies, Ahmedabad and Office of Regional Director, North Western Region Ministry of Corporate Affairs and has been initialed by us for identification purposes.

Management's Responsibility

4. The responsibility for the preparation of the undertaking and its compliance with the requirements of the circulars issued under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and relevant laws and regulations in connection with the Scheme is that of the Board of Directors of the Companies involved.

Auditor's Responsibility

5. Pursuant to the Circular, our responsibility is to provide reasonable assurance on the following reporting criteria:
 - a. whether the requirements in Para (A)(10)(a) read with Para (A)(10)(b) of Part I of the Circular are applicable to the proposed Scheme.
6. A reasonable assurance engagement includes performing procedures to obtain sufficient appropriate evidence on the reporting criteria. Accordingly, we have performed the following procedures in relation to the Certificate:
 - a. Read the Scheme and relevant guidelines to determine whether the requirements in Para (A)(10)(a) read with Para (A)(10)(b) of Part I of the Circular are applicable to the Company.
 - b. Read the Scheme and Undertaking provided by the Company.

S R B C & COLLP

Chartered Accountants

- c. Our examination did not extend to any aspects of a legal or propriety nature covered in the Proposed Scheme.

Further, our scope of work did not involve us performing any audit tests in the context of our examination. We have not performed an audit, the objective of which would be to express an opinion on the specified elements, accounts or items thereof, for the purpose of this certificate. Accordingly, we do not express such opinion. Nothing contained in this Certificate, nor anything said or done in the course of, or in connection with the services that are subject to this Certificate, will extend any duty of care that we may have in our capacity as the statutory auditors of any financial statements of the Company.

7. We conducted our examination in accordance with the Guidance Note on Reports or Certificates for Special Purposes (Revised) issued by the Institute of Chartered Accountants of India. The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by the Institute of Chartered Accountants of India.
8. We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and Other Assurance and Related Services Engagements.
9. We are issuing this revised certificate pursuant to observations received by the Company from National Stock Exchange of India Limited and BSE Limited on November 24, 2023 and November 29, 2023, respectively, in supersession of our earlier certificate dated November 21, 2023 vide UDIN 23105754BGQUSE1906, which hereby stands withdrawn. We have received an undertaking from the management that this certificate and the fact of supersession of the original certificate, will be brought to the attention of all the recipients of such previous (Superseded) certificate and such original certificate shall be replaced with this revised certificate, wherever such old certificate has been used/ distributed.

Opinion

10. Based on our examination and according to the information and explanations given to us, read with paragraph 6 above, in our opinion, the requirements in Para (A)(10)(a) read with Para (A)(10)(b) of Part I of the Circular are not applicable to the Scheme.

Restriction on Use

11. The certificate is addressed to and provided to the Board of Directors of the Company solely for the purpose to comply with the requirements of the circulars issued under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for onward submission to Securities and Exchange Board of India, BSE Limited and National Stock Exchange of India Limited, National Company Law Tribunal, Reserve Bank of India, Registrar of Companies, Ahmedabad and Office of Regional Director, North Western Region Ministry of Corporate Affairs. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this certificate is shown or into whose hands it may come without our prior intimation.

For S R B C & CO LLP
Chartered Accountants
ICAI Firm Registration Number: 324982E/E300003

**Paul
Alvares**
Digitally signed by Paul Alvares
DN: cn=Paul Alvares, c=IN,
o=Personal,
email=paul.alvares@srbc.in
Date: 2023.12.15 18:11:16 +05'30'

per Paul Alvares
Partner
Membership Number: 105754
UDIN: 23105754BGQUSJ8192
Place: Pune
Date: December 15, 2023

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



Undertaking in relation to the non-applicability of Paragraph A(10)(b) read with Paragraph A(10)(a) of Part I of the SEBI Master Circular no. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023 (“SEBI Master Circular”), pertaining to obtaining approval of the majority of public shareholders

1. Background

- 1.1 The Board of Directors of the Company at its meeting held on November 1, 2023 has approved the draft Composite Scheme of Arrangement (hereinafter referred to as “Scheme of Arrangement” or “Scheme”), involving:
 - a) Amalgamation of Wholly-owned subsidiary companies viz. Sun Pharmaceutical Medicare Limited, Green Eco Development Centre Limited, Faststone Mercantile Company Private Limited, Realstone Multitrade Private Limited, Skisen Labs Private Limited (“Transferor Companies”) with Sun Pharmaceutical Industries Limited (“Transferee Company” or “Company”), and
 - b) Reclassification of General Reserve of the Company to Retained Earnings
- 1.2 The Scheme involves amalgamation of Wholly-owned Subsidiaries into the Holding Company and reclassification of General Reserve of Transferee Company to Retained Earnings as such it does not involved any issuance of shares.

2. Requirement under the SEBI Master Circular

- 2.1 The SEBI Master Circular mandates all the listed companies to ensure that the Scheme submitted with the National Company Law Tribunal (“NCLT”) for sanction, shall be acted upon in certain cases as specified in Paragraph A(10)(b) of Part I of the SEBI Master Circular only if the votes cast by public shareholders in favour of the scheme are more than the number of votes cast by the public shareholders against the Scheme.
- 2.2 Further, in terms of Paragraph A(10)(c) of Part I of SEBI Master Circular, the listed entity is required to provide an undertaking certified by the auditor and duly approved by the Board of Directors of the Company, clearly stating the reasons for the non-applicability of the requirements set out in Paragraph A(10)(a) read with the conditions prescribed in Paragraph A(10)(b) of Part I of the SEBI Scheme Circular.
- 2.3 Based on the conditions provided in Paragraph A(10)(b) read with Paragraph A(10)(a) of Part I of the SEBI Master Circular, it is submitted that the Scheme of Arrangement does not envisage any of the five cases referred to in Paragraph A(10)(b) of Part I of the SEBI Master Circular.
- 2.4 Accordingly, the Company hereby undertakes that the requirements stated at Paragraph A(10)(a) read with paragraph A(10)(b) of Part I of the SEBI Master Circular pertaining to obtaining approval of the majority of public shareholders are not applicable to the Scheme for the reasons mentioned in Paragraph 3 below.

3. Reasons for non-applicability

The reasons for non-applicability of obtaining approval of majority of public shareholders to the Scheme are as follows:

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



3.1 Paragraph A(10)(b)(i) of Part I of the SEBI Master Circular

Where additional shares have been allotted to Promoter / Promoter Group, Related Parties of Promoter / Promoter Group, Associates of Promoter / Promoter Group, Subsidiary/(s) of Promoter / Promoter Group of the listed entity

Reasons for Non-applicability: The Scheme involves amalgamation of five Wholly-owned Subsidiaries into the Holding Company and reclassification of General Reserve of Transferee Company to Retained Earnings. Pursuant to Scheme, no shares are proposed to be issued or allotted by the Transferee Company, to the Promoter/ Promoter Group, Related Parties of the Promoter/ Promoter Group, Associates of Promoter/ Promoter Group, Subsidiary/(s) of Promoter/ Promoter Group of the Transferee Company. Accordingly, the provisions of Paragraph A(10)(b)(i) of Part I of the SEBI Master Circular are not applicable to the Scheme.

3.2 Paragraph A(10)(b)(ii) of Part I of the SEBI Master Circular

Where the Scheme of Arrangement involves the listed entity and any other entity involving Promoter / Promoter Group, Related Parties of Promoter / Promoter Group, Associates of Promoter / Promoter Group, Subsidiary/(s) of Promoter / Promoter Group.

Reasons for Non-applicability: The Scheme only provides amalgamation of five Wholly-owned Subsidiaries into the Holding Company and reclassification of General Reserve of Transferee Company to Retained Earnings. This Scheme does not involve any arrangement between the Transferee Company and any other entity involving Promoter/ Promoter Group, Related Parties of Promoter / Promoter Group, Associates of Promoter / Promoter Group, Subsidiary/(s) of Promoter / Promoter Group of the Transferee Company. Accordingly, the provisions of Paragraph A(10)(b)(ii) of Part I of the SEBI Master Circular are not applicable to the Scheme.

3.3 Paragraph A(10)(b)(iii) of Part I of the SEBI Master Circular

Where the parent listed entity has acquired, either directly or indirectly, the equity shares of the subsidiary from any of the shareholders of the subsidiary who may be Promoter / Promoter Group, Related Parties of Promoter / Promoter Group, Associates of Promoter / Promoter Group, Subsidiary/(s) of Promoter / Promoter Group of the parent listed entity, and if that subsidiary is being merged with the parent listed entity under the Scheme.

Reasons for Non-applicability: The Scheme only provides amalgamation of five Wholly-owned Subsidiaries into the Holding Company and reclassification of General Reserve of Transferee Company to Retained Earnings. The Transferee Company has not acquired directly or indirectly the equity shares of any of the Transferor Companies from any of the shareholders of the Transferor Companies who may be Promoter / Promoter Group, Related Parties of Promoter / Promoter Group, Associates of Promoter / Promoter Group, Subsidiary/(s) of Promoter / Promoter Group of the Transferee Company. Accordingly, the provisions of Paragraph A(10)(b)(iii) of Part I of the SEBI Master Circular are not applicable to the Scheme.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



3.4 Paragraph A(10)(b)(iv) of Part I of the SEBI Master Circular

Where the scheme involving merger of an unlisted entity results in reduction in the voting share of pre-scheme public shareholders of listed entity in the transferee / resulting company by more than 5% of the total capital of the merged entity

Reasons for Non-applicability: The Scheme does not involve any reduction in the voting share of the public shareholders in the Transferee Company. The Scheme does not involve merger of an unlisted entities which results in any reduction in the voting share of pre-scheme public shareholders of Transferee Company as no shares are proposed to be issued or allotted by the Transferee Company pursuant to the Scheme. Accordingly, the provisions of Paragraph A(10)(b)(iv) of Part I of the SEBI Master Circular are not applicable to the Scheme.

3.5 Paragraph A(10)(b)(v) of Part I of the SEBI Master Circular

Where the scheme involves transfer of whole or substantially the whole of the undertaking of the listed entity and the consideration for such transfer is not in the form of listed equity shares


For the purpose of this clause, the expression "substantially the whole of the undertaking" in any financial year shall mean twenty per cent or more of value of the company in terms of consolidated net worth or consolidated total income during previous financial year as specified in Section 180(1)(a)(ii) of the Companies Act, 2013.

Reasons for Non-applicability: The Scheme only provides amalgamation of five Wholly-owned Subsidiaries into the Holding Company and reclassification of General Reserve of Transferee Company to Retained Earnings. The Scheme does not provide for transfer of whole or substantially the whole of the undertaking of the Transferee Company. Accordingly, the provisions of Paragraph A(10)(b)(v) of Part I of the SEBI Master Circular are not applicable to the transaction contemplated pursuant to the Scheme.

In view of the aforesaid, the requirement of obtaining approval of majority of public shareholders, as stated at Paragraph A(10)(b) read with Paragraph A(10)(a) of the SEBI Master Circular is not applicable to the Scheme.

This undertaking is being issued pursuant to the authorisation given by the Board of Directors of the Company at their meeting held on November 01, 2023 and sought by the Stock Exchanges with reasons for non-applicability under Paragraph A(10)(c) of Part I of the SEBI Master Circular.

For Sun Pharmaceutical Industries Limited


(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No. A23983



Mumbai, December 15, 2023

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



December 15, 2023

To,
The General Manager,
Department of Corporate Services,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400 001.

Dear Sir / Madam,


Sub: Application under Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the proposed Composite Scheme of Arrangement

In connection with the above application, we hereby confirm that:

- a) The proposed Composite Scheme of Arrangement to be presented to any Court or Tribunal does not in any way violate or override or circumscribe the provisions of the SEBI Act, 1992, the Securities Contracts (Regulation) Act, 1956, securities contract (Regulations) Rules, 1957, RBI Act, The Depositories Act, 1996, Companies Act, 2013, the rules, regulations and guidelines made under these Acts, the provisions as explained in Regulation 11 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 and the requirements of SEBI circulars and BSE Limited.
- b) In the explanatory statement to be forwarded by the company to the shareholders u/s 230 of the Companies Act 2013, it shall disclose:
 - i) the pre and post-arrangement or amalgamation (expected) capital structure and shareholding pattern and
 - ii) Information about unlisted companies involved in the scheme as per the format provided for abridged prospectus of the SEBI ICDR Regulations – Not Applicable since the scheme involves Amalgamation of wholly-owned subsidiaries and upon the Scheme becoming effective, no shares of the Transferee Company shall be issued and allotted in lieu of shares held by it or its subsidiary companies in the Transferor Companies and the entire paid-up share capital of the Transferor Companies shall be cancelled and extinguished without any further act, deed or instrument as an integral part of this Scheme, there will be no change in the shareholding pattern of the Transferee Company.
 - iii) The Complaint report; and
 - iv) The observation letter issued by the stock exchanges
- c) The draft Composite Scheme of Arrangement together with all documents mentioned in Part-I(A)(8)(a) of SEBI Master Circular no. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023 has been disseminated on company's website at <https://sunpharma.com/investors-statutory-communications/>

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.



Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



- d) The company shall disclose the observation letter of the stock exchange on its website within 24 hours of receiving the same.
- e) The approval from the shareholders through e-voting, as required under Para (I)(A)(10)(a) of SEBI Circular SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023 is not applicable, therefore as required under Para (I)(A)(10)(c) of said SEBI circular, an undertaking certified by the auditor clearly stating the reasons for non-applicability of Para 10(a).
- f) The documents filed by the Company with the Exchange are same/ similar/ identical in all respect, which have been filled by the Company with Registrar of Companies/SEBI/Reserve Bank of India, wherever applicable.
- g) There will be no alteration in the Share Capital of the unlisted transferor company from the one given in the draft composite scheme arrangement.
- h) None of the promoters or directors of the companies involved in the scheme is a fugitive economic offender.

For Sun Pharmaceutical Industries Limited

(Anoop Deshpande)

Company Secretary & Compliance Officer

ICSI Membership No.: A23983



Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



February 05, 2024

BSE Limited

Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai - 400 001

Kind Attention: Ms. Tanmayi Lele, Assistant Manager (Listing Operations)

Sub: Application under Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023, for the proposed Composite Scheme of Arrangement

With reference to the above mentioned application, please find below our response on the additional clarification/ documents/details sought by your good office on January 30, 2024:

Sr. No.	Additional documents/details sought	Company's response
1	<p>Since the instant scheme provides for transfer of Rs. 51,435 million standing to the credit of General Reserves to Retained Earnings of the Sun Pharmaceuticals Industries Limited, kindly provide the following clarification:</p> <p>a. What is the rationale of the scheme, and whether it will be in the spirit of Section 123 of the Companies Act, 2013 and Companies (Declaration and Payment of Dividend) Rules, 2014.</p>	<p>Rationale for the Scheme for reclassification and transfer of the General Reserve of the Transferee Company to Retained Earnings, as mentioned in the Scheme, is as follows:</p> <p><i>“Over the years, the Transferee Company has built up significant reserves through transfer of profits to the general reserve in accordance with provisions of the erstwhile Companies Act, 1956 and erstwhile rules notified thereunder, namely, the Companies (Transfer of Profits to Reserves) Rules, 1975. While the excess reserves can be profitably utilized for the Company's overall growth strategy, the Board of Directors of the Transferee Company is of the view that even after considering the foreseeable investments required for such opportunities over the next few years, the fund represented by the General Reserve are in excess of the Transferee Company's current and anticipated operational needs.”</i></p>

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



Sr. No.	Additional documents/details sought	Company's response
		Considering the deliberate change from mandatory requirement to discretionary requirement in terms of transfer of profits to reserves upon declaration of dividend, under Companies Act, 2013 (“Act, 2013”), we believe that the Scheme is in spirit of Section 123 of Act, 2013.
	b. How does the company intend to create shareholder value and how the scheme will be in the interest of shareholders? c. How the Company proposes to use Rs.51,435 million which will be getting transferred from General Reserves to Retained Earnings of the Company.	Pursuant to the Scheme, the Company believes that reclassification of general reserve to retained earnings will provide greater flexibility to enable the Company, in utilisation of the funds, including but not limited to distribution as dividend to the shareholders. The Board of Directors will exercise its discretion on this from time to time considering the overall financial position of the Company in the best interest of the Company and its stakeholders. We believe that the Scheme is in the interest of shareholders and create higher shareholder value and is not prejudicial to the interest of any stakeholders.
2	Further, please submit Audited Standalone and Consolidated financials of the transferee/resulting and transferor/demerged companies for the last 3 financial years (financials not being more than 6 months old of unlisted company) as per Annexure IV of the checklist.	We have submitted the following financials at Annexure-7 of our letter dated November 21, 2023: (i) Audited Standalone and Consolidated financials of Sun Pharmaceutical Industries Limited, Transferee company (listed company) for the last 3 financial years and Limited Reviewed Unaudited Financial for the six months ended September 30, 2023; and (ii) Audited Financials of the Transferor Companies for the last 3 financial years. As per our discussion during the virtual meeting held before filing application with BSE, we had made a request for dispensation

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



Sr. No.	Additional documents/details sought	Company's response
		<p>of the requirement to provide Audited financials based on the following;</p> <ol style="list-style-type: none">1. This Composite Scheme of Arrangement (herein after referred to as “Scheme of Arrangement” or “Scheme”), contains two parts as follow;<ol style="list-style-type: none">a) Amalgamation of Five Wholly-owned Subsidiaries into the Holding Company/ Transferee Company andb) Reclassification of General Reserve of the Transferee Company to Retained Earnings.2. In the first part, wholly-owned subsidiaries are proposed to be merged into the holding Company. Upon the Scheme becoming effective, no shares of the Transferee Company shall be issued and allotted in lieu of shares held by it or its subsidiary companies in the Transferor Companies and the entire paid-up share capital of the Transferor Companies shall be cancelled and extinguished without any further act, deed or instrument as an integral part of this Scheme.3. Merger of wholly-owned subsidiaries into the holding company is not otherwise subjected to scrutiny under Regulation 37 but in this case, it is being referred only because the second part of the Scheme i.e. reclassification of general reserve to retained earnings. It is important to note here that the second part has no impact whatsoever on the first part and therefore there is no fundamental change where audited financial statements should be insisted

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



Sr. No.	Additional documents/details sought	Company's response
		upon. As audited financial statements would serve no additional purpose. Based on the conversation as mentioned above, our understating was that the requested for dispensation, being logical, was concurred by your office.

We hereby request you to take on records and issue no objection letter at the earliest.

Thank You.

For **Sun Pharmaceutical Industries Limited**

Anoop
Anjanikumar
Deshpande



Digitally signed by Anoop
Anjanikumar Deshpande
Date: 2024.02.05 18:00:07
+05'30'

(Anoop Deshpande)
Company Secretary & Compliance Officer
ICSI Membership No.: A23983

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



May 23, 2024

BSE Limited

Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai - 400 001

Kind Attention: Ms. Tanmayi Lele/ Ms. Jayanti Pradhan, Assistant Manager (Listing Operations)

Sub: Application under Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023, for the proposed Composite Scheme of Arrangement

This is further to our emails dated May 14 & 17, 2024 wherein we had sought additional time to respond your query in respect of the above-mentioned application.

Please find below our response on the additional clarification/ documents/details sought by your good office on April 26, 2024:

Sr. No.	Additional clarification/ documents/ details sought	Company's response
1	The entire paid-up share capital of Sun Pharmaceutical Medicare Ltd. (SPML) is held by Sun Pharma Laboratories Ltd. (SPLL), a wholly owned subsidiary of Sun Pharmaceutical Industries Limited (SPIL). As per the proposed scheme, SPML is proposed to be amalgamated into SPIL. As entire paid-up share capital of SPML is held by SPLL, after the scheme effected what will be status of SPLL. Clarify whether SPLL is also getting amalgamated into SPIL?	<p>Sun Pharma Laboratories Limited (SPLL) will not be getting amalgamated with Sun Pharmaceutical Industries Limited (SPIL), the Transferee Company. SPLL will remain as a wholly owned subsidiary of SPIL.</p> <p>Upon the Scheme becoming effective, no shares of the Transferee Company shall be issued and allotted in lieu of shares held by it or its subsidiary companies in the Transferor Companies and the entire paid-up share capital of the Transferor Companies shall be cancelled and extinguished without any further act, deed or instrument as contemplated in the Clause 14.1 in the Scheme of Arrangement. Hence the shares of SPML held by SPLL shall stand cancelled.</p>
2	Detailed reason/justification for transfer of Rs.51,435 million from General	Rationale for the Scheme for reclassification and transfer of the General Reserve of the Transferee Company to Retained Earnings, as mentioned in the Scheme, is as follows:

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



Sr. No.	Additional clarification/ documents/ details sought	Company's response
	Reserves to Retained Earnings.	<p><i>“Over the years, the Transferee Company has built up significant reserves through transfer of profits to the general reserve in accordance with provisions of the erstwhile Companies Act, 1956 and erstwhile rules notified thereunder, namely, the Companies (Transfer of Profits to Reserves) Rules, 1975. While the excess reserves can be profitably utilized for the Company's overall growth strategy, the Board of Directors of the Transferee Company is of the view that even after considering the foreseeable investments required for such opportunities over the next few years, the fund represented by the General Reserve are in excess of the Transferee Company's current and anticipated operational needs.”</i></p> <p>Detailed reason/justification for transfer of Rs.51,435 million from General Reserves to Retained Earnings as sought by you is as follows:</p> <ol style="list-style-type: none">1. As you are aware, Section 205(2A) of the Companies Act, 1956 read with the Companies (Transfer of Profits to Reserves) Rules 1975, mandated every company to transfer, in any financial year, a specific portion out of the profits of the company for that year arrived at, after providing for depreciation, to the general reserves account of the company, before declaring any dividend to the shareholders.2. With introduction of the Companies Act, 2013 (“Act, 2013”), the requirement of mandatory transfer to reserves is done away with considering the changing economic and regulatory scenario. This change suggests that the profits of the Company are fully distributable without having to create any reserves and the Board of Directors and the shareholders are allowed to exercise their own judgement on maintenance of general reserves, if any.3. Pursuant to the proposed Scheme, the Company believes that reclassification of general reserve to retained earnings will provide greater flexibility to enable the Company, among other things, distribution

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



Sr. No.	Additional clarification/ documents/ details sought	Company's response
		<p>of profits to the shareholders. The Board of Directors of the Company believes that such a transfer would not only be in the interest of shareholders and create higher shareholder value, but also not be prejudicial to the interest of any stakeholders.</p> <p>4. It is important to note that the reserves created upon declaration of dividend were created by way of a Board approval as it was a statutory requirement. As there is not provision mandating or prohibiting reclassification of general reserve, it can be said that the general reserve can be brought back to retained earnings only by passing a Board resolution. However, the Company has proposed to do it by way of a Scheme of Arrangement as it endeavours to follow best corporate governance practices where the Scheme will not only be approved by the shareholders at an NCLT directed meeting (convened pursuant to the requirements of Section 230 to 232 of the Act, 2013), but will also go through the scrutiny of various regulatory authorities before NCLT approves it.</p> <p>5. It may be noted that while transfer of amounts standing to credit of the general reserve account to retained earnings account is being proposed and once the Scheme is approved by NCLT, the utilisation of the amounts from the retained earnings account will be undertaken as may be permissible under the relevant provisions of the Act, 2013. The selection of method to reward the shareholders of the Company is dependent upon various external and internal factors like overall business environment of the Indian economy, financial position of the Company etc., which would be quite difficult for the Company to ascertain at this stage. However, kindly note that the Company will duly follow requisite provisions of the Act, 2013 while determining the exact method to reward its shareholders.</p> <p>6. In terms of provisions of Sections 230 to 232 of Act, 2013, the Board of Directors of the Company, at their</p>

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



Sr. No.	Additional clarification/ documents/ details sought	Company's response
		meeting held on November 01, 2023, had inter alia unanimously approved the Scheme of Arrangement taking on record that the Scheme is not detrimental to the interests of any of the stakeholders of the Company.
3	Built-up of General Reserve of Rs.51,435 million certified by Chartered Accountant.	CA certificate for built-up of General Reserve of Rs.51,435 million, is attached herewith.
4	Relevant statutory provisions which allows transfer of accumulated general reverse to retained earnings.	There is no specific statutory provision enabling conversion of general reserves to accumulated profits. At the same time, there is no provision prohibiting such conversion. As there is no provision mandating or prohibiting reclassification of general reserve, a view is possible that the same can be done only way of a Board resolution. However, the Company has proposed to do it by way of a Scheme of Arrangement as it endeavours to follow best practices where the Scheme will not only be approved by the shareholders but also approved by the NCLT.

Thank You.

For **Sun Pharmaceutical Industries Limited**

Anoop
Anjanikumar
Deshpande

Digitally signed by Anoop
Anjanikumar Deshpande
Date: 2024.05.23 18:25:55
+05'30'

(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.